

## Disclaimer

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at [info@sentinelssystem.org](mailto:info@sentinelssystem.org).

Overview	
<b><u>Request Description</u></b>	Mini-Sentinel's National Death Index (NDI) Workgroup requested execution of Modular Program #3 (MP3) to produce sample size estimates of anti-depressant drug product use among members in the Mini-Sentinel Distributed Database (MSDD). The drug products of interest included amitriptyline, amoxapine, citalopram, clomipramine, desipramine, desvenlafaxine, doxepin, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, protriptyline, sertraline, trazodone, trimipramine, venlafaxine, vilazodone, and vortioxetine. This involved two runs of MP3. No event was queried. The time window for the request was January 1, 2000 to March 31, 2013. The package was distributed to 18 Data Partners on February 26, 2014.
<b><u>Request ID</u></b>	to09y05_mpr_wp22_v01 (anti-depressants) This is report 2 of 2. The first report displays results for antibiotics.
<b><u>Glossary</u></b>	List of Terms found in this Report and their Definitions
<b><u>Table 1</u></b>	Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, Amount Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Drug Product
<b><u>Table 2</u></b>	Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, Amount Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Drug Product and Age Group
<b><u>Table 3</u></b>	Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, Amount Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Drug Product and Sex
<b><u>Table 4</u></b>	Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, Amount Supplied, Years at Risk, Eligible Members, Member-Years, New Users per 1,000 Eligible Members, Days Supplied per User, Dispensings per User, and Days Supplied per Dispensing by Drug Product and Year
<b><u>Appendix A</u></b>	List of Generic Names Included in this Request
<b><u>Appendix B</u></b>	Modular Program Specifications for Query ID to09y05_mpr_wp22_v01 - Anti-depressant Use
<b><u>Notes:</u></b>	Please contact the Sentinel Operations Center ( <a href="mailto:qf@sentinelssystem.org">qf@sentinelssystem.org</a> ) for questions and to provide comments/suggestions for future enhancements to this document.

### Glossary of Terms in Modular Program 3\*

**Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the "RxAmt" value in the MSCDM.

**Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

**Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA).

**Cohort Definition (drug/exposure)**- Indicates how the cohort will be defined: (1) 01: Cohort includes only the first valid incident treatment episode during the query period; (2) 02: Cohort includes all valid incident treatment episodes during the query period; (3) 03: Cohort includes all valid incident treatment episodes during the query period until an event occurs

**Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.

**Eligible Members** - Number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

**Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

**Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

**Event Deduplication** - specifies how events are counted by the MP algorithm.

**Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode.

**Lookback Period (pre-existing condition)** - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

**Member-Years** - sum of all days of enrollment with medical and drug coverage\*\* in the query period preceded by an exposure washout period all divided by 365.23.

**Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered

**Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered

**New Episodes** - new treatment episodes; length of episode is determined by days supplied in one dispensing (or consecutive dispensings bridged by the episode gap).

**New Users** - number of members with incident exposure during the query period. Member must have no evidence of exposure (s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.

**Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. YES will only consider diagnoses flagged as Principal

**Query Period** - period in which the modular program looks for exposures and outcomes of interest.

**Treatment Episode Truncation Indicator** - indicates whether observation of the incident query code during follow-up requires truncation of valid treatment episodes. A value of Y indicates that the treatment episodes should be truncated at the first occurrence of an incident query code. A value of N indicates that the treatment episodes should not be truncated at the occurrence of the incident query code.

**Washout Period (drug/exposure)\*\*** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

**Washout Period (event/outcome)\*\*** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

**Years at Risk** - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.23.

\*all terms may not be used in this report

\*\*incident treatment episodes must be incident to both the exposure and the event

**Table 1: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product and Incidence Criteria**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
<b>Amitriptyline</b>												
Incident with Respect to Itself	1,043,720	1,043,720	2,467,102	90,329,053	139,304,336	250,993.0	93,040,149	239,741,378.1	11.22	86.55	2.36	36.61
Incident with Respect to All Cyclics	1,000,616	1,000,616	2,314,321	84,125,398	128,413,239	233,816.3	92,819,608	237,756,042.6	10.78	84.07	2.31	36.35
<b>Amoxapine</b>												
Incident with Respect to Itself	1,031	1,031	3,104	104,040	418,748	288.8	93,264,553	243,658,425.4	0.01	100.91	3.01	33.52
Incident with Respect to All Cyclics	749	749	2,238	76,332	363,834	211.7	92,819,619	239,596,710.6	0.01	101.91	2.99	34.11
<b>Citalopram</b>												
Incident with Respect to Itself	2,101,536	2,101,536	7,326,995	278,632,558	303,974,484	777,972.2	92,791,916	237,903,592.9	22.65	132.59	3.49	38.03
Incident with Respect to All SSRIs	1,678,905	1,678,905	5,557,270	207,158,084	223,138,166	578,588.4	90,512,390	226,046,422.2	18.55	123.39	3.31	37.28
<b>Clomipramine</b>												
Incident with Respect to Itself	18,818	18,818	61,905	2,046,439	4,819,397	5,697.9	93,258,342	243,593,174.8	0.20	108.75	3.29	33.06
Incident with Respect to All Cyclics	16,345	16,345	51,636	1,701,320	4,004,315	4,740.6	92,819,619	239,574,419.1	0.18	104.09	3.16	32.95
<b>Desipramine</b>												
Incident with Respect to Itself	45,812	45,812	109,907	4,461,588	8,344,901	12,366.0	93,257,043	243,457,135.0	0.49	97.39	2.40	40.59
Incident with Respect to All Cyclics	35,196	35,196	81,196	3,217,627	5,927,993	8,925.6	92,819,619	239,513,639.7	0.38	91.42	2.31	39.63
<b>Desvenlafaxine</b>												
Incident with Respect to Itself	200,436	200,436	889,792	29,173,395	29,840,463	82,139.6	93,231,390	243,273,719.9	2.15	145.55	4.44	32.79
Incident with Respect to All SNRIs	158,467	158,467	667,665	21,675,116	22,066,211	61,108.1	92,563,511	239,994,757.7	1.71	136.78	4.21	32.46
<b>Doxepin</b>												
Incident with Respect to Itself	211,256	211,256	440,706	14,818,841	25,044,362	41,144.0	93,231,669	242,932,296.5	2.27	70.15	2.09	33.63
Incident with Respect to All Cyclics	187,245	187,245	368,942	12,224,291	20,122,864	33,951.5	92,819,619	239,263,159.6	2.02	65.29	1.97	33.13
<b>Duloxetine</b>												
Incident with Respect to Itself	727,543	727,543	2,896,756	100,983,672	122,449,790	282,479.4	93,021,782	241,662,175.5	7.82	138.80	3.98	34.86
Incident with Respect to All SNRIs	661,759	661,759	2,545,472	88,160,415	105,559,113	246,719.2	92,563,511	239,543,319.6	7.15	133.22	3.85	34.63
<b>Escitalopram</b>												
Incident with Respect to Itself	1,358,122	1,358,122	4,807,044	161,071,953	175,077,384	451,832.1	92,792,043	239,488,653.3	14.64	118.60	3.54	33.51
Incident with Respect to All SSRIs	1,092,785	1,092,785	3,689,315	122,726,188	130,717,185	344,462.3	90,512,390	226,545,175.3	12.07	112.31	3.38	33.27
<b>Fluoxetine</b>												
Incident with Respect to Itself	1,776,064	1,776,064	6,377,318	274,869,581	371,977,167	764,167.0	92,742,587	236,569,046.8	19.15	154.76	3.59	43.10
Incident with Respect to All SSRIs	1,507,773	1,507,773	5,198,117	227,515,551	302,518,077	632,491.8	90,512,390	225,291,193.1	16.66	150.90	3.45	43.77
<b>Fluvoxamine</b>												
Incident with Respect to Itself	46,222	46,222	177,122	6,049,436	10,779,957	16,875.8	93,247,869	243,491,161.7	0.50	130.88	3.83	34.15
Incident with Respect to All SSRIs	25,233	25,233	90,953	3,060,117	5,269,592	8,546.8	90,512,390	227,433,497.2	0.28	121.27	3.60	33.65

**Table 1: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product and Incidence Criteria**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
<b>Imipramine</b>												
Incident with Respect to Itself	124,257	124,257	325,915	13,075,597	23,479,594	36,261.5	93,237,962	243,076,302.1	1.33	105.23	2.62	40.12
Incident with Respect to All Cyclics	112,231	112,231	286,325	11,443,281	19,927,889	31,753.3	92,819,619	239,320,014.3	1.21	101.96	2.55	39.97
<b>Levomilnacipran</b>												
Incident with Respect to Itself	0	0	0	0	0	0.0	93,265,154	243,664,189.6	0.00	---	---	---
Incident with Respect to All SNRIs	0	0	0	0	0	0.0	92,563,511	240,081,783.3	0.00	---	---	---
<b>Maprotiline</b>												
Incident with Respect to Itself	823	823	2,558	88,380	193,709	246.0	93,264,529	243,659,216.1	0.01	107.39	3.11	34.55
Incident with Respect to All Cyclics	580	580	1,737	60,925	131,798	169.8	92,819,619	239,597,236.5	0.01	105.04	2.99	35.07
<b>Mirtazapine</b>												
Incident with Respect to Itself	480,030	480,030	1,589,433	54,171,869	61,242,676	150,409.6	93,193,813	242,325,286.9	5.15	112.85	3.31	34.08
Incident with Respect to All Cyclics	438,138	438,138	1,401,530	47,386,009	52,606,747	131,610.9	92,819,619	239,039,991.9	4.72	108.15	3.20	33.81
<b>Nefazodone</b>												
Incident with Respect to Itself	34,665	34,665	105,350	4,050,400	9,156,067	11,269.6	93,253,451	243,433,361.2	0.37	116.84	3.04	38.45
Incident with Respect to Miscellaneous Anti-Depressants	28,860	28,860	83,790	3,180,563	7,163,690	8,857.8	92,928,741	240,689,963.1	0.31	110.21	2.90	37.96
<b>Nortriptyline</b>												
Incident with Respect to Itself	639,138	639,138	1,417,061	62,737,018	123,603,428	173,850.3	93,201,332	241,256,286.4	6.86	98.16	2.22	44.27
Incident with Respect to All Cyclics	588,537	588,537	1,252,437	55,296,546	102,420,711	153,245.0	92,819,619	238,294,169.5	6.34	93.96	2.13	44.15
<b>Paroxetine</b>												
Incident with Respect to Itself	912,188	912,188	3,176,633	121,919,109	126,126,579	339,709.3	92,909,062	239,548,856.6	9.82	133.66	3.48	38.38
Incident with Respect to All SSRIs	741,546	741,546	2,483,569	94,761,957	96,314,927	264,147.4	90,512,390	226,299,942.3	8.19	127.79	3.35	38.16
<b>Protriptyline</b>												
Incident with Respect to Itself	7,493	7,493	18,539	678,986	1,657,228	1,890.8	93,264,023	243,633,974.8	0.08	90.62	2.47	36.62
Incident with Respect to All Cyclics	5,550	5,550	13,042	464,289	1,064,818	1,294.1	92,819,619	239,586,718.5	0.06	83.66	2.35	35.60
<b>Sertraline</b>												
Incident with Respect to Itself	1,924,572	1,924,572	7,018,555	250,546,421	287,726,733	700,105.8	92,537,381	237,446,849.1	20.80	130.18	3.65	35.70
Incident with Respect to All SSRIs	1,598,559	1,598,559	5,612,073	197,008,910	221,646,470	550,875.5	90,512,390	226,055,840.8	17.66	123.24	3.51	35.10
<b>Trazodone</b>												
Incident with Respect to Itself	1,660,781	1,660,781	3,683,751	134,580,988	182,880,036	373,459.0	92,940,532	238,136,174.8	17.87	81.03	2.22	36.53
Incident with Respect to Miscellaneous Anti-Depressants	1,656,475	1,656,475	3,667,302	133,952,601	181,732,604	371,715.0	92,928,741	238,070,676.6	17.83	80.87	2.21	36.53
<b>Trimipramine</b>												
Incident with Respect to Itself	773	773	2,406	88,871	187,289	245.9	93,264,852	243,659,266.3	0.01	114.97	3.11	36.94

**Table 1: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product and Incidence Criteria**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Incident with Respect to All Cyclics	495	495	1,478	52,612	110,512	145.8	92,819,619	239,596,744.6	0.01	106.29	2.99	35.60
<b>Venlafaxine</b>												
Incident with Respect to Itself	825,630	825,630	3,654,190	132,611,288	193,654,833	369,629.6	92,866,229	240,495,665.0	8.89	160.62	4.43	36.29
Incident with Respect to All SNRIs	774,729	774,729	3,394,304	123,261,384	180,344,121	343,590.4	92,563,511	239,046,345.7	8.37	159.10	4.38	36.31
<b>Vilazodone</b>												
Incident with Respect to Itself	38,411	38,411	110,467	3,512,341	3,618,672	9,875.7	93,262,007	243,634,900.3	0.41	91.44	2.88	31.80
Incident with Respect to All SSRIs	20,799	20,799	57,926	1,822,434	1,873,584	5,126.1	90,512,390	227,458,514.8	0.23	87.62	2.79	31.46
<b>Vortioxetine</b>												
Incident with Respect to Itself	0	0	0	0	0	0.0	93,265,154	243,664,189.6	0.00	---	---	---
Incident with Respect to Miscellaneous Anti-Depressants	0	0	0	0	0	0.0	92,928,741	240,792,312.9	0.00	---	---	---

**Table 2: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Age Group**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
<b>Amitriptyline</b>												
Incident with Respect to Itself												
00 to 17 Years	62,238	62,238	137,730	4,649,509	7,170,836	12,998.0	22,942,357	56,589,773.7	2.71	74.71	2.21	33.76
18 to 40 Years	317,959	317,959	637,504	21,160,883	31,632,751	58,910.9	36,968,544	72,638,593.4	8.60	66.55	2.00	33.19
41 to 64 Years	509,041	509,041	1,285,414	47,303,339	75,980,368	131,402.0	32,623,658	84,441,431.2	15.60	92.93	2.53	36.80
65 to 79 Years	123,701	123,701	328,587	14,047,211	20,400,691	38,904.5	7,171,919	19,738,912.8	17.25	113.56	2.66	42.75
80+ Years	30,781	30,781	77,867	3,168,111	4,119,689	8,777.6	2,172,573	6,332,667.0	14.17	102.92	2.53	40.69
Incident with Respect to All Cyclics												
00 to 17 Years	60,811	60,811	132,987	4,478,114	6,861,859	12,521.6	22,934,357	56,497,105.8	2.65	73.64	2.19	33.67
18 to 40 Years	305,808	305,808	601,287	19,817,937	29,328,657	55,186.5	36,922,638	72,280,879.3	8.28	64.81	1.97	32.96
41 to 64 Years	487,040	487,040	1,200,851	43,851,873	69,706,342	121,847.7	32,496,734	83,491,130.0	14.99	90.04	2.47	36.52
65 to 79 Years	117,815	117,815	306,902	13,054,739	18,804,210	36,160.7	7,115,052	19,355,484.3	16.56	110.81	2.60	42.54
80+ Years	29,142	29,142	72,294	2,922,735	3,712,171	8,099.7	2,142,610	6,131,443.2	13.60	100.29	2.48	40.43
<b>Amoxapine</b>												
Incident with Respect to Itself												
00 to 17 Years	36	36	88	2,352	5,107	6.6	22,947,419	56,711,079.5	0.00	65.33	2.44	26.73
18 to 40 Years	304	304	708	21,335	96,587	59.4	37,037,339	73,498,770.7	0.01	70.18	2.33	30.13
41 to 64 Years	548	548	1,810	62,037	285,925	172.2	32,823,255	86,504,705.8	0.02	113.21	3.30	34.27
65 to 79 Years	112	112	400	15,155	27,219	41.8	7,273,853	20,410,718.2	0.02	135.31	3.57	37.89
80+ Years	31	31	98	3,161	3,911	8.8	2,207,497	6,533,151.1	0.01	101.97	3.16	32.26
Incident with Respect to All Cyclics												
00 to 17 Years	31	31	77	1,968	4,438	5.6	22,934,357	56,554,822.4	0.00	63.48	2.48	25.56
18 to 40 Years	222	222	533	15,489	85,372	43.1	36,945,536	72,746,348.5	0.01	69.77	2.40	29.06
41 to 64 Years	378	378	1,209	42,558	247,270	118.1	32,547,827	84,438,958.3	0.01	112.59	3.20	35.20
65 to 79 Years	96	96	285	11,373	21,309	31.4	7,150,009	19,630,340.3	0.01	118.47	2.97	39.91
80+ Years	22	22	134	4,944	5,445	13.6	2,160,375	6,226,241.1	0.01	224.73	6.09	36.90
<b>Citalopram</b>												
Incident with Respect to Itself												
00 to 17 Years	96,933	96,933	338,455	11,508,620	14,970,612	32,219.0	22,935,089	56,535,344.7	4.23	118.73	3.49	34.00
18 to 40 Years	787,525	787,525	2,293,588	79,821,085	86,834,756	223,926.7	36,833,306	71,698,965.2	21.38	101.36	2.91	34.80
41 to 64 Years	902,180	902,180	3,372,703	130,577,891	142,186,177	364,564.1	32,465,392	83,703,686.8	27.79	144.74	3.74	38.72
65 to 79 Years	217,714	217,714	873,333	39,010,432	41,516,757	108,199.7	7,158,036	19,718,499.6	30.42	179.18	4.01	44.67

**Table 2: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Age Group**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
80+ Years	97,184	97,184	448,916	17,714,530	18,466,181	49,062.6	2,160,202	6,247,096.7	44.99	182.28	4.62	39.46
Incident with Respect to All SSRIs												
00 to 17 Years	74,160	74,160	249,090	8,262,015	10,806,607	23,154.6	22,840,931	55,997,330.9	3.25	111.41	3.36	33.17
18 to 40 Years	640,133	640,133	1,793,395	61,442,669	65,985,404	172,406.9	36,055,613	68,371,834.1	17.75	95.98	2.80	34.26
41 to 64 Years	715,112	715,112	2,529,880	95,900,139	102,825,689	267,822.6	31,131,484	77,622,005.3	22.97	134.11	3.54	37.91
65 to 79 Years	171,160	171,160	642,203	28,154,978	29,609,213	78,097.4	6,828,794	18,313,813.8	25.06	164.50	3.75	43.84
80+ Years	78,340	78,340	342,702	13,398,283	13,911,252	37,106.9	2,054,190	5,741,438.2	38.14	171.03	4.37	39.10
<b>Clomipramine</b>												
Incident with Respect to Itself												
00 to 17 Years	1,959	1,959	8,485	275,948	592,355	767.5	22,946,964	56,706,093.4	0.09	140.86	4.33	32.52
18 to 40 Years	8,685	8,685	25,568	808,760	2,071,125	2,256.7	37,034,285	73,474,327.7	0.23	93.12	2.94	31.63
41 to 64 Years	7,235	7,235	24,476	836,565	1,930,236	2,326.6	32,818,501	86,473,318.0	0.22	115.63	3.38	34.18
65 to 79 Years	804	804	2,826	104,550	196,442	290.1	7,272,989	20,406,802.4	0.11	130.04	3.51	37.00
80+ Years	135	135	550	20,616	29,239	57.1	2,207,415	6,532,633.2	0.06	152.71	4.07	37.48
Incident with Respect to All Cyclics												
00 to 17 Years	1,778	1,778	7,709	249,437	516,692	694.1	22,934,357	56,553,102.1	0.08	140.29	4.34	32.36
18 to 40 Years	7,740	7,740	22,032	696,623	1,800,868	1,944.6	36,944,998	72,736,881.3	0.21	90.00	2.85	31.62
41 to 64 Years	6,099	6,099	19,480	666,048	1,523,766	1,854.4	32,547,064	84,429,183.8	0.19	109.21	3.19	34.19
65 to 79 Years	624	624	2,009	73,478	140,390	204.1	7,149,771	19,629,198.8	0.09	117.75	3.22	36.57
80+ Years	104	104	406	15,734	22,600	43.5	2,160,343	6,226,053.2	0.05	151.29	3.90	38.75
<b>Desipramine</b>												
Incident with Respect to Itself												
00 to 17 Years	1,072	1,072	2,649	91,287	187,795	254.6	22,947,290	56,708,282.8	0.05	85.16	2.47	34.46
18 to 40 Years	13,067	13,067	27,751	1,022,867	1,872,259	2,842.0	37,035,003	73,461,108.8	0.35	78.28	2.12	36.86
41 to 64 Years	23,185	23,185	59,511	2,427,196	4,667,868	6,726.2	32,815,183	86,394,966.4	0.71	104.69	2.57	40.79
65 to 79 Years	6,539	6,539	15,651	725,038	1,329,721	2,003.1	7,269,550	20,373,095.5	0.90	110.88	2.39	46.33
80+ Years	1,949	1,949	4,345	195,200	287,259	540.0	2,205,651	6,519,681.6	0.88	100.15	2.23	44.93
Incident with Respect to All Cyclics												
00 to 17 Years	852	852	2,040	69,376	147,173	193.8	22,934,357	56,553,737.1	0.04	81.43	2.39	34.01
18 to 40 Years	10,190	10,190	20,831	755,304	1,367,114	2,099.9	36,945,100	72,730,183.6	0.28	74.12	2.04	36.26
41 to 64 Years	17,715	17,715	43,719	1,738,370	3,261,106	4,822.2	32,545,813	84,395,465.3	0.54	98.13	2.47	39.76
65 to 79 Years	4,919	4,919	11,318	510,758	944,240	1,411.6	7,148,224	19,614,734.5	0.69	103.83	2.30	45.13



**Table 2: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Age Group**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
80+ Years	1,520	1,520	3,288	143,819	208,361	398.1	2,159,315	6,219,519.1	0.70	94.62	2.16	43.74
<b>Desvenlafaxine</b>												
Incident with Respect to Itself												
00 to 17 Years	2,649	2,649	9,869	311,547	319,492	878.6	22,947,190	56,708,474.5	0.12	117.61	3.73	31.57
18 to 40 Years	79,542	79,542	314,384	9,784,160	9,985,330	27,655.4	37,022,274	73,365,537.6	2.15	123.01	3.95	31.12
41 to 64 Years	108,470	108,470	524,618	17,571,202	17,989,206	49,402.8	32,793,616	86,278,004.8	3.31	161.99	4.84	33.49
65 to 79 Years	8,319	8,319	34,512	1,282,217	1,317,640	3,576.9	7,269,694	20,391,764.5	1.14	154.13	4.15	37.15
80+ Years	1,456	1,456	6,409	224,269	228,794	625.9	2,206,944	6,529,938.4	0.66	154.03	4.40	34.99
Incident with Respect to All SNRIs												
00 to 17 Years	2,331	2,331	8,612	271,240	278,083	765.1	22,941,575	56,674,008.0	0.10	116.36	3.69	31.50
18 to 40 Years	65,841	65,841	249,049	7,707,552	7,839,214	21,808.4	36,827,858	72,553,029.1	1.79	117.06	3.78	30.95
41 to 64 Years	82,896	82,896	380,590	12,621,882	12,852,498	35,534.3	32,329,384	84,257,522.1	2.56	152.26	4.59	33.16
65 to 79 Years	6,232	6,232	24,432	903,054	921,920	2,522.0	7,187,036	20,060,398.7	0.87	144.91	3.92	36.96
80+ Years	1,167	1,167	4,982	171,388	174,496	478.3	2,190,605	6,449,799.8	0.53	146.86	4.27	34.40
<b>Doxepin</b>												
Incident with Respect to Itself												
00 to 17 Years	5,735	5,735	10,429	320,373	577,877	890.5	22,947,066	56,699,933.8	0.25	55.86	1.82	30.72
18 to 40 Years	59,611	59,611	104,722	3,156,158	5,453,536	8,772.8	37,029,596	73,352,632.7	1.61	52.95	1.76	30.14
41 to 64 Years	108,810	108,810	239,354	8,052,046	14,103,944	22,359.9	32,791,906	86,111,405.9	3.32	74.00	2.20	33.64
65 to 79 Years	28,099	28,099	64,902	2,514,297	3,827,586	6,968.5	7,255,069	20,281,702.2	3.87	89.48	2.31	38.74
80+ Years	9,001	9,001	21,299	775,967	1,081,419	2,152.4	2,199,820	6,486,621.9	4.09	86.21	2.37	36.43
Incident with Respect to All Cyclics												
00 to 17 Years	5,260	5,260	9,046	273,724	494,987	761.1	22,934,357	56,549,099.3	0.23	52.04	1.72	30.26
18 to 40 Years	52,853	52,853	88,172	2,617,349	4,448,705	7,276.4	36,943,430	72,670,762.1	1.43	49.52	1.67	29.68
41 to 64 Years	95,908	95,908	197,689	6,541,917	11,028,772	18,173.6	32,538,908	84,260,434.4	2.95	68.21	2.06	33.09
65 to 79 Years	25,106	25,106	55,482	2,118,242	3,215,803	5,873.2	7,143,251	19,577,338.4	3.51	84.37	2.21	38.18
80+ Years	8,118	8,118	18,553	673,059	934,597	1,867.2	2,156,810	6,205,525.3	3.76	82.91	2.29	36.28
<b>Duloxetine</b>												
Incident with Respect to Itself												
00 to 17 Years	10,995	10,995	40,591	1,340,022	1,625,277	3,746.6	22,945,571	56,695,564.0	0.48	121.88	3.69	33.01
18 to 40 Years	215,547	215,547	740,195	23,968,067	28,843,018	67,366.3	36,965,890	73,018,122.0	5.83	111.20	3.43	32.38
41 to 64 Years	405,794	405,794	1,744,701	61,915,081	75,930,823	173,093.6	32,626,263	85,288,984.2	12.44	152.58	4.30	35.49

**Table 2: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Age Group**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
65 to 79 Years	73,807	73,807	282,176	10,758,657	12,652,026	29,937.5	7,228,441	20,188,401.1	10.21	145.77	3.82	38.13
80+ Years	21,400	21,400	89,093	3,001,845	3,398,646	8,335.4	2,195,897	6,471,104.2	9.75	140.27	4.16	33.69
Incident with Respect to All SNRIs												
00 to 17 Years	10,341	10,341	37,575	1,234,822	1,490,405	3,454.0	22,941,575	56,670,361.2	0.45	119.41	3.63	32.86
18 to 40 Years	195,362	195,362	648,603	20,872,203	24,849,748	58,695.1	36,824,504	72,441,263.6	5.31	106.84	3.32	32.18
41 to 64 Years	366,205	366,205	1,516,108	53,407,030	64,573,680	149,390.3	32,313,515	84,000,723.9	11.33	145.84	4.14	35.23
65 to 79 Years	69,245	69,245	258,826	9,821,798	11,463,266	27,335.3	7,178,032	20,002,208.3	9.65	141.84	3.74	37.95
80+ Years	20,606	20,606	84,360	2,824,562	3,182,016	7,844.5	2,186,354	6,428,762.6	9.42	137.07	4.09	33.48
<b>Escitalopram</b>												
Incident with Respect to Itself												
00 to 17 Years	69,759	69,759	243,906	7,762,759	9,862,117	21,806.9	22,933,481	56,587,928.9	3.04	111.28	3.50	31.83
18 to 40 Years	544,037	544,037	1,657,280	52,773,949	57,293,197	148,676.1	36,831,249	72,093,398.3	14.77	97.00	3.05	31.84
41 to 64 Years	595,381	595,381	2,313,580	79,694,697	85,917,023	223,325.2	32,479,364	84,357,159.5	18.33	133.85	3.89	34.45
65 to 79 Years	103,219	103,219	388,325	14,162,536	15,178,852	39,443.1	7,204,128	20,062,806.4	14.33	137.21	3.76	36.47
80+ Years	45,726	45,726	203,953	6,678,012	6,826,194	18,580.7	2,179,958	6,387,360.2	20.98	146.04	4.46	32.74
Incident with Respect to All SSRIs												
00 to 17 Years	52,361	52,361	172,491	5,410,462	6,762,663	15,214.6	22,840,931	56,014,151.8	2.29	103.33	3.29	31.37
18 to 40 Years	443,074	443,074	1,296,300	40,927,575	43,445,690	115,374.5	36,062,636	68,512,822.4	12.29	92.37	2.93	31.57
41 to 64 Years	479,211	479,211	1,769,961	60,589,594	64,066,479	169,879.0	31,146,225	77,841,721.3	15.39	126.44	3.69	34.23
65 to 79 Years	81,484	81,484	291,547	10,598,082	11,185,040	29,526.7	6,839,640	18,397,607.9	11.91	130.06	3.58	36.35
80+ Years	36,655	36,655	159,016	5,200,475	5,257,313	14,467.5	2,061,600	5,778,871.9	17.78	141.88	4.34	32.70
<b>Fluoxetine</b>												
Incident with Respect to Itself												
00 to 17 Years	170,917	170,917	641,876	23,496,053	33,516,765	65,518.9	22,918,358	56,355,942.1	7.46	137.47	3.76	36.61
18 to 40 Years	677,960	677,960	2,051,852	79,689,356	107,971,074	222,273.0	36,794,964	71,425,124.4	18.43	117.54	3.03	38.84
41 to 64 Years	726,277	726,277	2,887,361	129,339,016	178,123,348	359,328.0	32,397,562	82,979,629.3	22.42	178.08	3.98	44.79
65 to 79 Years	146,649	146,649	586,583	31,666,035	40,033,580	87,546.5	7,143,086	19,572,963.2	20.53	215.93	4.00	53.98
80+ Years	54,261	54,261	209,646	10,679,121	12,332,400	29,500.6	2,161,435	6,235,387.9	25.10	196.81	3.86	50.94
Incident with Respect to All SSRIs												
00 to 17 Years	146,551	146,551	523,569	19,172,228	27,188,769	53,487.2	22,840,931	55,946,160.9	6.42	130.82	3.57	36.62
18 to 40 Years	569,389	569,389	1,644,293	64,695,423	86,025,525	180,429.0	36,028,361	68,162,395.2	15.80	113.62	2.89	39.35
41 to 64 Years	618,647	618,647	2,364,079	107,706,838	145,507,301	299,235.6	31,108,378	77,265,565.3	19.89	174.10	3.82	45.56

**Table 2: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Age Group**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
65 to 79 Years	125,503	125,503	486,543	26,686,443	33,193,816	73,776.2	6,814,936	18,215,961.0	18.42	212.64	3.88	54.85
80+ Years	47,683	47,683	179,633	9,254,619	10,602,666	25,563.9	2,047,740	5,701,110.7	23.29	194.09	3.77	51.52
<b>Fluvoxamine</b>												
Incident with Respect to Itself												
00 to 17 Years	7,816	7,816	37,853	1,259,930	2,185,728	3,515.7	22,945,105	56,689,590.4	0.34	161.20	4.84	33.28
18 to 40 Years	21,111	21,111	74,980	2,451,966	4,431,739	6,857.1	37,026,560	73,431,262.2	0.57	116.15	3.55	32.70
41 to 64 Years	15,297	15,297	56,714	2,048,941	3,699,712	5,703.3	32,813,150	86,435,713.5	0.47	133.94	3.71	36.13
65 to 79 Years	1,579	1,579	5,789	230,464	385,536	638.3	7,272,192	20,402,790.1	0.22	145.96	3.67	39.81
80+ Years	419	419	1,786	58,135	77,243	161.3	2,207,255	6,531,805.5	0.19	138.75	4.26	32.55
Incident with Respect to All SSRIs												
00 to 17 Years	4,178	4,178	18,839	610,026	1,013,391	1,703.4	22,840,931	56,035,141.5	0.18	146.01	4.51	32.38
18 to 40 Years	11,711	11,711	39,796	1,287,364	2,234,246	3,606.2	36,080,209	68,858,261.4	0.32	109.93	3.40	32.35
41 to 64 Years	8,259	8,259	28,311	1,011,564	1,791,042	2,818.5	31,185,131	78,272,840.9	0.26	122.48	3.43	35.73
65 to 79 Years	844	844	2,985	118,573	187,075	328.2	6,851,230	18,461,501.8	0.12	140.49	3.54	39.72
80+ Years	241	241	1,022	32,590	43,838	90.5	2,067,045	5,805,751.7	0.12	135.23	4.24	31.89
<b>Imipramine</b>												
Incident with Respect to Itself												
00 to 17 Years	27,148	27,148	72,777	2,432,184	3,875,380	6,792.8	22,944,902	56,606,972.2	1.18	89.59	2.68	33.42
18 to 40 Years	26,403	26,403	59,521	2,162,008	4,410,183	5,993.8	37,025,186	73,398,186.2	0.71	81.88	2.25	36.32
41 to 64 Years	46,089	46,089	128,136	5,347,914	10,413,124	14,806.6	32,801,271	86,272,617.7	1.41	116.03	2.78	41.74
65 to 79 Years	18,446	18,446	50,153	2,420,007	3,776,401	6,694.0	7,261,196	20,307,003.9	2.54	131.19	2.72	48.25
80+ Years	6,171	6,171	15,328	713,484	1,004,506	1,974.3	2,201,358	6,491,522.1	2.80	115.62	2.48	46.55
Incident with Respect to All Cyclics												
00 to 17 Years	26,381	26,381	69,591	2,322,174	3,665,899	6,488.1	22,934,357	56,492,833.8	1.15	88.02	2.64	33.37
18 to 40 Years	23,090	23,090	50,162	1,816,999	3,503,413	5,040.5	36,938,168	72,691,506.8	0.63	78.69	2.17	36.22
41 to 64 Years	40,291	40,291	108,312	4,518,431	8,553,069	12,516.6	32,543,266	84,344,913.0	1.24	112.14	2.69	41.72
65 to 79 Years	16,776	16,776	44,429	2,146,335	3,305,363	5,938.6	7,145,570	19,586,595.1	2.35	127.94	2.65	48.31
80+ Years	5,693	5,693	13,831	639,342	900,145	1,769.5	2,156,646	6,204,165.6	2.64	112.30	2.43	46.23
<b>Levomilnacipran</b>												
Incident with Respect to Itself												
00 to 17 Years	0	0	0	0	0	0.0	22,947,425	56,711,179.7	0.00	---	---	---
18 to 40 Years	0	0	0	0	0	0.0	37,037,394	73,499,829.0	0.00	---	---	---

**Table 2: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Age Group**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
41 to 64 Years	0	0	0	0	0	0.0	32,823,681	86,507,874.1	0.00	---	---	---
65 to 79 Years	0	0	0	0	0	0.0	7,274,113	20,411,789.5	0.00	---	---	---
80+ Years	0	0	0	0	0	0.0	2,207,605	6,533,517.2	0.00	---	---	---
Incident with Respect to All SNRIs												
00 to 17 Years	0	0	0	0	0	0.0	22,941,575	56,674,571.3	0.00	---	---	---
18 to 40 Years	0	0	0	0	0	0.0	36,828,672	72,585,527.2	0.00	---	---	---
41 to 64 Years	0	0	0	0	0	0.0	32,334,147	84,306,029.2	0.00	---	---	---
65 to 79 Years	0	0	0	0	0	0.0	7,188,153	20,064,948.6	0.00	---	---	---
80+ Years	0	0	0	0	0	0.0	2,190,829	6,450,706.9	0.00	---	---	---
<b>Maprotiline</b>												
Incident with Respect to Itself												
00 to 17 Years	8	8	42	1,260	1,920	3.6	22,947,423	56,711,152.0	0.00	157.50	5.25	30.00
18 to 40 Years	200	200	540	16,352	40,981	45.9	37,037,348	73,499,274.6	0.01	81.76	2.70	30.28
41 to 64 Years	469	469	1,589	54,436	123,087	151.3	32,823,245	86,505,081.5	0.01	116.07	3.39	34.26
65 to 79 Years	120	120	334	14,261	24,330	39.4	7,273,843	20,410,579.5	0.02	118.84	2.78	42.70
80+ Years	26	26	53	2,071	3,392	5.8	2,207,512	6,533,128.5	0.01	79.65	2.04	39.08
Incident with Respect to All Cyclics												
00 to 17 Years	7	7	41	1,230	1,890	3.5	22,934,357	56,554,858.8	0.00	175.71	5.86	30.00
18 to 40 Years	141	141	333	10,167	25,985	28.6	36,945,544	72,746,601.6	0.00	72.11	2.36	30.53
41 to 64 Years	319	319	1,062	35,990	81,933	100.2	32,547,834	84,439,196.8	0.01	112.82	3.33	33.89
65 to 79 Years	93	93	254	11,706	18,848	32.4	7,150,017	19,630,317.1	0.01	125.87	2.73	46.09
80+ Years	20	20	47	1,832	3,143	5.1	2,160,383	6,226,262.2	0.01	91.60	2.35	38.98
<b>Mirtazapine</b>												
Incident with Respect to Itself												
00 to 17 Years	28,614	28,614	91,327	2,826,868	3,231,958	7,886.9	22,944,380	56,641,932.5	1.25	98.79	3.19	30.95
18 to 40 Years	114,992	114,992	281,220	8,794,774	11,234,755	24,481.4	37,012,280	73,192,714.6	3.11	76.48	2.45	31.27
41 to 64 Years	176,944	176,944	576,108	19,738,091	23,937,569	54,794.1	32,769,944	85,920,865.6	5.40	111.55	3.26	34.26
65 to 79 Years	79,511	79,511	297,298	11,086,633	11,577,659	30,726.7	7,247,398	20,215,540.2	10.97	139.44	3.74	37.29
80+ Years	79,969	79,969	343,480	11,725,503	11,260,736	32,520.5	2,181,254	6,354,234.2	36.66	146.63	4.30	34.14
Incident with Respect to All Cyclics												
00 to 17 Years	27,366	27,366	86,278	2,664,187	3,037,440	7,434.0	22,934,357	56,522,612.5	1.19	97.35	3.15	30.88
18 to 40 Years	104,892	104,892	246,543	7,666,240	9,756,188	21,346.1	36,935,437	72,589,033.2	2.84	73.09	2.35	31.09

**Table 2: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Age Group**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
41 to 64 Years	157,433	157,433	484,421	16,470,000	19,500,189	45,744.5	32,532,271	84,188,197.7	4.84	104.62	3.08	34.00
65 to 79 Years	72,508	72,508	262,020	9,664,257	9,959,573	26,792.5	7,142,306	19,566,102.4	10.15	133.29	3.61	36.88
80+ Years	75,939	75,939	322,268	10,921,325	10,353,357	30,293.8	2,152,978	6,174,046.1	35.27	143.82	4.24	33.89
<b>Nefazodone</b>												
Incident with Respect to Itself												
00 to 17 Years	805	805	2,058	68,750	126,154	191.5	22,947,319	56,708,928.4	0.04	85.40	2.56	33.41
18 to 40 Years	13,059	13,059	34,416	1,231,283	2,927,369	3,436.0	37,034,092	73,442,593.3	0.35	94.29	2.64	35.78
41 to 64 Years	18,353	18,353	61,572	2,441,500	5,542,816	6,785.6	32,809,915	86,360,615.5	0.56	133.03	3.35	39.65
65 to 79 Years	2,018	2,018	6,062	258,542	481,389	717.0	7,270,519	20,391,379.3	0.28	128.12	3.00	42.65
80+ Years	430	430	1,242	50,325	78,340	139.5	2,206,982	6,529,844.6	0.19	117.03	2.89	40.52
Incident with Respect to Miscellaneous Anti-Depressants												
00 to 17 Years	698	698	1,755	58,715	109,293	163.6	22,939,233	56,627,511.1	0.03	84.12	2.51	33.46
18 to 40 Years	11,020	11,020	27,902	988,626	2,213,898	2,761.8	36,958,649	72,875,644.8	0.30	89.71	2.53	35.43
41 to 64 Years	15,084	15,084	48,116	1,880,702	4,391,302	5,231.8	32,589,481	84,833,197.5	0.46	124.68	3.19	39.09
65 to 79 Years	1,690	1,690	4,967	209,664	383,803	582.0	7,202,030	19,975,890.1	0.23	124.06	2.94	42.21
80+ Years	368	368	1,050	42,856	65,394	118.6	2,186,393	6,377,719.7	0.17	116.46	2.85	40.82
<b>Nortriptyline</b>												
Incident with Respect to Itself												
00 to 17 Years	17,565	17,565	38,832	1,317,207	3,039,820	3,680.7	22,946,053	56,673,631.1	0.77	74.99	2.21	33.92
18 to 40 Years	176,288	176,288	339,458	13,220,970	32,101,279	36,722.4	37,012,994	73,032,577.8	4.76	75.00	1.93	38.95
41 to 64 Years	317,062	317,062	733,545	32,639,715	61,168,992	90,434.1	32,747,831	85,262,577.8	9.68	102.94	2.31	44.50
65 to 79 Years	99,244	99,244	237,915	12,325,601	22,065,702	34,073.5	7,222,953	19,931,047.5	13.74	124.19	2.40	51.81
80+ Years	28,979	28,979	67,311	3,233,525	5,227,634	8,939.6	2,181,729	6,356,452.1	13.28	111.58	2.32	48.04
Incident with Respect to All Cyclics												
00 to 17 Years	16,086	16,086	34,915	1,178,419	2,741,493	3,293.9	22,934,357	56,536,611.4	0.70	73.26	2.17	33.75
18 to 40 Years	163,570	163,570	306,464	11,947,826	22,142,955	33,186.0	36,938,502	72,493,080.2	4.43	73.04	1.87	38.99
41 to 64 Years	292,442	292,442	650,037	28,906,514	54,141,055	80,097.3	32,517,335	83,773,946.3	8.99	98.85	2.22	44.47
65 to 79 Years	90,195	90,195	203,774	10,495,318	18,891,525	29,015.1	7,119,871	19,368,143.1	12.67	116.36	2.26	51.50
80+ Years	26,244	26,244	57,247	2,768,469	4,503,684	7,652.6	2,142,629	6,122,388.5	12.25	105.49	2.18	48.36
<b>Paroxetine</b>												
Incident with Respect to Itself												
00 to 17 Years	38,873	38,873	123,880	4,227,632	5,063,625	11,823.7	22,941,417	56,608,202.6	1.69	108.75	3.19	34.13

**Table 2: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Age Group**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
18 to 40 Years	351,412	351,412	1,026,214	36,076,258	38,079,818	100,911.6	36,913,559	72,320,364.4	9.52	102.66	2.92	35.15
41 to 64 Years	389,064	389,064	1,501,655	58,504,047	61,075,080	162,943.2	32,548,457	84,446,922.3	11.95	150.37	3.86	38.96
65 to 79 Years	95,928	95,928	373,451	16,841,600	16,050,523	46,666.9	7,176,498	19,854,046.1	13.37	175.57	3.89	45.10
80+ Years	36,911	36,911	151,433	6,269,572	5,857,533	17,363.9	2,168,265	6,319,321.2	17.02	169.86	4.10	41.40
<b>Incident with Respect to All SSRIs</b>												
00 to 17 Years	30,703	30,703	92,909	3,139,102	3,760,326	8,784.5	22,840,931	56,004,258.9	1.34	102.24	3.03	33.79
18 to 40 Years	283,501	283,501	797,876	27,803,418	28,863,503	77,810.5	36,064,763	68,483,299.1	7.86	98.07	2.81	34.85
41 to 64 Years	317,569	317,569	1,177,149	45,641,826	46,626,007	127,176.6	31,144,505	77,730,517.5	10.20	143.72	3.71	38.77
65 to 79 Years	79,083	79,083	294,621	13,196,919	12,473,392	36,577.6	6,832,610	18,330,191.9	11.57	166.87	3.73	44.79
80+ Years	30,690	30,690	121,014	4,980,692	4,591,699	13,798.2	2,056,625	5,751,674.9	14.92	162.29	3.94	41.16
<b>Protriptyline</b>												
<b>Incident with Respect to Itself</b>												
00 to 17 Years	352	352	816	27,813	67,679	77.6	22,947,404	56,710,632.2	0.02	79.01	2.32	34.08
18 to 40 Years	2,700	2,700	6,569	224,821	532,322	627.3	37,036,788	73,491,714.3	0.07	83.27	2.43	34.22
41 to 64 Years	3,839	3,839	9,613	363,735	920,661	1,011.9	32,822,374	86,490,431.8	0.12	94.75	2.50	37.84
65 to 79 Years	523	523	1,291	54,048	122,112	149.9	7,273,618	20,408,386.7	0.07	103.34	2.47	41.87
80+ Years	79	79	250	8,569	14,455	24.1	2,207,477	6,532,809.7	0.04	108.47	3.16	34.28
<b>Incident with Respect to All Cyclics</b>												
00 to 17 Years	254	254	557	19,122	44,791	53.2	22,934,357	56,554,697.2	0.01	75.28	2.19	34.33
18 to 40 Years	1,988	1,988	4,608	155,809	357,982	435.0	36,945,404	72,743,678.9	0.05	78.37	2.32	33.81
41 to 64 Years	2,864	2,864	6,888	249,980	572,371	696.5	32,547,525	84,433,175.9	0.09	87.28	2.41	36.29
65 to 79 Years	387	387	863	34,970	83,716	97.0	7,149,817	19,629,157.3	0.05	90.36	2.23	40.52
80+ Years	57	57	126	4,408	5,958	12.3	2,160,333	6,226,009.1	0.03	77.33	2.21	34.98
<b>Sertraline</b>												
<b>Incident with Respect to Itself</b>												
00 to 17 Years	168,765	168,765	670,404	22,029,714	26,501,578	61,683.4	22,910,745	56,352,682.3	7.37	130.53	3.97	32.86
18 to 40 Years	801,590	801,590	2,532,575	85,460,561	97,991,283	239,666.9	36,715,341	71,363,390.5	21.83	106.61	3.16	33.74
41 to 64 Years	717,890	717,890	2,839,974	103,959,346	120,739,684	290,290.9	32,337,750	83,670,901.2	22.20	144.81	3.96	36.61
65 to 79 Years	163,613	163,613	655,557	27,109,180	30,067,896	75,228.8	7,145,044	19,781,183.1	22.90	165.69	4.01	41.35
80+ Years	72,714	72,714	320,045	11,987,620	12,426,293	33,235.7	2,157,699	6,278,691.9	33.70	164.86	4.40	37.46
<b>Incident with Respect to All SSRIs</b>												
00 to 17 Years	141,504	141,504	546,985	17,629,745	20,903,059	49,408.0	22,840,931	55,950,497.1	6.20	124.59	3.87	32.23

**Table 2: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Age Group**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
18 to 40 Years	671,432	671,432	2,046,849	68,166,671	76,667,638	191,277.5	36,039,147	68,292,084.1	18.63	101.52	3.05	33.30
41 to 64 Years	590,539	590,539	2,244,782	80,802,346	91,597,880	225,789.8	31,132,367	77,709,202.6	18.97	136.83	3.80	36.00
65 to 79 Years	133,839	133,839	514,043	20,853,443	22,668,999	57,895.3	6,833,944	18,349,686.6	19.58	155.81	3.84	40.57
80+ Years	61,245	61,245	259,414	9,556,705	9,808,894	26,504.9	2,056,729	5,754,370.4	29.78	156.04	4.24	36.84
<b>Trazodone</b>												
Incident with Respect to Itself												
00 to 17 Years	76,789	76,789	188,510	5,844,505	7,609,293	16,284.7	22,939,343	56,564,506.6	3.35	76.11	2.45	31.00
18 to 40 Years	517,237	517,237	937,829	30,388,793	42,343,989	84,505.5	36,927,780	72,213,719.6	14.01	58.75	1.81	32.40
41 to 64 Years	792,039	792,039	1,847,118	68,666,498	97,967,687	190,589.8	32,524,756	83,522,411.9	24.35	86.70	2.33	37.17
65 to 79 Years	188,473	188,473	467,113	20,091,897	24,970,730	55,567.4	7,156,102	19,615,831.2	26.34	106.60	2.48	43.01
80+ Years	86,243	86,243	243,181	9,589,295	9,988,336	26,511.6	2,161,016	6,219,705.5	39.91	111.19	2.82	39.43
Incident with Respect to Miscellaneous Anti-Depressants												
00 to 17 Years	76,726	76,726	188,343	5,839,367	7,602,662	16,270.4	22,939,233	56,563,769.4	3.34	76.11	2.45	31.00
18 to 40 Years	515,868	515,868	933,847	30,254,428	42,118,355	84,131.4	36,925,117	72,199,467.4	13.97	58.65	1.81	32.40
41 to 64 Years	789,494	789,494	1,836,351	68,245,807	97,159,961	189,422.3	32,516,179	83,479,148.6	24.28	86.44	2.33	37.16
65 to 79 Years	188,198	188,198	465,766	20,032,032	24,873,473	55,402.3	7,154,758	19,609,623.1	26.30	106.44	2.47	43.01
80+ Years	86,189	86,189	242,995	9,580,967	9,978,153	26,488.6	2,160,834	6,218,668.0	39.89	111.16	2.82	39.43
<b>Trimipramine</b>												
Incident with Respect to Itself												
00 to 17 Years	4	4	4	93	189	0.3	22,947,423	56,711,170.2	0.00	23.25	1.00	23.25
18 to 40 Years	236	236	647	20,236	42,055	56.1	37,037,366	73,499,006.0	0.01	85.75	2.74	31.28
41 to 64 Years	454	454	1,509	57,577	120,949	159.2	32,823,383	86,504,755.5	0.01	126.82	3.32	38.16
65 to 79 Years	67	67	233	10,405	23,397	28.8	7,273,960	20,411,048.1	0.01	155.30	3.48	44.66
80+ Years	12	12	13	560	699	1.5	2,207,569	6,533,286.5	0.01	46.67	1.08	43.08
Incident with Respect to All Cyclics												
00 to 17 Years	3	3	3	63	99	0.2	22,934,357	56,554,871.7	0.00	21.00	1.00	21.00
18 to 40 Years	152	152	353	11,163	21,245	30.9	36,945,548	72,746,469.0	0.00	73.44	2.32	31.62
41 to 64 Years	285	285	946	33,393	70,528	92.6	32,547,823	84,438,873.8	0.01	117.17	3.32	35.30
65 to 79 Years	46	46	166	7,583	18,151	21.0	7,149,999	19,630,276.8	0.01	164.85	3.61	45.68
80+ Years	9	9	10	410	489	1.1	2,160,385	6,226,253.3	0.00	45.56	1.11	41.00
<b>Venlafaxine</b>												
Incident with Respect to Itself												



**Table 2: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Age Group**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
00 to 17 Years	21,108	21,108	86,382	3,036,603	4,489,294	8,452.5	22,943,731	56,669,795.7	0.92	143.86	4.09	35.15
18 to 40 Years	296,921	296,921	1,170,669	39,655,931	58,604,476	110,827.1	36,904,236	72,591,673.9	8.05	133.56	3.94	33.87
41 to 64 Years	428,746	428,746	2,052,262	76,232,127	110,901,940	212,378.1	32,509,293	84,638,360.5	13.19	177.80	4.79	37.15
65 to 79 Years	62,806	62,806	267,672	10,916,053	15,961,349	30,289.5	7,210,303	20,128,906.2	8.71	173.81	4.26	40.78
80+ Years	16,049	16,049	77,205	2,770,574	3,697,773	7,682.3	2,193,529	6,466,928.7	7.32	172.63	4.81	35.89
<b>Incident with Respect to All SNRIs</b>												
00 to 17 Years	20,646	20,646	83,678	2,940,029	4,359,388	8,185.5	22,941,575	56,657,875.7	0.90	142.40	4.05	35.14
18 to 40 Years	282,098	282,098	1,098,959	37,241,327	55,172,704	104,090.0	36,817,416	72,240,245.1	7.66	132.02	3.90	33.89
41 to 64 Years	398,820	398,820	1,892,627	70,429,205	102,637,479	196,217.6	32,297,142	83,740,511.3	12.35	176.59	4.75	37.21
65 to 79 Years	58,011	58,011	246,561	10,051,092	14,708,134	27,888.3	7,173,063	19,978,860.8	8.09	173.26	4.25	40.77
80+ Years	15,154	15,154	72,479	2,599,731	3,466,416	7,208.9	2,186,337	6,428,852.7	6.93	171.55	4.78	35.87
<b>Vilazodone</b>												
<b>Incident with Respect to Itself</b>												
00 to 17 Years	350	350	904	27,539	28,691	77.5	22,947,404	56,710,979.0	0.02	78.68	2.58	30.46
18 to 40 Years	14,180	14,180	38,458	1,171,363	1,206,391	3,301.9	37,035,894	73,489,679.6	0.38	82.61	2.71	30.46
41 to 64 Years	21,384	21,384	63,935	2,067,695	2,132,308	5,808.8	32,821,239	86,491,041.4	0.65	96.69	2.99	32.34
65 to 79 Years	2,159	2,159	6,162	213,259	218,780	597.3	7,273,692	20,409,948.4	0.30	98.78	2.85	34.61
80+ Years	338	338	1,008	32,485	32,502	90.3	2,207,558	6,533,251.9	0.15	96.11	2.98	32.23
<b>Incident with Respect to All SSRIs</b>												
00 to 17 Years	162	162	346	10,100	10,343	28.3	22,840,931	56,038,517.3	0.01	62.35	2.14	29.19
18 to 40 Years	7,686	7,686	20,020	601,870	620,408	1,697.4	36,081,248	68,868,691.8	0.21	78.31	2.60	30.06
41 to 64 Years	11,655	11,655	33,931	1,088,068	1,118,074	3,057.2	31,185,912	78,282,587.9	0.37	93.36	2.91	32.07
65 to 79 Years	1,131	1,131	3,116	106,466	108,942	298.8	6,851,492	18,462,723.9	0.17	94.13	2.76	34.17
80+ Years	165	165	513	15,930	15,818	44.4	2,067,098	5,805,993.9	0.08	96.55	3.11	31.05
<b>Vortioxetine</b>												
<b>Incident with Respect to Itself</b>												
00 to 17 Years	0	0	0	0	0	0.0	22,947,425	56,711,179.7	0.00	---	---	---
18 to 40 Years	0	0	0	0	0	0.0	37,037,394	73,499,829.0	0.00	---	---	---
41 to 64 Years	0	0	0	0	0	0.0	32,823,681	86,507,874.1	0.00	---	---	---
65 to 79 Years	0	0	0	0	0	0.0	7,274,113	20,411,789.5	0.00	---	---	---
80+ Years	0	0	0	0	0	0.0	2,207,605	6,533,517.2	0.00	---	---	---
<b>Incident with Respect to Miscellaneous Anti-Depressants</b>												



**Table 2: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Age Group**

	<b>New Users</b>	<b>New Episodes</b>	<b>Dispensings</b>	<b>Days Supplied</b>	<b>Amount Supplied</b>	<b>Years at Risk</b>	<b>Eligible Members</b>	<b>Member- Years</b>	<b>New Users / 1K Eligible Members</b>	<b>Days Supplied/ User</b>	<b>Dispensings / User</b>	<b>Days Supplied/ Dispensing</b>
00 to 17 Years	0	0	0	0	0	0.0	22,939,233	56,628,647.2	0.00	---	---	---
18 to 40 Years	0	0	0	0	0	0.0	36,959,157	72,903,805.4	0.00	---	---	---
41 to 64 Years	0	0	0	0	0	0.0	32,593,169	84,895,949.2	0.00	---	---	---
65 to 79 Years	0	0	0	0	0	0.0	7,203,568	19,984,513.9	0.00	---	---	---
80+ Years	0	0	0	0	0	0.0	2,186,710	6,379,397.2	0.00	---	---	---

**Table 3: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Sex**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
<b>Amitriptyline</b>												
Incident with Respect to Itself												
Female	726,736	726,736	1,728,566	63,419,981	96,986,732	176,244.8	47,297,944	123,214,702.7	15.37	87.27	2.38	36.69
Male	316,764	316,764	737,919	26,889,762	42,285,423	74,694.6	45,721,425	116,485,407.9	6.93	84.89	2.33	36.44
Unknown	220	220	617	19,310	32,181	53.6	20,780	41,267.5	10.59	87.77	2.80	31.30
Incident with Respect to All Cyclics												
Female	696,576	696,576	1,620,042	58,968,295	89,269,678	163,918.5	47,154,050	121,916,229.2	14.77	84.65	2.33	36.40
Male	303,831	303,831	693,717	25,139,443	39,115,997	69,848.7	45,644,799	115,798,809.2	6.66	82.74	2.28	36.24
Unknown	209	209	562	17,660	27,564	49.1	20,759	41,004.2	10.07	84.50	2.69	31.42
<b>Amoxapine</b>												
Incident with Respect to Itself												
Female	694	694	2,020	69,560	348,431	193.0	47,462,772	126,013,077.0	0.01	100.23	2.91	34.44
Male	337	337	1,084	34,480	70,317	95.8	45,780,980	117,603,300.4	0.01	102.31	3.22	31.81
Unknown	0	0	0	0	0	0.0	20,801	42,048.0	0.00	---	---	---
Incident with Respect to All Cyclics												
Female	509	509	1,471	52,122	314,040	144.6	47,154,053	123,206,481.3	0.01	102.40	2.89	35.43
Male	240	240	767	24,210	49,793	67.2	45,644,807	116,348,889.6	0.01	100.88	3.20	31.56
Unknown	0	0	0	0	0	0.0	20,759	41,339.7	0.00	---	---	---
<b>Citalopram</b>												
Incident with Respect to Itself												
Female	1,428,617	1,428,617	4,980,116	190,044,676	206,702,688	530,664.8	47,133,669	121,987,994.2	30.31	133.03	3.49	38.16
Male	672,666	672,666	2,345,976	88,559,511	97,242,626	247,227.6	45,637,496	115,874,257.8	14.74	131.65	3.49	37.75
Unknown	253	253	903	28,371	29,170	79.8	20,751	41,341.0	12.19	112.14	3.57	31.42
Incident with Respect to All SSRIs												
Female	1,124,716	1,124,716	3,712,907	138,764,616	149,043,065	387,602.5	45,530,708	113,664,878.9	24.70	123.38	3.30	37.37
Male	553,984	553,984	1,843,665	68,371,495	74,072,868	190,924.0	44,961,198	112,342,533.2	12.32	123.42	3.33	37.08
Unknown	205	205	698	21,973	22,233	61.9	20,484	39,010.1	10.01	107.19	3.40	31.48
<b>Clomipramine</b>												
Incident with Respect to Itself												
Female	9,282	9,282	32,316	1,073,726	2,369,016	2,990.0	47,459,693	125,980,744.3	0.20	115.68	3.48	33.23
Male	9,532	9,532	29,575	972,328	2,449,570	2,706.8	45,777,848	117,570,403.3	0.21	102.01	3.10	32.88
Unknown	4	4	14	385	810	1.1	20,801	42,027.1	0.19	96.25	3.50	27.50
Incident with Respect to All Cyclics												
Female	7,804	7,804	26,126	867,606	1,901,531	2,418.6	47,154,053	123,196,279.8	0.17	111.17	3.35	33.21

**Table 3: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Sex**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Male	8,537	8,537	25,497	833,359	2,102,034	2,321.0	45,644,807	116,336,813.5	0.19	97.62	2.99	32.68
Unknown	4	4	13	355	750	1.0	20,759	41,325.8	0.19	88.75	3.25	27.31
<b>Desipramine</b>												
Incident with Respect to Itself												
Female	31,740	31,740	76,166	3,121,836	5,769,782	8,650.3	47,457,449	125,870,264.7	0.67	98.36	2.40	40.99
Male	14,060	14,060	33,700	1,338,037	2,572,965	3,711.0	45,778,793	117,544,878.0	0.31	95.17	2.40	39.70
Unknown	12	12	41	1,715	2,155	4.8	20,801	41,992.3	0.58	142.92	3.42	41.83
Incident with Respect to All Cyclics												
Female	24,149	24,149	55,408	2,215,655	4,026,502	6,144.4	47,154,053	123,148,958.6	0.51	91.75	2.29	39.99
Male	11,037	11,037	25,752	1,000,407	1,899,786	2,776.8	45,644,807	116,323,365.2	0.24	90.64	2.33	38.85
Unknown	10	10	36	1,565	1,705	4.4	20,759	41,315.9	0.48	156.50	3.60	43.47
<b>Desvenlafaxine</b>												
Incident with Respect to Itself												
Female	147,249	147,249	658,535	21,621,298	22,110,488	60,887.0	47,438,103	125,727,593.6	3.10	146.83	4.47	32.83
Male	53,170	53,170	231,176	7,549,481	7,727,359	21,245.2	45,772,488	117,504,106.6	1.16	141.99	4.35	32.66
Unknown	17	17	81	2,616	2,616	7.4	20,799	42,019.7	0.82	153.88	4.76	32.30
Incident with Respect to All SNRIs												
Female	115,185	115,185	488,721	15,895,025	16,181,599	44,819.5	46,941,997	123,291,150.2	2.45	138.00	4.24	32.52
Male	43,272	43,272	178,884	5,778,149	5,882,670	16,283.1	45,600,783	116,662,188.4	0.95	133.53	4.13	32.30
Unknown	10	10	60	1,942	1,942	5.5	20,731	41,419.1	0.48	194.20	6.00	32.37
<b>Doxepin</b>												
Incident with Respect to Itself												
Female	137,952	137,952	285,660	9,625,717	16,283,701	26,721.8	47,440,699	125,521,882.9	2.91	69.78	2.07	33.70
Male	73,270	73,270	154,987	5,191,409	8,757,559	14,417.4	45,770,169	117,368,447.2	1.60	70.85	2.12	33.50
Unknown	34	34	59	1,715	3,102	4.8	20,801	41,966.4	1.63	50.44	1.74	29.07
Incident with Respect to All Cyclics												
Female	121,269	121,269	236,564	7,838,828	12,856,468	21,768.4	47,154,053	122,982,766.3	2.57	64.64	1.95	33.14
Male	65,944	65,944	132,332	4,384,046	7,263,860	12,179.2	45,644,807	116,239,098.3	1.44	66.48	2.01	33.13
Unknown	32	32	46	1,417	2,536	3.9	20,759	41,294.9	1.54	44.28	1.44	30.80
<b>Duloxetine</b>												
Incident with Respect to Itself												
Female	521,623	521,623	2,099,670	73,333,210	88,944,882	205,180.6	47,282,107	124,549,192.5	11.03	140.59	4.03	34.93
Male	205,772	205,772	796,594	27,634,423	33,483,315	77,253.7	45,718,893	117,071,318.6	4.50	134.30	3.87	34.69
Unknown	148	148	492	16,039	21,593	45.1	20,782	41,664.3	7.12	108.37	3.32	32.60

**Table 3: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Sex**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
<b>Incident with Respect to All SNRIs</b>												
Female	470,786	470,786	1,828,489	63,422,865	75,928,736	177,539.6	46,941,997	122,971,553.0	10.03	134.72	3.88	34.69
Male	190,841	190,841	716,539	24,723,084	29,610,624	69,139.1	45,600,783	116,530,508.7	4.19	129.55	3.75	34.50
Unknown	132	132	444	14,466	19,753	40.5	20,731	41,257.9	6.37	109.59	3.36	32.58
<b>Escitalopram</b>												
<b>Incident with Respect to Itself</b>												
Female	925,874	925,874	3,260,544	109,579,534	118,762,476	307,396.4	47,137,555	123,110,844.8	19.64	118.35	3.52	33.61
Male	431,988	431,988	1,545,354	51,454,886	56,275,541	144,330.0	45,633,733	116,336,789.5	9.47	119.11	3.58	33.30
Unknown	260	260	1,146	37,533	39,367	105.7	20,755	41,019.0	12.53	144.36	4.41	32.75
<b>Incident with Respect to All SSRIs</b>												
Female	734,608	734,608	2,458,378	82,069,138	87,084,633	230,355.7	45,530,708	114,004,875.8	16.13	111.72	3.35	33.38
Male	357,974	357,974	1,230,047	40,627,645	43,601,673	114,024.0	44,961,198	112,501,373.0	7.96	113.49	3.44	33.03
Unknown	203	203	890	29,405	30,879	82.6	20,484	38,926.5	9.91	144.85	4.38	33.04
<b>Fluoxetine</b>												
<b>Incident with Respect to Itself</b>												
Female	1,255,439	1,255,439	4,468,298	191,948,048	257,468,592	533,816.3	47,073,566	120,874,510.3	26.67	152.89	3.56	42.96
Male	520,354	520,354	1,908,113	82,890,286	114,472,860	230,263.2	45,648,288	115,653,557.8	11.40	159.30	3.67	43.44
Unknown	271	271	907	31,247	35,715	87.5	20,733	40,978.6	13.07	115.30	3.35	34.45
<b>Incident with Respect to All SSRIs</b>												
Female	1,059,380	1,059,380	3,609,379	157,525,327	207,347,263	438,071.1	45,530,708	113,109,031.7	23.27	148.70	3.41	43.64
Male	448,168	448,168	1,588,017	69,965,265	95,143,218	194,350.6	44,961,198	112,143,219.1	9.97	156.11	3.54	44.06
Unknown	225	225	721	24,959	27,596	70.1	20,484	38,942.3	10.98	110.93	3.20	34.62
<b>Fluvoxamine</b>												
<b>Incident with Respect to Itself</b>												
Female	27,066	27,066	97,410	3,360,516	5,920,781	9,372.5	47,454,226	125,917,016.0	0.57	124.16	3.60	34.50
Male	19,148	19,148	79,677	2,687,812	4,856,653	7,500.2	45,772,845	117,532,129.4	0.42	140.37	4.16	33.73
Unknown	8	8	35	1,108	2,523	3.1	20,798	42,016.4	0.38	138.50	4.38	31.66
<b>Incident with Respect to All SSRIs</b>												
Female	14,071	14,071	47,147	1,603,829	2,686,841	4,477.9	45,530,708	114,607,901.9	0.31	113.98	3.35	34.02
Male	11,158	11,158	43,797	1,455,958	2,582,211	4,067.9	44,961,198	112,786,365.9	0.25	130.49	3.93	33.24
Unknown	4	4	9	330	540	1.0	20,484	39,229.4	0.20	82.50	2.25	36.67
<b>Imipramine</b>												
<b>Incident with Respect to Itself</b>												
Female	78,005	78,005	203,144	8,453,444	15,067,686	23,420.1	47,444,977	125,631,040.9	1.64	108.37	2.60	41.61

**Table 3: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Sex**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Male	46,226	46,226	122,732	4,621,022	8,410,233	12,838.2	45,772,188	117,403,324.5	1.01	99.97	2.66	37.65
Unknown	26	26	39	1,131	1,676	3.1	20,797	41,936.7	1.25	43.50	1.50	29.00
Incident with Respect to All Cyclics												
Female	69,298	69,298	174,965	7,258,841	12,600,614	20,121.7	47,154,053	123,031,937.2	1.47	104.75	2.52	41.49
Male	42,908	42,908	111,323	4,183,309	7,325,600	11,628.4	45,644,807	116,246,775.9	0.94	97.49	2.59	37.58
Unknown	25	25	37	1,131	1,676	3.1	20,759	41,301.2	1.20	45.24	1.48	30.57
<b>Levomilnacipran</b>												
Incident with Respect to Itself												
Female	0	0	0	0	0	0.0	47,463,208	126,017,228.8	0.00	---	---	---
Male	0	0	0	0	0	0.0	45,781,145	117,604,912.8	0.00	---	---	---
Unknown	0	0	0	0	0	0.0	20,801	42,048.0	0.00	---	---	---
Incident with Respect to All SNRIs												
Female	0	0	0	0	0	0.0	46,941,997	123,354,184.8	0.00	---	---	---
Male	0	0	0	0	0	0.0	45,600,783	116,686,174.2	0.00	---	---	---
Unknown	0	0	0	0	0	0.0	20,731	41,424.3	0.00	---	---	---
<b>Maprotiline</b>												
Incident with Respect to Itself												
Female	533	533	1,662	56,646	120,686	157.8	47,462,759	126,013,815.3	0.01	106.28	3.12	34.08
Male	290	290	896	31,734	73,023	88.2	45,780,969	117,603,352.8	0.01	109.43	3.09	35.42
Unknown	0	0	0	0	0	0.0	20,801	42,048.0	0.00	---	---	---
Incident with Respect to All Cyclics												
Female	366	366	1,151	40,425	85,770	112.7	47,154,053	123,206,942.0	0.01	110.45	3.14	35.12
Male	214	214	586	20,500	46,028	57.1	45,644,807	116,348,954.8	0.00	95.79	2.74	34.98
Unknown	0	0	0	0	0	0.0	20,759	41,339.7	0.00	---	---	---
<b>Mirtazapine</b>												
Incident with Respect to Itself												
Female	283,274	283,274	950,559	32,267,130	36,088,655	89,556.2	47,423,301	125,205,091.2	5.97	113.91	3.36	33.95
Male	196,671	196,671	638,650	21,897,458	25,146,129	60,833.1	45,749,718	117,078,333.7	4.30	111.34	3.25	34.29
Unknown	85	85	224	7,281	7,893	20.3	20,794	41,862.0	4.09	85.66	2.64	32.50
Incident with Respect to All Cyclics												
Female	255,655	255,655	827,541	27,818,912	30,604,025	77,235.1	47,154,053	122,867,394.7	5.42	108.81	3.24	33.62
Male	182,407	182,407	573,800	19,561,006	21,996,099	54,358.8	45,644,807	116,131,345.3	4.00	107.24	3.15	34.09
Unknown	76	76	189	6,091	6,624	17.0	20,759	41,251.9	3.66	80.14	2.49	32.23
<b>Nefazodone</b>												

**Table 3: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Sex**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
<b>Incident with Respect to Itself</b>												
Female	22,751	22,751	67,099	2,572,867	5,793,828	7,156.2	47,456,223	125,864,760.3	0.48	113.09	2.95	38.34
Male	11,912	11,912	38,249	1,477,443	3,361,940	4,113.2	45,776,428	117,526,563.8	0.26	124.03	3.21	38.63
Unknown	2	2	2	90	300	0.2	20,800	42,037.0	0.10	45.00	1.00	45.00
<b>Incident with Respect to Miscellaneous Anti-Depressants</b>												
Female	18,732	18,732	52,482	1,978,357	4,437,481	5,507.6	47,230,380	123,994,266.0	0.40	105.61	2.80	37.70
Male	10,126	10,126	31,306	1,202,116	2,725,909	3,349.9	45,677,605	116,654,211.0	0.22	118.72	3.09	38.40
Unknown	2	2	2	90	300	0.2	20,756	41,486.1	0.10	45.00	1.00	45.00
<b>Nortriptyline</b>												
<b>Incident with Respect to Itself</b>												
Female	440,500	440,500	983,741	43,460,113	87,509,283	120,436.7	47,416,563	124,326,251.8	9.29	98.66	2.23	44.18
Male	198,543	198,543	433,161	19,271,477	36,083,420	53,398.4	45,763,980	116,888,324.6	4.34	97.06	2.18	44.49
Unknown	95	95	159	5,428	10,725	15.2	20,789	41,710.0	4.57	57.14	1.67	34.14
<b>Incident with Respect to All Cyclics</b>												
Female	403,762	403,762	864,535	38,067,091	70,178,340	105,502.3	47,154,053	122,308,878.1	8.56	94.28	2.14	44.03
Male	184,697	184,697	387,772	17,225,167	32,233,959	47,730.6	45,644,807	115,944,125.9	4.05	93.26	2.10	44.42
Unknown	78	78	130	4,288	8,412	12.0	20,759	41,165.5	3.76	54.97	1.67	32.98
<b>Paroxetine</b>												
<b>Incident with Respect to Itself</b>												
Female	592,953	592,953	2,060,837	79,544,643	82,200,107	221,604.5	47,232,323	123,217,384.1	12.55	134.15	3.48	38.60
Male	319,053	319,053	1,115,197	42,353,499	43,905,572	118,046.0	45,655,980	116,290,164.9	6.99	132.75	3.50	37.98
Unknown	182	182	599	20,967	20,901	58.8	20,759	41,307.7	8.77	115.20	3.29	35.00
<b>Incident with Respect to All SSRIs</b>												
Female	474,491	474,491	1,583,788	60,869,391	61,712,186	169,633.7	45,530,708	113,850,160.1	10.42	128.28	3.34	38.43
Male	266,896	266,896	899,284	33,874,924	34,585,286	94,464.1	44,961,198	112,410,751.3	5.94	126.92	3.37	37.67
Unknown	159	159	497	17,642	17,456	49.5	20,484	39,030.8	7.76	110.96	3.13	35.50
<b>Protriptyline</b>												
<b>Incident with Respect to Itself</b>												
Female	5,667	5,667	14,341	529,048	1,315,714	1,473.6	47,462,373	125,994,216.1	0.12	93.36	2.53	36.89
Male	1,825	1,825	4,197	149,908	341,424	417.2	45,780,849	117,597,712.1	0.04	82.14	2.30	35.72
Unknown	1	1	1	30	90	0.1	20,801	42,046.6	0.05	30.00	1.00	30.00
<b>Incident with Respect to All Cyclics</b>												
Female	4,185	4,185	10,105	361,183	846,767	1,006.7	47,154,053	123,198,921.0	0.09	86.30	2.41	35.74
Male	1,364	1,364	2,936	103,076	217,961	287.2	45,644,807	116,346,458.6	0.03	75.57	2.15	35.11

**Table 3: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Sex**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Unknown	1	1	1	30	90	0.1	20,759	41,338.9	0.05	30.00	1.00	30.00
<b>Sertraline</b>												
Incident with Respect to Itself												
Female	1,317,217	1,317,217	4,757,985	170,800,160	195,591,881	477,313.2	46,951,125	121,630,823.0	28.06	129.67	3.61	35.90
Male	607,036	607,036	2,259,393	79,708,013	92,094,383	222,684.6	45,565,539	115,775,186.8	13.32	131.31	3.72	35.28
Unknown	319	319	1,177	38,248	40,469	108.0	20,717	40,839.3	15.40	119.90	3.69	32.50
Incident with Respect to All SSRIs												
Female	1,083,656	1,083,656	3,756,905	132,603,895	148,675,592	370,819.6	45,530,708	113,660,087.4	23.80	122.37	3.47	35.30
Male	514,634	514,634	1,854,216	64,373,862	72,938,583	179,968.1	44,961,198	112,356,833.8	11.45	125.09	3.60	34.72
Unknown	269	269	952	31,153	32,296	87.8	20,484	38,919.5	13.13	115.81	3.54	32.72
<b>Trazodone</b>												
Incident with Respect to Itself												
Female	1,074,909	1,074,909	2,371,534	87,072,771	118,364,605	241,621.1	47,237,472	122,266,117.0	22.76	81.00	2.21	36.72
Male	585,531	585,531	1,311,560	47,487,201	64,488,878	131,779.5	45,682,303	115,829,128.3	12.82	81.10	2.24	36.21
Unknown	341	341	657	21,016	26,553	58.3	20,757	40,929.5	16.43	61.63	1.93	31.99
Incident with Respect to Miscellaneous Anti-Depressants												
Female	1,071,975	1,071,975	2,360,248	86,648,332	117,595,010	240,443.3	47,230,380	122,227,024.4	22.70	80.83	2.20	36.71
Male	584,159	584,159	1,306,397	47,283,253	64,111,041	131,213.4	45,677,605	115,802,727.3	12.79	80.94	2.24	36.19
Unknown	341	341	657	21,016	26,553	58.3	20,756	40,924.8	16.43	61.63	1.93	31.99
<b>Trimipramine</b>												
Incident with Respect to Itself												
Female	525	525	1,620	61,224	127,800	169.4	47,462,992	126,013,694.1	0.01	116.62	3.09	37.79
Male	248	248	786	27,647	59,489	76.5	45,781,059	117,603,524.2	0.01	111.48	3.17	35.17
Unknown	0	0	0	0	0	0.0	20,801	42,048.0	0.00	---	---	---
Incident with Respect to All Cyclics												
Female	343	343	1,110	40,301	86,731	111.7	47,154,053	123,206,515.7	0.01	117.50	3.24	36.31
Male	152	152	368	12,311	23,780	34.1	45,644,807	116,348,889.2	0.00	80.99	2.42	33.45
Unknown	0	0	0	0	0	0.0	20,759	41,339.7	0.00	---	---	---
<b>Venlafaxine</b>												
Incident with Respect to Itself												
Female	609,116	609,116	2,703,826	98,450,861	142,627,577	274,454.6	47,168,068	123,641,907.5	12.91	161.63	4.44	36.41
Male	216,321	216,321	949,482	34,132,674	50,987,919	95,097.1	45,677,407	116,812,422.8	4.74	157.79	4.39	35.95
Unknown	193	193	882	27,753	39,337	77.8	20,754	41,334.7	9.30	143.80	4.57	31.47
Incident with Respect to All SNRIs												

**Table 3: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Sex**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Female	570,228	570,228	2,505,770	91,319,527	132,477,166	254,590.8	46,941,997	122,576,659.0	12.15	160.15	4.39	36.44
Male	204,318	204,318	887,705	31,915,875	47,830,946	88,926.7	45,600,783	116,428,509.0	4.48	156.21	4.34	35.95
Unknown	183	183	829	25,982	36,008	72.9	20,731	41,177.6	8.83	141.98	4.53	31.34
<b>Vilazodone</b>												
Incident with Respect to Itself												
Female	26,019	26,019	73,270	2,331,007	2,396,954	6,554.6	47,461,131	125,997,438.6	0.55	89.59	2.82	31.81
Male	12,387	12,387	37,190	1,181,138	1,221,512	3,320.6	45,780,075	117,595,416.8	0.27	95.35	3.00	31.76
Unknown	5	5	7	196	207	0.6	20,801	42,044.8	0.24	39.20	1.40	28.00
Incident with Respect to All SSRIs												
Female	13,862	13,862	38,053	1,194,845	1,224,279	3,361.0	45,530,708	114,621,828.5	0.30	86.20	2.75	31.40
Male	6,936	6,936	19,871	627,529	649,245	1,764.9	44,961,198	112,797,455.5	0.15	90.47	2.86	31.58
Unknown	1	1	2	60	60	0.2	20,484	39,230.8	0.05	60.00	2.00	30.00
<b>Vortioxetine</b>												
Incident with Respect to Itself												
Female	0	0	0	0	0	0.0	47,463,208	126,017,228.8	0.00	---	---	---
Male	0	0	0	0	0	0.0	45,781,145	117,604,912.8	0.00	---	---	---
Unknown	0	0	0	0	0	0.0	20,801	42,048.0	0.00	---	---	---
Incident with Respect to Miscellaneous Anti-Depressants												
Female	0	0	0	0	0	0.0	47,230,380	124,062,971.1	0.00	---	---	---
Male	0	0	0	0	0	0.0	45,677,605	116,687,849.7	0.00	---	---	---
Unknown	0	0	0	0	0	0.0	20,756	41,492.1	0.00	---	---	---



**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
<b>Amitriptyline</b>												
Incident with Respect to Itself												
2000	35,817	35,817	88,116	3,560,133	5,289,864	9,854.6	7,201,507	3,320,598.8	4.97	99.40	2.46	40.40
2001	65,348	65,348	164,159	6,607,788	10,316,044	18,294.6	7,764,349	6,558,214.7	8.42	101.12	2.51	40.25
2002	57,939	57,939	144,990	6,001,605	10,113,336	16,616.7	7,862,029	6,616,327.6	7.37	103.58	2.50	41.39
2003	48,436	48,436	120,805	4,987,488	10,281,883	13,810.9	7,770,460	6,538,034.1	6.23	102.97	2.49	41.29
2004	42,343	42,343	106,523	4,277,494	12,948,488	11,855.6	8,297,823	6,724,267.0	5.10	101.02	2.52	40.16
2005	36,390	36,390	78,065	3,208,276	4,734,023	8,884.0	8,541,734	7,091,288.4	4.26	88.16	2.15	41.10
2006	50,119	50,119	123,232	4,872,136	7,136,274	13,509.3	19,452,510	11,882,322.7	2.58	97.21	2.46	39.54
2007	66,397	66,397	160,747	5,861,978	8,310,724	16,301.7	23,243,708	16,980,136.1	2.86	88.29	2.42	36.47
2008	109,172	109,172	258,787	9,049,266	12,529,364	25,197.3	44,437,639	28,114,955.4	2.46	82.89	2.37	34.97
2009	137,479	137,479	330,296	11,467,648	15,910,864	31,938.2	46,277,582	36,144,842.8	2.97	83.41	2.40	34.72
2010	129,090	129,090	313,451	10,907,949	15,010,615	30,370.7	44,458,024	34,879,427.2	2.90	84.50	2.43	34.80
2011	122,610	122,610	286,674	9,927,762	13,646,583	27,635.0	43,265,174	34,296,950.7	2.83	80.97	2.34	34.63
2012	117,924	117,924	250,317	8,388,838	11,421,141	23,358.0	42,145,592	33,106,821.6	2.80	71.14	2.12	33.51
2013	24,656	24,656	40,940	1,210,692	1,655,135	3,366.3	31,711,741	7,487,191.1	0.78	49.10	1.66	29.57
Incident with Respect to All Cyclics												
2000	33,769	33,769	79,750	3,205,605	4,695,754	8,874.7	7,137,140	3,277,670.9	4.73	94.93	2.36	40.20
2001	61,253	61,253	147,645	5,936,077	9,000,165	16,436.3	7,711,827	6,472,152.9	7.94	96.91	2.41	40.21
2002	54,573	54,573	131,236	5,426,025	8,914,336	15,025.2	7,809,816	6,528,436.1	6.99	99.43	2.40	41.35
2003	45,676	45,676	109,437	4,498,396	9,168,554	12,457.4	7,719,688	6,449,733.9	5.92	98.48	2.40	41.10
2004	39,796	39,796	97,558	3,880,119	12,078,276	10,756.7	8,238,748	6,625,945.2	4.83	97.50	2.45	39.77
2005	34,292	34,292	71,385	2,898,641	4,216,380	8,029.1	8,483,554	6,990,368.6	4.04	84.53	2.08	40.61
2006	48,129	48,129	115,350	4,505,403	6,515,671	12,497.2	19,360,999	11,769,644.7	2.49	93.61	2.40	39.06
2007	63,978	63,978	151,921	5,490,481	7,726,495	15,273.4	23,134,753	16,839,417.5	2.77	85.82	2.37	36.14
2008	105,529	105,529	245,821	8,546,035	11,740,521	23,800.9	44,267,649	27,913,958.4	2.38	80.98	2.33	34.77
2009	133,058	133,058	314,720	10,860,618	14,967,071	30,256.3	46,115,064	35,905,605.9	2.89	81.62	2.37	34.51
2010	124,721	124,721	298,710	10,346,446	14,159,003	28,814.3	44,296,168	34,641,405.7	2.82	82.96	2.40	34.64
2011	118,326	118,326	272,600	9,393,920	12,840,669	26,154.4	43,103,337	34,052,048.0	2.75	79.39	2.30	34.46
2012	113,786	113,786	239,020	7,983,472	10,821,075	22,230.8	41,979,462	32,859,442.0	2.71	70.16	2.10	33.40
2013	23,730	23,730	39,168	1,154,160	1,569,269	3,209.5	31,511,909	7,430,212.9	0.75	48.64	1.65	29.47
<b>Amoxapine</b>												

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Incident with Respect to Itself												
2000	48	48	130	3,987	6,634	11.0	7,277,800	3,374,288.2	0.01	83.06	2.71	30.67
2001	94	94	244	8,215	16,939	22.9	7,850,502	6,677,378.1	0.01	87.39	2.60	33.67
2002	64	64	147	4,556	98,554	12.6	7,996,767	6,772,923.2	0.01	71.19	2.30	30.99
2003	65	65	230	7,989	13,607	22.1	7,941,545	6,722,717.3	0.01	122.91	3.54	34.73
2004	65	65	218	7,726	135,754	21.4	8,502,637	6,933,441.5	0.01	118.86	3.35	35.44
2005	51	51	123	3,489	6,819	9.6	8,765,836	7,314,471.5	0.01	68.41	2.41	28.37
2006	53	53	244	8,209	14,850	22.7	19,699,513	12,108,214.9	0.00	154.89	4.60	33.64
2007	79	79	234	8,550	14,368	23.8	23,534,739	17,252,934.9	0.00	108.23	2.96	36.54
2008	102	102	311	9,052	21,061	25.2	44,824,787	28,485,958.0	0.00	88.75	3.05	29.11
2009	119	119	426	16,190	35,864	44.7	46,705,351	36,591,304.3	0.00	136.05	3.58	38.00
2010	105	105	302	9,915	22,569	27.8	44,937,483	35,365,615.7	0.00	94.43	2.88	32.83
2011	72	72	202	6,732	12,181	18.7	43,783,437	34,816,301.8	0.00	93.50	2.81	33.33
2012	91	91	248	8,175	16,777	22.8	42,693,674	33,639,709.2	0.00	89.84	2.73	32.96
2013	23	23	45	1,255	2,771	3.5	32,177,833	7,603,166.7	0.00	54.57	1.96	27.89
Incident with Respect to All Cyclics												
2000	38	38	87	2,696	4,293	7.4	7,137,141	3,277,671.0	0.01	70.95	2.29	30.99
2001	57	57	139	4,452	9,324	12.5	7,734,921	6,486,563.5	0.01	78.11	2.44	32.03
2002	44	44	112	3,437	96,277	9.5	7,877,075	6,577,477.2	0.01	78.11	2.55	30.69
2003	49	49	163	5,745	11,165	15.9	7,821,939	6,527,925.0	0.01	117.24	3.33	35.25
2004	49	49	168	5,955	132,440	16.5	8,368,513	6,728,825.6	0.01	121.53	3.43	35.45
2005	40	40	134	4,617	6,555	12.7	8,633,679	7,109,772.8	0.00	115.43	3.35	34.46
2006	37	37	199	6,932	13,233	19.2	19,503,191	11,885,266.8	0.00	187.35	5.38	34.83
2007	65	65	197	7,008	10,460	19.5	23,296,752	16,972,279.7	0.00	107.82	3.03	35.57
2008	71	71	240	7,080	16,560	19.6	44,462,391	28,073,627.1	0.00	99.72	3.38	29.50
2009	87	87	258	10,120	26,334	27.9	46,360,977	36,102,042.7	0.00	116.32	2.97	39.22
2010	70	70	187	6,610	14,949	18.6	44,595,887	34,882,073.3	0.00	94.43	2.67	35.35
2011	56	56	136	4,755	8,492	13.2	43,443,260	34,327,268.1	0.00	84.91	2.43	34.96
2012	72	72	194	6,306	12,389	17.6	42,347,814	33,152,273.4	0.00	87.58	2.69	32.51
2013	14	14	24	619	1,365	1.8	31,787,495	7,493,644.4	0.00	44.21	1.71	25.79

**Citalopram**

Incident with Respect to Itself

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2000	21,561	21,561	99,661	3,391,352	3,761,247	9,478.9	7,255,246	3,356,799.6	2.97	157.29	4.62	34.03
2001	48,827	48,827	215,486	7,350,154	7,888,176	20,548.4	7,812,584	6,620,017.9	6.25	150.53	4.41	34.11
2002	49,001	49,001	208,365	7,462,134	8,268,022	20,830.9	7,915,477	6,675,343.7	6.19	152.29	4.25	35.81
2003	26,713	26,713	107,563	4,537,690	5,444,724	12,624.3	7,825,762	6,604,515.5	3.41	169.87	4.03	42.19
2004	22,368	22,368	90,060	4,092,852	5,732,072	11,368.4	8,371,167	6,805,936.7	2.67	182.98	4.03	45.45
2005	57,879	57,879	222,808	10,623,809	12,048,552	29,473.4	8,625,400	7,167,713.1	6.71	183.55	3.85	47.68
2006	98,438	98,438	392,295	17,161,263	19,263,183	47,712.1	19,486,371	11,902,812.7	5.05	174.34	3.99	43.75
2007	132,050	132,050	516,225	21,228,278	23,708,437	59,151.7	23,224,137	16,941,161.5	5.69	160.76	3.91	41.12
2008	239,071	239,071	873,107	33,730,940	37,054,130	94,212.8	44,266,170	27,964,409.3	5.40	141.09	3.65	38.63
2009	336,092	336,092	1,193,333	44,836,335	48,687,259	125,344.1	46,011,095	35,843,562.2	7.30	133.40	3.55	37.57
2010	348,466	348,466	1,228,469	46,235,620	49,896,262	129,223.7	44,058,825	34,458,803.7	7.91	132.68	3.53	37.64
2011	375,984	375,984	1,250,916	45,944,940	48,788,179	128,453.9	42,728,691	33,737,495.2	8.80	122.20	3.33	36.73
2012	289,604	289,604	819,889	28,671,004	29,937,641	80,158.9	41,481,982	32,476,971.1	6.98	99.00	2.83	34.97
2013	55,482	55,482	108,818	3,366,187	3,496,599	9,390.6	31,149,096	7,348,050.6	1.78	60.67	1.96	30.93
Incident with Respect to All SSRIs												
2000	14,691	14,691	63,381	2,085,076	2,206,128	5,838.5	7,004,124	3,206,703.1	2.10	141.93	4.31	32.90
2001	34,544	34,544	144,448	4,762,259	4,934,755	13,332.8	7,574,791	6,300,849.4	4.56	137.86	4.18	32.97
2002	34,901	34,901	141,205	4,838,691	5,055,345	13,526.5	7,647,676	6,314,211.8	4.56	138.64	4.05	34.27
2003	17,921	17,921	67,882	2,632,097	3,053,723	7,343.4	7,528,923	6,206,762.0	2.38	146.87	3.79	38.77
2004	14,622	14,622	55,662	2,347,249	3,315,748	6,531.4	8,009,230	6,359,675.0	1.83	160.53	3.81	42.17
2005	35,196	35,196	129,548	6,093,870	6,725,897	16,916.9	8,260,295	6,723,066.2	4.26	173.14	3.68	47.04
2006	69,618	69,618	256,303	11,093,369	12,279,701	30,857.4	18,701,734	11,278,778.4	3.72	159.35	3.68	43.28
2007	102,136	102,136	380,267	15,325,801	16,852,502	42,721.0	22,307,387	16,051,193.6	4.58	150.05	3.72	40.30
2008	188,442	188,442	654,039	24,942,036	27,168,143	69,654.3	42,581,390	26,526,699.1	4.43	132.36	3.47	38.14
2009	269,596	269,596	910,491	33,806,409	36,441,837	94,496.6	44,422,424	34,076,057.8	6.07	125.40	3.38	37.13
2010	285,300	285,300	966,454	35,879,553	38,465,816	100,290.8	42,571,353	32,815,170.8	6.70	125.76	3.39	37.12
2011	309,013	309,013	988,064	35,984,621	38,134,321	100,581.4	41,335,082	32,184,327.6	7.48	116.45	3.20	36.42
2012	253,301	253,301	702,992	24,391,384	25,419,863	68,195.3	40,149,641	31,001,000.7	6.31	96.29	2.78	34.70
2013	49,624	49,624	96,534	2,975,669	3,084,388	8,302.0	29,833,537	7,001,926.7	1.66	59.96	1.95	30.83
<b>Clomipramine</b>												
Incident with Respect to Itself												
2000	447	447	1,811	66,486	147,014	183.9	7,276,741	3,373,623.6	0.06	148.74	4.05	36.71

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2001	769	769	2,809	98,156	283,762	272.7	7,849,350	6,675,901.6	0.10	127.64	3.65	34.94
2002	690	690	2,783	104,261	230,371	289.8	7,995,136	6,771,061.6	0.09	151.10	4.03	37.46
2003	606	606	2,342	86,127	319,659	238.5	7,939,491	6,720,535.4	0.08	142.12	3.86	36.77
2004	597	597	2,146	73,369	400,826	203.8	8,500,183	6,930,936.9	0.07	122.90	3.59	34.19
2005	616	616	2,248	75,566	179,744	210.8	8,763,092	7,311,697.9	0.07	122.67	3.65	33.61
2006	902	902	3,245	121,366	254,159	337.2	19,695,607	12,104,890.1	0.05	134.55	3.60	37.40
2007	1,345	1,345	4,841	161,498	358,449	450.3	23,530,258	17,248,545.6	0.06	120.07	3.60	33.36
2008	2,161	2,161	7,518	242,275	532,982	675.3	44,817,468	28,479,432.3	0.05	112.11	3.48	32.23
2009	2,779	2,779	8,729	283,004	600,061	788.8	46,697,090	36,582,877.9	0.06	101.84	3.14	32.42
2010	2,595	2,595	8,544	273,547	576,739	762.6	44,928,303	35,356,503.8	0.06	105.41	3.29	32.02
2011	2,358	2,358	6,979	221,361	455,502	617.0	43,773,493	34,806,508.0	0.05	93.88	2.96	31.72
2012	2,368	2,368	6,753	207,316	421,007	577.6	42,683,261	33,629,694.3	0.06	87.55	2.85	30.70
2013	585	585	1,157	32,107	59,120	89.5	32,168,993	7,600,965.7	0.02	54.88	1.98	27.75
<b>Incident with Respect to All Cyclics</b>												
2000	351	351	1,282	49,060	106,949	135.6	7,137,141	3,277,671.0	0.05	139.77	3.65	38.27
2001	613	613	1,977	72,405	221,503	201.3	7,734,745	6,486,456.6	0.08	118.12	3.23	36.62
2002	539	539	2,111	77,237	175,236	214.8	7,876,518	6,577,074.4	0.07	143.30	3.92	36.59
2003	501	501	1,849	68,961	280,470	191.0	7,821,044	6,527,249.6	0.06	137.65	3.69	37.30
2004	469	469	1,610	55,843	330,608	155.2	8,367,392	6,727,919.8	0.06	119.07	3.43	34.69
2005	510	510	1,690	56,549	129,660	158.0	8,632,355	7,108,710.6	0.06	110.88	3.31	33.46
2006	789	789	2,888	106,657	221,602	296.5	19,501,880	11,884,193.5	0.04	135.18	3.66	36.93
2007	1,191	1,191	4,287	142,709	323,078	398.4	23,295,083	16,970,919.5	0.05	119.82	3.60	33.29
2008	1,916	1,916	6,347	202,231	439,379	564.2	44,460,138	28,071,811.9	0.04	105.55	3.31	31.86
2009	2,510	2,510	7,633	245,529	506,474	685.1	46,357,823	36,099,562.4	0.05	97.82	3.04	32.17
2010	2,287	2,287	7,255	232,585	486,307	648.9	44,591,762	34,878,827.8	0.05	101.70	3.17	32.06
2011	2,075	2,075	5,911	186,507	374,861	519.9	43,438,288	34,323,336.6	0.05	89.88	2.85	31.55
2012	2,072	2,072	5,781	176,862	356,459	493.0	42,342,335	33,147,979.0	0.05	85.36	2.79	30.59
2013	522	522	1,015	28,185	51,731	78.7	31,783,386	7,492,706.4	0.02	53.99	1.94	27.77
<b>Desipramine</b>												
<b>Incident with Respect to Itself</b>												
2000	2,000	2,000	4,690	186,021	368,026	515.7	7,273,121	3,371,012.4	0.27	93.01	2.35	39.66
2001	3,503	3,503	8,482	363,284	660,593	1,004.0	7,845,787	6,670,837.1	0.45	103.71	2.42	42.83

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2002	3,661	3,661	8,484	385,297	673,532	1,064.3	7,989,709	6,764,474.2	0.46	105.24	2.32	45.41
2003	3,268	3,268	8,483	425,772	793,776	1,174.1	7,932,098	6,712,183.2	0.41	130.29	2.60	50.19
2004	2,827	2,827	6,991	332,195	792,641	917.5	8,490,886	6,921,131.0	0.33	117.51	2.47	47.52
2005	2,390	2,390	5,941	272,544	525,591	753.1	8,752,636	7,301,018.9	0.27	114.04	2.49	45.88
2006	2,728	2,728	6,667	290,768	543,876	805.2	19,684,660	12,093,927.8	0.14	106.59	2.44	43.61
2007	3,140	3,140	8,264	335,476	625,665	930.6	23,518,580	17,236,854.2	0.13	106.84	2.63	40.59
2008	3,993	3,993	9,988	377,034	695,462	1,048.8	44,805,128	28,466,921.9	0.09	94.42	2.50	37.75
2009	4,887	4,887	11,660	409,071	739,900	1,139.4	46,684,416	36,569,819.4	0.10	83.71	2.39	35.08
2010	4,556	4,556	10,868	410,749	753,984	1,140.9	44,914,869	35,342,883.5	0.10	90.16	2.39	37.79
2011	4,122	4,122	9,643	348,086	605,373	967.4	43,759,602	34,792,483.4	0.09	84.45	2.34	36.10
2012	3,903	3,903	8,404	284,614	492,471	792.1	42,669,219	33,615,813.8	0.09	72.92	2.15	33.87
2013	834	834	1,342	40,677	74,011	113.0	32,156,049	7,597,774.1	0.03	48.77	1.61	30.31
Incident with Respect to All Cyclics												
2000	1,428	1,428	3,185	128,595	239,791	356.7	7,137,141	3,277,671.0	0.20	90.05	2.23	40.38
2001	2,535	2,535	5,771	244,201	436,835	675.3	7,734,010	6,486,007.1	0.33	96.33	2.28	42.32
2002	2,700	2,700	5,742	258,170	433,079	713.5	7,874,347	6,575,495.3	0.34	95.62	2.13	44.96
2003	2,427	2,427	6,068	296,391	557,314	818.1	7,817,447	6,524,529.0	0.31	122.12	2.50	48.84
2004	2,067	2,067	4,843	226,911	559,638	626.5	8,362,543	6,724,045.2	0.25	109.78	2.34	46.85
2005	1,699	1,699	3,949	177,827	337,553	491.3	8,626,517	7,103,979.2	0.20	104.67	2.32	45.03
2006	2,100	2,100	4,914	209,545	379,035	580.6	19,495,734	11,879,111.1	0.11	99.78	2.34	42.64
2007	2,417	2,417	6,099	238,323	441,350	661.9	23,288,383	16,965,357.3	0.10	98.60	2.52	39.08
2008	3,202	3,202	7,901	294,508	541,404	819.6	44,452,914	28,065,654.8	0.07	91.98	2.47	37.27
2009	3,971	3,971	9,168	315,693	551,099	880.1	46,350,085	36,092,932.4	0.09	79.50	2.31	34.43
2010	3,623	3,623	8,408	309,809	559,213	861.2	44,583,326	34,871,680.8	0.08	85.51	2.32	36.85
2011	3,275	3,275	7,462	264,494	454,487	735.7	43,429,627	34,315,878.3	0.08	80.76	2.28	35.45
2012	3,094	3,094	6,637	221,588	380,169	617.1	42,333,437	33,140,377.5	0.07	71.62	2.15	33.39
2013	658	658	1,049	31,572	57,027	87.9	31,775,807	7,490,920.7	0.02	47.98	1.59	30.10
<b>Desvenlafaxine</b>												
Incident with Respect to Itself												
2000	0	0	0	0	0	0.0	7,278,111	3,374,478.6	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,850,755	6,677,703.2	0.00	---	---	---
2002	0	0	0	0	0	0.0	7,997,059	6,773,247.6	0.00	---	---	---

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2003	0	0	0	0	0	0.0	7,941,850	6,723,049.5	0.00	---	---	---
2004	0	0	0	0	0	0.0	8,502,991	6,933,805.3	0.00	---	---	---
2005	0	0	0	0	0	0.0	8,766,218	7,314,842.3	0.00	---	---	---
2006	0	0	0	0	0	0.0	19,699,906	12,108,539.1	0.00	---	---	---
2007	0	0	0	0	0	0.0	23,535,225	17,253,347.2	0.00	---	---	---
2008	22,580	22,580	100,049	3,375,729	3,497,473	9,503.3	44,822,952	28,481,069.6	0.50	149.50	4.43	33.74
2009	61,762	61,762	295,959	9,861,081	10,109,272	27,779.2	46,674,740	36,542,680.3	1.32	159.66	4.79	33.32
2010	47,072	47,072	224,957	7,367,634	7,539,564	20,741.8	44,855,435	35,276,967.4	1.05	156.52	4.78	32.75
2011	37,596	37,596	163,709	5,312,692	5,396,276	14,947.4	43,676,127	34,708,500.1	0.86	141.31	4.35	32.45
2012	26,048	26,048	92,876	2,908,263	2,944,688	8,190.8	42,577,412	33,528,562.3	0.61	111.65	3.57	31.31
2013	5,378	5,378	12,242	347,996	353,190	977.1	32,071,564	7,576,927.2	0.17	64.71	2.28	28.43
Incident with Respect to All SNRIs												
2000	0	0	0	0	0	0.0	7,258,584	3,361,047.7	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,830,259	6,643,331.0	0.00	---	---	---
2002	0	0	0	0	0	0.0	7,968,180	6,725,255.1	0.00	---	---	---
2003	0	0	0	0	0	0.0	7,902,272	6,661,078.1	0.00	---	---	---
2004	0	0	0	0	0	0.0	8,449,622	6,860,241.6	0.00	---	---	---
2005	0	0	0	0	0	0.0	8,703,208	7,227,229.1	0.00	---	---	---
2006	0	0	0	0	0	0.0	19,522,077	11,967,952.8	0.00	---	---	---
2007	0	0	0	0	0	0.0	23,299,406	17,015,725.9	0.00	---	---	---
2008	15,907	15,907	64,777	2,161,125	2,217,499	6,094.8	44,305,218	28,044,862.0	0.36	135.86	4.07	33.36
2009	47,710	47,710	216,958	7,164,281	7,313,174	20,212.0	46,168,965	35,995,218.8	1.03	150.16	4.55	33.02
2010	38,073	38,073	173,162	5,613,055	5,719,462	15,822.2	44,386,469	34,774,034.2	0.86	147.43	4.55	32.42
2011	30,964	30,964	128,853	4,149,644	4,203,418	11,688.5	43,229,509	34,218,819.3	0.72	134.02	4.16	32.20
2012	21,544	21,544	74,225	2,310,792	2,332,528	6,514.3	42,125,565	33,037,140.1	0.51	107.26	3.45	31.13
2013	4,269	4,269	9,690	276,219	280,131	776.2	31,634,827	7,462,822.0	0.13	64.70	2.27	28.51
<b>Doxepin</b>												
Incident with Respect to Itself												
2000	6,662	6,662	16,199	563,336	947,229	1,563.6	7,262,878	3,363,596.3	0.92	84.56	2.43	34.78
2001	11,854	11,854	28,941	1,031,479	1,799,836	2,861.7	7,834,260	6,654,827.9	1.51	87.02	2.44	35.64
2002	10,003	10,003	23,093	835,531	1,406,500	2,317.4	7,971,916	6,744,197.5	1.25	83.53	2.31	36.18
2003	8,803	8,803	19,548	706,090	1,250,016	1,959.0	7,910,697	6,689,214.2	1.11	80.21	2.22	36.12

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2004	8,479	8,479	19,552	712,109	2,178,863	1,976.4	8,465,237	6,894,798.9	1.00	83.99	2.31	36.42
2005	7,799	7,799	15,196	572,290	963,658	1,584.3	8,724,372	7,272,252.1	0.89	73.38	1.95	37.66
2006	9,167	9,167	19,297	731,852	1,248,644	2,027.3	19,656,551	12,067,703.5	0.47	79.84	2.11	37.93
2007	12,006	12,006	24,532	849,367	1,452,967	2,356.7	23,484,376	17,204,364.4	0.51	70.75	2.04	34.62
2008	19,230	19,230	39,198	1,297,678	2,146,864	3,603.3	44,760,034	28,421,682.2	0.43	67.48	2.04	33.11
2009	24,082	24,082	49,142	1,595,100	2,666,984	4,431.0	46,632,304	36,513,943.0	0.52	66.24	2.04	32.46
2010	24,423	24,423	50,632	1,634,820	2,616,092	4,544.7	44,854,374	35,280,577.2	0.54	66.94	2.07	32.29
2011	32,763	32,763	68,872	2,229,958	3,310,615	6,198.0	43,690,319	34,717,450.3	0.75	68.06	2.10	32.38
2012	29,747	29,747	56,965	1,790,374	2,654,417	4,973.9	42,585,270	33,529,433.2	0.70	60.19	1.91	31.43
2013	6,238	6,238	9,539	268,857	401,677	746.8	32,078,238	7,578,255.8	0.19	43.10	1.53	28.19
Incident with Respect to All Cyclics												
2000	5,403	5,403	11,557	393,945	645,743	1,094.7	7,137,141	3,277,671.0	0.76	72.91	2.14	34.09
2001	9,649	9,649	21,004	734,745	1,227,634	2,039.1	7,731,132	6,484,105.2	1.25	76.15	2.18	34.98
2002	8,192	8,192	17,098	613,197	1,008,050	1,700.9	7,866,080	6,569,426.1	1.04	74.85	2.09	35.86
2003	7,309	7,309	14,471	514,609	928,885	1,427.9	7,805,571	6,515,282.7	0.94	70.41	1.98	35.56
2004	7,091	7,091	15,282	542,791	1,506,929	1,507.4	8,347,519	6,711,967.8	0.85	76.55	2.16	35.52
2005	6,642	6,642	11,897	438,461	718,691	1,214.4	8,608,643	7,089,680.5	0.77	66.01	1.79	36.85
2006	8,181	8,181	16,703	624,243	1,053,237	1,729.6	19,479,228	11,865,529.6	0.42	76.30	2.04	37.37
2007	10,850	10,850	20,893	712,083	1,202,071	1,976.6	23,268,966	16,949,128.1	0.47	65.63	1.93	34.08
2008	17,511	17,511	34,171	1,115,766	1,815,270	3,099.0	44,428,280	28,045,215.7	0.39	63.72	1.95	32.65
2009	21,907	21,907	42,793	1,378,810	2,288,951	3,830.6	46,317,599	36,066,737.7	0.47	62.94	1.95	32.22
2010	22,186	22,186	43,913	1,406,776	2,209,746	3,911.9	44,542,943	34,838,629.3	0.50	63.41	1.98	32.04
2011	29,670	29,670	60,148	1,931,083	2,834,337	5,369.1	43,381,943	34,276,469.3	0.68	65.09	2.03	32.11
2012	27,009	27,009	50,535	1,580,477	2,330,834	4,391.3	42,274,922	33,093,349.2	0.64	58.52	1.87	31.27
2013	5,645	5,645	8,477	237,305	352,485	658.9	31,727,924	7,479,967.5	0.18	42.04	1.50	27.99
<b>Duloxetine</b>												
Incident with Respect to Itself												
2000	0	0	0	0	0	0.0	7,278,111	3,374,478.6	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,850,755	6,677,703.2	0.00	---	---	---
2002	0	0	0	0	0	0.0	7,997,059	6,773,247.6	0.00	---	---	---
2003	0	0	0	0	0	0.0	7,941,850	6,723,049.5	0.00	---	---	---
2004	9,442	9,442	41,903	1,301,423	1,701,263	3,625.9	8,502,698	6,932,206.8	1.11	137.83	4.44	31.06

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2005	23,411	23,411	89,255	2,979,844	4,111,083	8,298.4	8,754,997	7,292,833.1	2.67	127.28	3.81	33.39
2006	41,393	41,393	205,543	7,784,067	10,105,585	21,683.9	19,638,645	12,056,717.9	2.11	188.05	4.97	37.87
2007	66,554	66,554	321,528	11,692,164	14,798,266	32,650.4	23,421,730	17,141,016.4	2.84	175.68	4.83	36.36
2008	108,779	108,779	464,140	16,303,559	19,896,501	45,653.5	44,560,366	28,253,987.3	2.44	149.88	4.27	35.13
2009	129,068	129,068	531,101	18,618,252	22,304,385	52,150.1	46,390,112	36,260,931.5	2.78	144.25	4.11	35.06
2010	105,720	105,720	429,105	14,884,925	17,755,204	41,680.9	44,573,166	35,007,044.7	2.37	140.80	4.06	34.69
2011	114,088	114,088	432,450	14,910,131	17,361,154	41,731.2	43,392,590	34,430,773.2	2.63	130.69	3.79	34.48
2012	107,325	107,325	335,254	11,127,000	12,833,656	31,141.3	42,271,538	33,230,889.1	2.54	103.68	3.12	33.19
2013	21,763	21,763	46,477	1,382,307	1,582,692	3,863.9	31,791,686	7,507,296.6	0.68	63.52	2.14	29.74
<b>Incident with Respect to All SNRIs</b>												
2000	0	0	0	0	0	0.0	7,258,584	3,361,047.7	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,830,259	6,643,331.0	0.00	---	---	---
2002	0	0	0	0	0	0.0	7,968,180	6,725,255.1	0.00	---	---	---
2003	0	0	0	0	0	0.0	7,902,272	6,661,078.1	0.00	---	---	---
2004	7,605	7,605	32,153	992,472	1,274,224	2,767.5	8,449,622	6,860,241.6	0.90	130.50	4.23	30.87
2005	19,693	19,693	70,940	2,325,790	3,143,027	6,480.9	8,699,352	7,225,079.6	2.26	118.10	3.60	32.79
2006	36,575	36,575	172,617	6,473,136	8,244,173	18,043.3	19,509,571	11,959,290.0	1.87	176.98	4.72	37.50
2007	59,498	59,498	274,980	9,887,813	12,346,112	27,630.3	23,270,864	16,995,914.7	2.56	166.19	4.62	35.96
2008	99,009	99,009	407,170	14,212,334	17,156,215	39,816.8	44,248,506	28,004,010.3	2.24	143.55	4.11	34.91
2009	117,931	117,931	469,504	16,379,165	19,411,948	45,894.3	46,078,638	35,930,368.4	2.56	138.89	3.98	34.89
2010	96,596	96,596	380,393	13,128,523	15,488,154	36,776.0	44,273,281	34,688,285.7	2.18	135.91	3.94	34.51
2011	105,088	105,088	389,767	13,384,367	15,456,019	37,470.5	43,102,869	34,120,688.3	2.44	127.36	3.71	34.34
2012	99,458	99,458	304,956	10,099,982	11,582,429	28,269.8	41,986,534	32,930,885.3	2.37	101.55	3.07	33.12
2013	20,306	20,306	42,992	1,276,833	1,456,811	3,569.8	31,524,322	7,437,843.9	0.64	62.88	2.12	29.70
<b>Escitalopram</b>												
<b>Incident with Respect to Itself</b>												
2000	0	0	0	0	0	0.0	7,278,111	3,374,478.6	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,850,755	6,677,703.2	0.00	---	---	---
2002	11,863	11,863	57,662	1,739,837	2,195,919	4,867.3	7,996,723	6,771,560.1	1.48	146.66	4.86	30.17
2003	53,573	53,573	244,686	7,693,762	9,875,593	21,542.9	7,925,151	6,685,657.3	6.76	143.61	4.57	31.44
2004	57,384	57,384	235,888	7,445,670	13,246,230	20,851.1	8,428,937	6,842,995.0	6.81	129.75	4.11	31.56
2005	35,686	35,686	117,668	3,764,526	4,029,390	10,535.5	8,644,817	7,190,167.4	4.13	105.49	3.30	31.99



**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2006	79,762	79,762	324,860	11,796,592	12,338,151	33,016.2	19,448,812	11,921,433.2	4.10	147.90	4.07	36.31
2007	123,891	123,891	509,676	17,544,257	18,285,645	49,268.8	23,212,828	16,948,954.5	5.34	141.61	4.11	34.42
2008	203,880	203,880	733,186	24,759,234	25,741,786	69,595.6	44,215,644	27,960,743.5	4.61	121.44	3.60	33.77
2009	231,813	231,813	793,355	26,960,960	27,926,287	75,737.1	46,048,549	35,912,239.5	5.03	116.30	3.42	33.98
2010	186,285	186,285	628,750	21,382,365	22,172,753	60,016.2	44,233,066	34,672,223.1	4.21	114.78	3.38	34.01
2011	148,936	148,936	495,120	16,897,765	17,531,739	47,346.6	43,068,393	34,120,898.2	3.46	113.46	3.32	34.13
2012	174,507	174,507	554,012	17,788,224	18,338,984	49,839.2	41,986,575	32,966,291.7	4.16	101.93	3.17	32.11
2013	50,542	50,542	112,181	3,298,761	3,394,907	9,215.5	31,538,176	7,443,307.9	1.60	65.27	2.22	29.41
Incident with Respect to All SSRIs												
2000	0	0	0	0	0	0.0	7,004,124	3,206,703.1	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,581,236	6,304,385.0	0.00	---	---	---
2002	5,323	5,323	21,989	653,894	725,561	1,830.8	7,671,319	6,329,107.4	0.69	122.84	4.13	29.74
2003	31,876	31,876	131,200	4,078,551	4,851,705	11,426.6	7,566,563	6,231,577.1	4.21	127.95	4.12	31.09
2004	39,550	39,550	148,671	4,604,089	8,294,218	12,905.7	8,038,266	6,381,793.5	4.92	116.41	3.76	30.97
2005	26,155	26,155	78,402	2,444,718	2,563,039	6,842.9	8,272,076	6,734,842.6	3.16	93.47	3.00	31.18
2006	66,402	66,402	258,915	9,259,445	9,595,634	25,938.3	18,715,608	11,289,120.7	3.55	139.45	3.90	35.76
2007	103,141	103,141	406,043	13,798,543	14,239,450	38,776.9	22,327,138	16,067,401.2	4.62	133.78	3.94	33.98
2008	170,865	170,865	593,696	19,898,603	20,557,982	55,958.6	42,604,091	26,545,703.4	4.01	116.46	3.47	33.52
2009	192,928	192,928	638,542	21,519,304	22,088,535	60,479.7	44,463,400	34,109,071.6	4.34	111.54	3.31	33.70
2010	155,329	155,329	504,719	17,039,626	17,563,035	47,848.0	42,651,938	32,874,493.7	3.64	109.70	3.25	33.76
2011	122,537	122,537	392,918	13,295,209	13,713,989	37,267.7	41,472,125	32,283,679.4	2.95	108.50	3.21	33.84
2012	137,945	137,945	424,767	13,522,274	13,851,777	37,890.6	40,368,242	31,150,919.5	3.42	98.03	3.08	31.83
2013	40,734	40,734	89,453	2,611,932	2,672,259	7,296.7	29,988,600	7,036,377.0	1.36	64.12	2.20	29.20
<b>Fluoxetine</b>												
Incident with Respect to Itself												
2000	30,694	30,694	129,285	5,549,769	9,373,725	15,396.1	7,181,212	3,315,468.5	4.27	180.81	4.21	42.93
2001	77,223	77,223	324,923	15,304,116	23,494,543	42,399.9	7,747,169	6,542,474.9	9.97	198.18	4.21	47.10
2002	100,767	100,767	413,460	22,231,812	31,023,268	61,469.9	7,832,089	6,572,788.1	12.87	220.63	4.10	53.77
2003	101,436	101,436	402,200	22,457,175	31,598,248	62,088.7	7,702,365	6,456,056.9	13.17	221.39	3.97	55.84
2004	98,365	98,365	377,872	20,517,810	33,204,084	56,752.4	8,176,026	6,595,254.1	12.03	208.59	3.84	54.30
2005	85,089	85,089	307,418	16,186,140	22,277,013	44,798.7	8,382,088	6,925,244.4	10.15	190.23	3.61	52.65
2006	108,999	108,999	417,530	19,808,946	26,770,675	54,980.6	19,185,666	11,644,390.7	5.68	181.74	3.83	47.44

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2007	128,078	128,078	485,530	21,387,937	28,397,945	59,465.2	22,944,750	16,688,561.9	5.58	166.99	3.79	44.05
2008	182,083	182,083	652,323	25,819,436	33,101,507	71,985.8	44,004,479	27,746,466.0	4.14	141.80	3.58	39.58
2009	222,812	222,812	792,079	30,030,381	38,135,500	83,821.9	45,842,023	35,720,005.9	4.86	134.78	3.55	37.91
2010	205,434	205,434	732,316	27,524,223	34,918,378	76,836.0	44,010,238	34,454,330.7	4.67	133.98	3.56	37.59
2011	200,617	200,617	682,525	25,148,429	31,564,877	70,218.0	42,802,142	33,857,597.2	4.69	125.36	3.40	36.85
2012	191,401	191,401	570,123	20,147,962	24,794,362	56,265.6	41,672,725	32,667,225.7	4.59	105.27	2.98	35.34
2013	43,066	43,066	89,734	2,755,445	3,323,042	7,688.3	31,289,929	7,383,181.8	1.38	63.98	2.08	30.71
Incident with Respect to All SSRIs												
2000	25,506	25,506	100,774	4,348,682	7,251,041	12,067.7	7,004,124	3,206,703.1	3.64	170.50	3.95	43.15
2001	64,095	64,095	254,536	12,153,203	18,221,108	33,671.0	7,569,849	6,298,477.7	8.47	189.61	3.97	47.75
2002	87,078	87,078	343,026	18,674,307	25,489,423	51,625.8	7,627,359	6,302,228.0	11.42	214.45	3.94	54.44
2003	89,946	89,946	340,945	19,350,332	26,457,164	53,494.1	7,481,578	6,175,950.7	12.02	215.13	3.79	56.75
2004	87,142	87,142	321,658	17,734,373	27,309,453	49,053.1	7,923,929	6,300,731.2	11.00	203.51	3.69	55.13
2005	75,103	75,103	263,067	14,130,969	19,193,637	39,104.6	8,135,605	6,633,194.0	9.23	188.15	3.50	53.72
2006	95,573	95,573	352,271	16,971,155	22,661,447	47,100.6	18,556,273	11,168,344.5	5.15	177.57	3.69	48.18
2007	110,343	110,343	397,949	17,836,876	23,352,578	49,588.1	22,156,451	15,933,908.8	4.98	161.65	3.61	44.82
2008	153,694	153,694	527,600	21,114,037	26,770,903	58,867.2	42,433,633	26,408,239.1	3.62	137.38	3.43	40.02
2009	187,018	187,018	636,501	24,357,162	30,569,270	68,001.3	44,301,003	33,973,196.2	4.22	130.24	3.40	38.27
2010	171,817	171,817	586,816	22,264,899	27,930,519	62,170.3	42,493,670	32,742,137.4	4.04	129.58	3.42	37.94
2011	166,061	166,061	544,115	20,158,720	24,952,981	56,299.7	41,306,760	32,145,345.3	4.02	121.39	3.28	37.05
2012	158,444	158,444	455,746	16,168,842	19,657,194	45,165.4	40,180,280	31,001,187.2	3.94	102.05	2.88	35.48
2013	35,953	35,953	73,113	2,251,994	2,701,361	6,283.1	29,840,530	7,001,550.0	1.20	62.64	2.03	30.80
<b>Fluvoxamine</b>												
Incident with Respect to Itself												
2000	1,122	1,122	4,827	176,913	324,699	491.7	7,275,491	3,372,710.3	0.15	157.68	4.30	36.65
2001	2,212	2,212	9,511	339,100	660,317	940.9	7,847,775	6,673,680.4	0.28	153.30	4.30	35.65
2002	1,795	1,795	7,718	291,660	613,595	808.8	7,992,400	6,767,964.0	0.22	162.48	4.30	37.79
2003	1,421	1,421	5,834	233,281	468,525	647.5	7,936,097	6,717,008.9	0.18	164.17	4.11	39.99
2004	1,397	1,397	5,905	239,456	878,645	664.7	8,496,221	6,926,899.6	0.16	171.41	4.23	40.55
2005	1,251	1,251	5,124	200,467	372,724	556.2	8,758,735	7,307,374.1	0.14	160.25	4.10	39.12
2006	1,854	1,854	8,189	294,894	530,891	820.1	19,689,477	12,099,900.0	0.09	159.06	4.42	36.01
2007	2,475	2,475	11,040	391,091	662,997	1,088.0	23,523,471	17,242,126.0	0.11	158.02	4.46	35.42

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2008	5,389	5,389	21,286	724,471	1,200,257	2,023.6	44,806,711	28,470,265.0	0.12	134.44	3.95	34.04
2009	7,008	7,008	28,472	930,337	1,521,556	2,602.8	46,684,407	36,569,984.4	0.15	132.75	4.06	32.68
2010	6,632	6,632	24,750	814,096	1,320,804	2,278.0	44,913,717	35,342,001.2	0.15	122.75	3.73	32.89
2011	6,380	6,380	22,960	745,427	1,194,490	2,087.5	43,757,312	34,790,701.3	0.15	116.84	3.60	32.47
2012	5,919	5,919	18,580	586,927	908,630	1,639.1	42,665,976	33,613,170.5	0.14	99.16	3.14	31.59
2013	1,367	1,367	2,926	81,316	121,827	226.9	32,154,498	7,597,375.9	0.04	59.49	2.14	27.79
<b>Incident with Respect to All SSRIs</b>												
2000	606	606	2,448	90,538	169,942	252.4	7,004,124	3,206,703.1	0.09	149.40	4.04	36.98
2001	1,180	1,180	4,601	159,742	305,551	444.4	7,580,960	6,304,239.6	0.16	135.37	3.90	34.72
2002	880	880	3,574	136,698	281,056	379.0	7,670,450	6,328,545.7	0.11	155.34	4.06	38.25
2003	689	689	2,742	105,387	206,073	292.7	7,567,590	6,232,148.7	0.09	152.96	3.98	38.43
2004	641	641	2,474	103,427	402,607	287.4	8,055,285	6,391,908.5	0.08	161.35	3.86	41.81
2005	590	590	2,239	88,168	142,187	245.4	8,310,422	6,759,188.0	0.07	149.44	3.79	39.38
2006	1,059	1,059	4,734	166,571	291,060	463.6	18,757,501	11,318,084.0	0.06	157.29	4.47	35.19
2007	1,392	1,392	5,844	197,833	319,091	550.7	22,392,438	16,110,959.8	0.06	142.12	4.20	33.85
2008	2,962	2,962	11,253	382,400	631,937	1,068.0	42,713,333	26,619,537.4	0.07	129.10	3.80	33.98
2009	3,954	3,954	15,190	488,322	773,217	1,368.5	44,634,697	34,222,110.2	0.09	123.50	3.84	32.15
2010	3,710	3,710	12,745	414,074	650,329	1,160.5	42,884,806	33,033,765.8	0.09	111.61	3.44	32.49
2011	3,588	3,588	11,907	382,717	575,252	1,073.2	41,742,534	32,473,754.3	0.09	106.67	3.32	32.14
2012	3,212	3,212	9,557	298,371	453,741	833.0	40,647,252	31,350,783.5	0.08	92.89	2.98	31.22
2013	770	770	1,645	45,869	67,548	128.0	30,193,365	7,081,768.6	0.03	59.57	2.14	27.88
<b>Imipramine</b>												
<b>Incident with Respect to Itself</b>												
2000	5,669	5,669	15,257	625,265	1,067,366	1,732.8	7,263,740	3,364,523.3	0.78	110.30	2.69	40.98
2001	9,939	9,939	27,078	1,130,879	1,957,794	3,134.3	7,836,072	6,657,247.8	1.27	113.78	2.72	41.76
2002	8,810	8,810	24,596	1,080,533	1,882,535	2,991.0	7,975,327	6,747,734.5	1.10	122.65	2.79	43.93
2003	7,780	7,780	22,054	978,523	1,786,577	2,708.2	7,914,552	6,693,142.6	0.98	125.77	2.83	44.37
2004	7,938	7,938	22,467	986,949	3,094,267	2,726.9	8,469,575	6,899,025.1	0.94	124.33	2.83	43.93
2005	7,108	7,108	17,135	790,825	1,364,127	2,183.7	8,728,315	7,275,834.0	0.81	111.26	2.41	46.15
2006	7,525	7,525	19,591	879,984	1,487,118	2,432.6	19,656,732	12,068,013.0	0.38	116.94	2.60	44.92
2007	8,483	8,483	23,122	949,903	1,602,070	2,634.2	23,487,027	17,206,858.7	0.36	111.98	2.73	41.08
2008	12,306	12,306	33,340	1,238,441	2,023,758	3,443.7	44,765,240	28,429,379.5	0.27	100.64	2.71	37.15

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2009	14,229	14,229	37,076	1,361,873	2,245,137	3,787.2	46,641,908	36,526,938.6	0.31	95.71	2.61	36.73
2010	12,293	12,293	32,288	1,203,300	1,976,541	3,344.7	44,869,848	35,298,552.9	0.27	97.88	2.63	37.27
2011	10,745	10,745	27,296	996,802	1,624,642	2,772.6	43,713,585	34,747,604.8	0.25	92.77	2.54	36.52
2012	9,642	9,642	21,614	762,669	1,221,263	2,120.4	42,622,881	33,571,787.1	0.23	79.10	2.24	35.29
2013	1,790	1,790	3,001	89,651	146,398	249.3	32,123,161	7,589,660.1	0.06	50.08	1.68	29.87
Incident with Respect to All Cyclics												
2000	4,949	4,949	12,937	530,467	883,722	1,470.8	7,137,141	3,277,671.0	0.69	107.19	2.61	41.00
2001	8,706	8,706	22,914	961,687	1,610,007	2,666.0	7,731,589	6,484,547.9	1.13	110.46	2.63	41.97
2002	7,750	7,750	20,423	899,633	1,506,748	2,491.4	7,867,286	6,570,369.3	0.99	116.08	2.64	44.05
2003	6,857	6,857	18,430	811,160	1,380,178	2,246.9	7,806,980	6,516,375.2	0.88	118.30	2.69	44.01
2004	6,936	6,936	18,996	832,995	2,491,311	2,303.4	8,348,982	6,713,244.6	0.83	120.10	2.74	43.85
2005	6,318	6,318	15,015	689,176	1,169,220	1,903.9	8,609,918	7,090,650.9	0.73	109.08	2.38	45.90
2006	6,900	6,900	17,700	791,725	1,326,084	2,189.8	19,478,402	11,864,814.4	0.35	114.74	2.57	44.73
2007	7,811	7,811	20,757	849,272	1,415,381	2,355.9	23,268,723	16,948,919.7	0.34	108.73	2.66	40.91
2008	11,288	11,288	29,565	1,101,594	1,766,160	3,064.6	44,430,313	28,046,906.9	0.25	97.59	2.62	37.26
2009	13,142	13,142	33,508	1,224,670	2,000,911	3,407.6	46,323,876	36,071,471.8	0.28	93.19	2.55	36.55
2010	11,269	11,269	29,077	1,081,308	1,731,570	3,007.6	44,553,461	34,846,963.4	0.25	95.95	2.58	37.19
2011	9,869	9,869	24,697	900,796	1,430,222	2,506.4	43,397,483	34,289,034.6	0.23	91.28	2.50	36.47
2012	8,800	8,800	19,547	686,470	1,083,564	1,910.0	42,300,283	33,113,024.2	0.21	78.01	2.22	35.12
2013	1,636	1,636	2,759	82,328	132,810	229.0	31,754,802	7,486,020.5	0.05	50.32	1.69	29.84
<b>Levomilnacipran</b>												
Incident with Respect to Itself												
2000	0	0	0	0	0	0.0	7,278,111	3,374,478.6	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,850,755	6,677,703.2	0.00	---	---	---
2002	0	0	0	0	0	0.0	7,997,059	6,773,247.6	0.00	---	---	---
2003	0	0	0	0	0	0.0	7,941,850	6,723,049.5	0.00	---	---	---
2004	0	0	0	0	0	0.0	8,502,991	6,933,805.3	0.00	---	---	---
2005	0	0	0	0	0	0.0	8,766,218	7,314,842.3	0.00	---	---	---
2006	0	0	0	0	0	0.0	19,699,906	12,108,539.1	0.00	---	---	---
2007	0	0	0	0	0	0.0	23,535,225	17,253,347.2	0.00	---	---	---
2008	0	0	0	0	0	0.0	44,825,438	28,486,529.2	0.00	---	---	---
2009	0	0	0	0	0	0.0	46,706,004	36,591,937.2	0.00	---	---	---

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2010	0	0	0	0	0	0.0	44,938,147	35,366,232.5	0.00	---	---	---
2011	0	0	0	0	0	0.0	43,784,086	34,816,911.2	0.00	---	---	---
2012	0	0	0	0	0	0.0	42,694,307	33,640,292.0	0.00	---	---	---
2013	0	0	0	0	0	0.0	32,178,261	7,603,274.6	0.00	---	---	---
Incident with Respect to All SNRIs												
2000	0	0	0	0	0	0.0	7,258,584	3,361,047.7	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,830,259	6,643,331.0	0.00	---	---	---
2002	0	0	0	0	0	0.0	7,968,180	6,725,255.1	0.00	---	---	---
2003	0	0	0	0	0	0.0	7,902,272	6,661,078.1	0.00	---	---	---
2004	0	0	0	0	0	0.0	8,449,622	6,860,241.6	0.00	---	---	---
2005	0	0	0	0	0	0.0	8,703,208	7,227,229.1	0.00	---	---	---
2006	0	0	0	0	0	0.0	19,522,077	11,967,952.8	0.00	---	---	---
2007	0	0	0	0	0	0.0	23,299,406	17,015,725.9	0.00	---	---	---
2008	0	0	0	0	0	0.0	44,305,218	28,044,863.1	0.00	---	---	---
2009	0	0	0	0	0	0.0	46,174,920	35,998,382.4	0.00	---	---	---
2010	0	0	0	0	0	0.0	44,410,890	34,789,100.6	0.00	---	---	---
2011	0	0	0	0	0	0.0	43,267,266	34,245,191.2	0.00	---	---	---
2012	0	0	0	0	0	0.0	42,171,542	33,070,839.7	0.00	---	---	---
2013	0	0	0	0	0	0.0	31,673,435	7,471,545.0	0.00	---	---	---
<b>Maprotiline</b>												
Incident with Respect to Itself												
2000	31	31	216	6,609	18,268	18.7	7,277,886	3,374,340.9	0.00	213.19	6.97	30.60
2001	39	39	133	5,716	14,706	15.7	7,850,547	6,677,475.4	0.00	146.56	3.41	42.98
2002	37	37	170	6,701	15,643	18.5	7,996,854	6,773,026.3	0.00	181.11	4.59	39.42
2003	49	49	105	3,175	8,130	8.8	7,941,645	6,722,824.4	0.01	64.80	2.14	30.24
2004	40	40	89	3,213	7,560	9.0	8,502,751	6,933,568.4	0.00	80.33	2.23	36.10
2005	23	23	45	1,297	2,789	3.7	8,765,968	7,314,594.5	0.00	56.39	1.96	28.82
2006	49	49	162	6,313	11,863	17.5	19,699,583	12,108,280.1	0.00	128.84	3.31	38.97
2007	64	64	210	7,840	23,518	21.7	23,534,827	17,252,999.9	0.00	122.50	3.28	37.33
2008	96	96	242	7,989	14,910	22.2	44,824,832	28,486,014.0	0.00	83.22	2.52	33.01
2009	106	106	289	10,183	25,722	28.3	46,705,371	36,591,315.3	0.00	96.07	2.73	35.24
2010	108	108	416	13,460	23,561	37.6	44,937,517	35,365,629.3	0.00	124.63	3.85	32.36

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2011	84	84	244	7,980	14,418	22.2	43,783,445	34,816,295.6	0.00	95.00	2.90	32.70
2012	84	84	214	7,064	11,516	19.8	42,693,677	33,639,702.1	0.00	84.10	2.55	33.01
2013	13	13	23	840	1,106	2.3	32,177,757	7,603,149.8	0.00	64.62	1.77	36.52
Incident with Respect to All Cyclics												
2000	23	23	150	4,615	13,623	13.1	7,137,141	3,277,671.0	0.00	200.65	6.52	30.77
2001	30	30	73	2,472	5,845	6.8	7,734,948	6,486,581.1	0.00	82.40	2.43	33.86
2002	25	25	95	4,291	10,698	11.8	7,877,113	6,577,508.5	0.00	171.64	3.80	45.17
2003	28	28	60	1,901	4,942	5.3	7,821,990	6,527,968.8	0.00	67.89	2.14	31.68
2004	21	21	50	2,034	5,175	5.7	8,368,587	6,728,884.0	0.00	96.86	2.38	40.68
2005	12	12	23	678	1,255	1.9	8,633,764	7,109,833.6	0.00	56.50	1.92	29.48
2006	34	34	129	4,806	9,522	13.4	19,503,247	11,885,307.5	0.00	141.35	3.79	37.26
2007	45	45	171	6,669	19,991	18.4	23,296,805	16,972,325.8	0.00	148.20	3.80	39.00
2008	75	75	170	5,867	9,877	16.3	44,462,456	28,073,676.4	0.00	78.23	2.27	34.51
2009	79	79	195	7,154	17,078	20.0	46,361,045	36,102,095.3	0.00	90.56	2.47	36.69
2010	78	78	317	10,409	16,614	29.1	44,595,946	34,882,125.9	0.00	133.45	4.06	32.84
2011	65	65	136	4,367	8,715	12.2	43,443,313	34,327,314.3	0.00	67.18	2.09	32.11
2012	57	57	152	5,014	7,741	14.1	42,347,852	33,152,305.2	0.00	87.96	2.67	32.99
2013	8	8	16	648	723	1.8	31,787,476	7,493,639.3	0.00	81.00	2.00	40.50
<b>Mirtazapine</b>												
Incident with Respect to Itself												
2000	9,320	9,320	38,802	1,197,620	1,510,007	3,332.4	7,269,561	3,367,414.0	1.28	128.50	4.16	30.86
2001	22,631	22,631	92,993	2,938,662	3,524,057	8,170.6	7,835,515	6,652,616.3	2.89	129.85	4.11	31.60
2002	23,462	23,462	88,146	2,854,591	3,391,469	7,940.1	7,961,627	6,729,167.8	2.95	121.67	3.76	32.38
2003	20,661	20,661	74,087	2,497,617	3,888,240	6,945.6	7,888,826	6,664,914.3	2.62	120.89	3.59	33.71
2004	20,466	20,466	73,252	2,577,078	5,794,580	7,155.4	8,434,665	6,862,314.8	2.43	125.92	3.58	35.18
2005	17,046	17,046	52,853	1,995,403	2,164,950	5,529.2	8,686,853	7,235,788.0	1.96	117.06	3.10	37.75
2006	20,460	20,460	75,314	2,861,847	3,098,851	7,925.0	19,625,776	12,040,431.3	1.04	139.88	3.68	38.00
2007	28,192	28,192	106,815	3,868,045	4,073,164	10,719.8	23,445,804	17,167,366.6	1.20	137.20	3.79	36.21
2008	47,399	47,399	169,642	5,800,238	5,995,329	16,102.6	44,700,819	28,364,989.6	1.06	122.37	3.58	34.19
2009	60,972	60,972	208,840	7,097,476	7,224,903	19,711.7	46,561,063	36,439,427.7	1.31	116.41	3.43	33.99
2010	63,033	63,033	207,001	7,121,432	7,235,966	19,770.9	44,769,050	35,192,271.8	1.41	112.98	3.28	34.40
2011	63,157	63,157	194,118	6,630,259	6,675,595	18,409.4	43,592,392	34,621,398.2	1.45	104.98	3.07	34.16

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2012	66,712	66,712	176,017	5,804,786	5,748,443	16,124.4	42,482,370	33,428,848.0	1.57	87.01	2.64	32.98
2013	16,519	16,519	31,553	926,815	917,124	2,572.4	32,000,109	7,558,338.5	0.52	56.11	1.91	29.37
Incident with Respect to All Cyclics												
2000	7,054	7,054	25,805	792,860	1,050,354	2,208.7	7,137,141	3,277,671.0	0.99	112.40	3.66	30.73
2001	18,256	18,256	68,058	2,135,426	2,476,256	5,943.9	7,730,903	6,484,131.2	2.36	116.97	3.73	31.38
2002	20,033	20,033	69,086	2,215,379	2,528,505	6,168.9	7,861,298	6,566,514.6	2.55	110.59	3.45	32.07
2003	18,074	18,074	62,418	2,069,438	3,121,534	5,759.7	7,794,030	6,507,539.7	2.32	114.50	3.45	33.15
2004	18,117	18,117	62,599	2,166,378	4,802,925	6,017.5	8,330,008	6,699,214.0	2.17	119.58	3.46	34.61
2005	15,290	15,290	45,534	1,675,312	1,773,500	4,645.2	8,585,810	7,073,229.0	1.78	109.57	2.98	36.79
2006	18,710	18,710	66,676	2,488,363	2,657,668	6,893.9	19,463,372	11,853,910.2	0.96	133.00	3.56	37.32
2007	26,011	26,011	95,647	3,423,216	3,587,491	9,489.6	23,250,313	16,934,796.5	1.12	131.61	3.68	35.79
2008	44,183	44,183	154,527	5,250,875	5,394,267	14,580.4	44,403,922	28,026,989.5	1.00	118.84	3.50	33.98
2009	56,883	56,883	191,556	6,455,553	6,530,347	17,932.6	46,284,780	36,043,608.7	1.23	113.49	3.37	33.70
2010	58,908	58,908	189,367	6,471,342	6,523,413	17,971.1	44,500,815	34,808,438.1	1.32	109.86	3.21	34.17
2011	58,854	58,854	177,920	6,029,438	6,031,358	16,743.5	43,329,180	34,238,065.4	1.36	102.45	3.02	33.89
2012	62,322	62,322	162,999	5,355,062	5,283,771	14,876.0	42,218,558	33,052,395.1	1.48	85.93	2.62	32.85
2013	15,443	15,443	29,338	857,367	845,358	2,380.0	31,698,222	7,473,488.8	0.49	55.52	1.90	29.22
<b>Nefazodone</b>												
Incident with Respect to Itself												
2000	5,897	5,897	19,663	727,175	1,538,879	2,022.8	7,269,080	3,367,779.9	0.81	123.31	3.33	36.98
2001	12,975	12,975	39,885	1,535,126	3,240,314	4,274.3	7,838,931	6,659,696.0	1.66	118.31	3.07	38.49
2002	3,828	3,828	10,795	426,201	926,360	1,183.4	7,975,624	6,750,449.6	0.48	111.34	2.82	39.48
2003	2,022	2,022	5,550	229,718	486,783	638.5	7,920,059	6,701,586.9	0.26	113.61	2.74	41.39
2004	1,095	1,095	2,854	122,456	827,568	339.7	8,481,403	6,913,066.0	0.13	111.83	2.61	42.91
2005	512	512	1,377	63,904	128,576	177.0	8,746,063	7,295,964.1	0.06	124.81	2.69	46.41
2006	908	908	3,251	137,711	317,050	382.4	19,681,460	12,092,473.8	0.05	151.66	3.58	42.36
2007	1,101	1,101	3,710	145,095	309,452	403.5	23,517,287	17,236,738.7	0.05	131.78	3.37	39.11
2008	1,378	1,378	4,012	149,346	312,232	416.6	44,804,568	28,468,322.4	0.03	108.38	2.91	37.22
2009	1,542	1,542	4,989	183,064	389,453	510.1	46,685,861	36,573,172.0	0.03	118.72	3.24	36.69
2010	1,246	1,246	3,714	135,372	276,150	377.8	44,919,232	35,348,578.0	0.03	108.65	2.98	36.45
2011	1,078	1,078	3,120	112,211	230,275	312.5	43,766,109	34,800,097.4	0.02	104.09	2.89	35.97
2012	867	867	2,036	71,120	149,765	197.9	42,677,473	33,625,001.4	0.02	82.03	2.35	34.93

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2013	216	216	394	11,901	23,210	33.2	32,166,698	7,600,434.8	0.01	55.10	1.82	30.21
Incident with Respect to Miscellaneous Anti-Depressants												
2000	4,782	4,782	14,897	544,951	1,135,537	1,517.6	7,200,994	3,320,591.3	0.66	113.96	3.12	36.58
2001	10,628	10,628	30,942	1,173,460	2,438,940	3,270.1	7,782,456	6,565,446.4	1.37	110.41	2.91	37.92
2002	3,197	3,197	8,613	337,146	688,298	937.2	7,917,136	6,650,152.9	0.40	105.46	2.69	39.14
2003	1,672	1,672	4,280	175,554	370,716	488.5	7,857,433	6,594,969.4	0.21	105.00	2.56	41.02
2004	922	922	2,359	98,821	754,068	274.3	8,405,449	6,796,173.9	0.11	107.18	2.56	41.89
2005	445	445	1,120	50,243	92,928	139.3	8,667,986	7,171,524.7	0.05	112.91	2.52	44.86
2006	794	794	2,863	119,732	278,636	332.7	19,560,441	11,948,691.6	0.04	150.80	3.61	41.82
2007	961	961	3,062	118,527	249,291	329.9	23,368,756	17,048,292.1	0.04	123.34	3.19	38.71
2008	1,213	1,213	3,555	130,620	268,355	364.6	44,559,797	28,191,899.1	0.03	107.68	2.93	36.74
2009	1,338	1,338	4,259	154,836	317,984	431.8	46,442,251	36,227,428.5	0.03	115.72	3.18	36.36
2010	1,085	1,085	3,168	114,355	233,979	319.4	44,665,304	34,992,379.5	0.02	105.40	2.92	36.10
2011	908	908	2,632	93,743	191,068	261.3	43,501,083	34,425,719.8	0.02	103.24	2.90	35.62
2012	733	733	1,710	58,610	125,074	163.4	42,397,369	33,244,360.8	0.02	79.96	2.33	34.27
2013	182	182	330	9,965	18,817	27.7	31,854,272	7,512,333.0	0.01	54.75	1.81	30.20
<b>Nortriptyline</b>												
Incident with Respect to Itself												
2000	11,351	11,351	30,734	1,314,423	9,727,417	3,638.9	7,258,327	3,359,802.0	1.56	115.80	2.71	42.77
2001	23,220	23,220	59,643	2,650,420	4,459,646	7,335.8	7,827,430	6,643,196.0	2.97	114.14	2.57	44.44
2002	25,029	25,029	63,862	3,080,950	5,209,337	8,514.8	7,955,523	6,722,004.5	3.15	123.10	2.55	48.24
2003	35,792	35,792	82,454	4,297,562	8,387,835	11,872.6	7,881,691	6,651,540.4	4.54	120.07	2.30	52.12
2004	42,719	42,719	93,192	4,926,344	10,954,258	13,611.8	8,411,428	6,828,812.1	5.08	115.32	2.18	52.86
2005	41,406	41,406	89,903	4,743,235	8,885,365	13,102.0	8,642,565	7,179,860.9	4.79	114.55	2.17	52.76
2006	46,083	46,083	104,098	5,182,598	9,634,629	14,331.6	19,541,618	11,946,018.0	2.36	112.46	2.26	49.79
2007	50,160	50,160	112,650	5,326,959	9,887,422	14,748.1	23,344,747	17,056,896.5	2.15	106.20	2.25	47.29
2008	59,338	59,338	132,851	5,670,738	10,298,110	15,734.4	44,585,568	28,244,822.7	1.33	95.57	2.24	42.68
2009	70,774	70,774	161,587	6,562,130	11,859,489	18,230.7	46,437,272	36,310,672.5	1.52	92.72	2.28	40.61
2010	72,158	72,158	164,701	6,648,927	12,070,385	18,470.4	44,634,788	35,053,345.2	1.62	92.14	2.28	40.37
2011	72,173	72,173	155,877	6,216,634	11,238,174	17,267.4	43,447,598	34,472,824.3	1.66	86.14	2.16	39.88
2012	72,076	72,076	139,730	5,312,249	9,518,578	14,759.4	42,327,141	33,272,363.7	1.70	73.70	1.94	38.02
2013	16,859	16,859	25,779	803,849	1,472,784	2,232.5	31,820,154	7,514,127.6	0.53	47.68	1.53	31.18



**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
Incident with Respect to All Cyclics												
2000	9,424	9,424	24,065	1,041,590	1,755,232	2,883.4	7,137,141	3,277,671.0	1.32	110.53	2.55	43.28
2001	19,553	19,553	47,492	2,085,267	3,459,496	5,773.9	7,728,617	6,482,703.5	2.53	106.65	2.43	43.91
2002	21,442	21,442	51,268	2,470,161	4,103,685	6,826.5	7,856,574	6,562,555.9	2.73	115.20	2.39	48.18
2003	31,710	31,710	69,561	3,596,062	6,945,964	9,936.0	7,786,882	6,501,219.0	4.07	113.40	2.19	51.70
2004	39,137	39,137	81,257	4,310,618	9,636,411	11,909.4	8,312,327	6,685,177.6	4.71	110.14	2.08	53.05
2005	38,280	38,280	79,095	4,160,922	7,790,244	11,493.5	8,551,188	7,044,444.8	4.48	108.70	2.07	52.61
2006	43,099	43,099	93,294	4,646,182	8,605,979	12,847.6	19,399,991	11,801,466.3	2.22	107.80	2.16	49.80
2007	46,919	46,919	101,086	4,792,099	8,909,762	13,266.2	23,168,352	16,866,476.3	2.03	102.14	2.15	47.41
2008	55,354	55,354	119,227	5,099,340	9,300,560	14,148.6	44,306,703	27,942,937.0	1.25	92.12	2.15	42.77
2009	65,815	65,815	145,261	5,882,863	10,672,379	16,345.7	46,176,321	35,946,729.3	1.43	89.38	2.21	40.50
2010	67,341	67,341	148,870	6,007,814	10,943,411	16,690.0	44,379,896	34,700,237.8	1.52	89.21	2.21	40.36
2011	67,292	67,292	140,853	5,623,966	10,225,044	15,621.2	43,198,367	34,120,290.1	1.56	83.58	2.09	39.93
2012	67,489	67,489	127,459	4,844,621	8,713,214	13,461.7	42,076,843	32,924,752.0	1.60	71.78	1.89	38.01
2013	15,682	15,682	23,649	735,041	1,359,330	2,041.2	31,546,649	7,437,508.7	0.50	46.87	1.51	31.08
<b>Paroxetine</b>												
Incident with Respect to Itself												
2000	44,699	44,699	172,810	7,560,196	7,096,367	20,971.6	7,189,054	3,314,783.9	6.22	169.14	3.87	43.75
2001	82,248	82,248	308,284	13,511,681	12,837,436	37,486.4	7,745,195	6,534,343.7	10.62	164.28	3.75	43.83
2002	77,403	77,403	303,292	12,392,120	12,222,073	34,443.0	7,829,710	6,580,321.0	9.89	160.10	3.92	40.86
2003	53,560	53,560	201,644	8,510,824	9,615,842	23,635.3	7,725,832	6,498,454.5	6.93	158.90	3.76	42.21
2004	43,448	43,448	158,883	6,940,307	9,210,013	19,251.7	8,252,608	6,686,755.2	5.26	159.74	3.66	43.68
2005	31,919	31,919	104,029	4,573,279	4,224,908	12,687.8	8,502,199	7,061,666.6	3.75	143.28	3.26	43.96
2006	47,996	47,996	182,511	7,376,863	7,127,312	20,528.7	19,383,992	11,841,189.2	2.48	153.70	3.80	40.42
2007	55,850	55,850	211,741	7,851,614	7,957,900	21,904.3	23,184,752	16,935,645.1	2.41	140.58	3.79	37.08
2008	88,333	88,333	312,165	10,790,213	11,339,500	30,184.7	44,345,642	28,072,032.3	1.99	122.15	3.53	34.57
2009	108,320	108,320	365,470	12,650,825	13,265,600	35,412.9	46,219,148	36,115,232.2	2.34	116.79	3.37	34.62
2010	94,632	94,632	319,330	11,260,420	11,845,835	31,501.1	44,442,061	34,889,318.1	2.13	118.99	3.37	35.26
2011	86,470	86,470	277,213	9,756,100	10,230,486	27,275.4	43,284,995	34,339,208.2	2.00	112.83	3.21	35.19
2012	80,140	80,140	225,262	7,701,951	8,060,514	21,518.8	42,194,190	33,173,763.2	1.90	96.11	2.81	34.19
2013	17,170	17,170	33,999	1,042,716	1,092,793	2,907.6	31,785,281	7,506,143.6	0.54	60.73	1.98	30.67

Incident with Respect to All SSRIs

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2000	39,066	39,066	145,080	6,361,790	5,847,421	17,651.5	7,004,124	3,206,703.1	5.58	162.85	3.71	43.85
2001	70,668	70,668	255,144	11,214,008	10,364,520	31,116.8	7,562,580	6,294,337.4	9.34	158.69	3.61	43.95
2002	62,533	62,533	236,256	9,563,853	9,179,611	26,602.0	7,613,831	6,291,860.8	8.21	152.94	3.78	40.48
2003	42,201	42,201	151,889	6,281,660	6,862,916	17,458.2	7,481,966	6,173,438.1	5.64	148.85	3.60	41.36
2004	33,290	33,290	117,625	5,002,414	6,573,792	13,887.4	7,950,161	6,315,888.5	4.19	150.27	3.53	42.53
2005	24,680	24,680	75,903	3,304,573	2,990,511	9,171.9	8,191,973	6,671,714.4	3.01	133.90	3.08	43.54
2006	38,688	38,688	141,571	5,651,180	5,400,675	15,740.0	18,645,510	11,233,094.0	2.07	146.07	3.66	39.92
2007	45,136	45,136	163,442	6,024,009	6,048,751	16,812.8	22,270,723	16,017,715.3	2.03	133.46	3.62	36.86
2008	71,665	71,665	241,697	8,299,517	8,647,391	23,228.7	42,576,009	26,514,719.0	1.68	115.81	3.37	34.34
2009	88,258	88,258	285,972	9,854,255	10,238,491	27,589.1	44,475,352	34,103,475.3	1.98	111.65	3.24	34.46
2010	77,042	77,042	250,136	8,789,934	9,171,352	24,597.4	42,703,734	32,898,260.6	1.80	114.09	3.25	35.14
2011	69,770	69,770	215,713	7,584,418	7,893,228	21,209.0	41,547,975	32,326,862.2	1.68	108.71	3.09	35.16
2012	64,547	64,547	175,898	5,995,341	6,225,017	16,754.2	40,445,183	31,200,157.5	1.60	92.88	2.73	34.08
2013	14,002	14,002	27,243	835,005	871,251	2,328.4	30,060,875	7,051,716.3	0.47	59.63	1.95	30.65
<b>Protriptyline</b>												
Incident with Respect to Itself												
2000	242	242	648	26,653	67,290	73.5	7,277,709	3,374,172.5	0.03	110.14	2.68	41.13
2001	532	532	1,376	56,395	136,462	156.0	7,850,270	6,676,952.4	0.07	106.01	2.59	40.98
2002	478	478	1,313	55,155	123,447	152.5	7,996,129	6,772,135.1	0.06	115.39	2.75	42.01
2003	471	471	1,222	50,047	115,031	138.7	7,940,588	6,721,620.3	0.06	106.26	2.59	40.95
2004	381	381	805	32,199	179,881	89.3	8,501,365	6,932,095.6	0.04	84.51	2.11	40.00
2005	313	313	965	38,779	78,227	107.9	8,764,399	7,312,991.2	0.04	123.89	3.08	40.19
2006	412	412	1,022	36,776	84,779	102.9	19,697,748	12,106,543.6	0.02	89.26	2.48	35.98
2007	503	503	1,088	40,690	103,129	113.5	23,532,895	17,250,991.5	0.02	80.89	2.16	37.40
2008	681	681	1,602	55,918	121,791	156.7	44,822,458	28,483,638.8	0.02	82.11	2.35	34.91
2009	816	816	2,219	74,456	173,697	208.3	46,702,782	36,588,606.9	0.02	91.25	2.72	33.55
2010	917	917	2,355	82,827	192,453	230.6	44,934,608	35,362,636.4	0.02	90.32	2.57	35.17
2011	842	842	1,949	65,075	141,129	181.9	43,780,243	34,812,998.4	0.02	77.29	2.31	33.39
2012	760	760	1,729	57,124	126,847	159.6	42,690,252	33,636,255.2	0.02	75.16	2.28	33.04
2013	145	145	246	6,892	13,068	19.4	32,174,468	7,602,336.8	0.00	47.53	1.70	28.02
Incident with Respect to All Cyclics												
2000	155	155	426	18,320	49,640	50.5	7,137,141	3,277,671.0	0.02	118.19	2.75	43.00

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2001	375	375	903	34,007	75,930	94.2	7,734,846	6,486,515.5	0.05	90.69	2.41	37.66
2002	322	322	815	32,702	72,235	90.4	7,876,777	6,577,262.5	0.04	101.56	2.53	40.13
2003	322	322	749	30,894	65,363	85.6	7,821,462	6,527,560.9	0.04	95.94	2.33	41.25
2004	240	240	502	19,202	91,646	53.3	8,367,853	6,728,309.0	0.03	80.01	2.09	38.25
2005	229	229	643	24,185	47,583	67.3	8,632,935	7,109,167.3	0.03	105.61	2.81	37.61
2006	292	292	643	23,053	50,452	64.5	19,502,398	11,884,612.9	0.01	78.95	2.20	35.85
2007	395	395	793	29,362	71,076	81.8	23,295,816	16,971,526.1	0.02	74.33	2.01	37.03
2008	530	530	1,234	42,690	90,801	119.7	44,461,274	28,072,699.5	0.01	80.55	2.33	34.59
2009	626	626	1,651	54,526	124,521	152.7	46,359,642	36,100,948.8	0.01	87.10	2.64	33.03
2010	721	721	1,747	59,866	127,187	166.8	44,594,306	34,880,795.4	0.02	83.03	2.42	34.27
2011	636	636	1,415	46,737	96,352	130.5	43,441,455	34,325,781.9	0.01	73.49	2.22	33.03
2012	593	593	1,331	43,258	91,657	121.3	42,345,809	33,150,634.5	0.01	72.95	2.24	32.50
2013	114	114	190	5,487	10,374	15.4	31,785,720	7,493,233.1	0.00	48.13	1.67	28.88
<b>Sertraline</b>												
Incident with Respect to Itself												
2000	27,168	27,168	112,747	4,016,245	4,461,511	11,201.2	7,215,308	3,334,560.2	3.77	147.83	4.15	35.62
2001	55,274	55,274	235,496	8,346,805	9,371,499	23,287.9	7,777,927	6,583,005.9	7.11	151.01	4.26	35.44
2002	53,689	53,689	227,634	8,175,492	9,485,027	22,801.5	7,881,878	6,642,064.0	6.81	152.27	4.24	35.92
2003	50,682	50,682	204,007	7,552,612	10,381,127	21,054.8	7,790,773	6,563,409.0	6.51	149.02	4.03	37.02
2004	47,649	47,649	185,911	6,838,286	11,041,157	19,063.5	8,309,967	6,741,139.4	5.73	143.51	3.90	36.78
2005	35,720	35,720	123,675	4,640,398	5,134,954	12,933.6	8,549,980	7,105,183.1	4.18	129.91	3.46	37.52
2006	76,375	76,375	333,988	12,653,480	14,115,082	35,296.8	19,364,403	11,846,058.9	3.94	165.68	4.37	37.89
2007	122,219	122,219	499,864	18,548,312	20,824,972	51,810.4	23,122,428	16,873,463.9	5.29	151.76	4.09	37.11
2008	221,119	221,119	849,481	30,461,418	34,493,116	85,200.9	44,090,939	27,861,647.3	5.02	137.76	3.84	35.86
2009	305,140	305,140	1,154,740	41,097,524	46,669,444	114,951.7	45,882,675	35,749,381.5	6.65	134.68	3.78	35.59
2010	289,001	289,001	1,076,062	38,305,617	43,485,551	107,121.0	43,993,956	34,431,054.5	6.57	132.54	3.72	35.60
2011	289,934	289,934	1,020,636	36,129,754	40,727,312	101,013.6	42,744,080	33,795,219.1	6.78	124.61	3.52	35.40
2012	286,382	286,382	861,119	29,739,297	33,127,696	83,094.6	41,568,372	32,561,525.3	6.89	103.84	3.01	34.54
2013	64,220	64,220	133,195	4,041,181	4,408,287	11,274.2	31,197,380	7,359,137.0	2.06	62.93	2.07	30.34
Incident with Respect to All SSRIs												
2000	21,698	21,698	86,729	3,016,004	3,248,733	8,418.0	7,004,124	3,206,703.1	3.10	139.00	4.00	34.78
2001	42,882	42,882	174,487	6,019,879	6,444,875	16,816.4	7,571,534	6,299,200.1	5.66	140.38	4.07	34.50

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2002	40,706	40,706	165,279	5,737,956	6,512,108	16,026.0	7,639,517	6,309,234.5	5.33	140.96	4.06	34.72
2003	38,379	38,379	146,409	5,207,371	6,817,521	14,540.2	7,518,051	6,199,560.3	5.10	135.68	3.81	35.57
2004	36,239	36,239	133,885	4,755,267	7,570,176	13,273.5	7,987,679	6,345,658.8	4.54	131.22	3.69	35.52
2005	27,660	27,660	90,326	3,286,365	3,528,972	9,172.3	8,226,723	6,700,421.8	3.36	118.81	3.27	36.38
2006	63,071	63,071	264,137	9,793,911	10,737,620	27,349.3	18,676,372	11,259,559.6	3.38	155.28	4.19	37.08
2007	100,332	100,332	395,474	14,319,874	15,733,577	40,036.4	22,292,746	16,039,814.8	4.50	142.72	3.94	36.21
2008	185,244	185,244	685,739	24,204,965	26,913,513	67,746.0	42,570,889	26,519,488.1	4.35	130.67	3.70	35.30
2009	257,503	257,503	939,552	33,054,616	36,904,676	92,492.5	44,423,032	34,077,368.1	5.80	128.37	3.65	35.18
2010	244,324	244,324	878,972	30,961,586	34,647,293	86,619.2	42,584,215	32,826,082.2	5.74	126.72	3.60	35.22
2011	243,334	243,334	830,005	29,022,892	32,239,514	81,179.7	41,371,038	32,211,268.9	5.88	119.27	3.41	34.97
2012	242,460	242,460	709,411	24,262,210	26,697,977	67,814.1	40,218,148	31,047,761.7	6.03	100.07	2.93	34.20
2013	54,727	54,727	111,668	3,366,014	3,649,915	9,391.8	29,885,444	7,013,718.7	1.83	61.51	2.04	30.14
<b>Trazodone</b>												
Incident with Respect to Itself												
2000	34,425	34,425	86,005	3,264,648	4,498,330	9,052.0	7,209,363	3,326,208.6	4.78	94.83	2.50	37.96
2001	67,758	67,758	167,041	6,322,774	8,793,041	17,532.2	7,770,691	6,565,953.5	8.72	93.31	2.47	37.85
2002	70,032	70,032	171,216	6,706,112	10,099,573	18,583.2	7,865,371	6,616,687.6	8.90	95.76	2.44	39.17
2003	67,890	67,890	162,605	6,464,359	10,504,724	17,910.7	7,761,286	6,523,984.6	8.75	95.22	2.40	39.75
2004	69,334	69,334	165,521	6,479,086	14,102,948	17,950.9	8,268,097	6,688,724.3	8.39	93.45	2.39	39.14
2005	67,331	67,331	140,994	5,747,537	7,628,777	15,900.6	8,490,467	7,031,505.6	7.93	85.36	2.09	40.76
2006	89,211	89,211	198,544	8,105,317	10,603,337	22,434.4	19,371,266	11,795,786.2	4.61	90.86	2.23	40.82
2007	111,773	111,773	248,483	9,667,765	12,576,361	26,792.5	23,137,705	16,861,452.2	4.83	86.49	2.22	38.91
2008	164,683	164,683	375,663	13,574,184	17,456,037	37,689.1	44,274,294	27,958,656.7	3.72	82.43	2.28	36.13
2009	215,016	215,016	491,370	17,255,043	22,134,589	47,954.8	46,080,062	35,939,035.6	4.67	80.25	2.29	35.12
2010	215,251	215,251	488,999	17,251,491	22,109,629	47,926.6	44,217,908	34,634,420.8	4.87	80.15	2.27	35.28
2011	216,389	216,389	471,440	16,556,925	20,938,800	45,993.9	42,977,182	34,004,177.1	5.03	76.51	2.18	35.12
2012	216,523	216,523	430,814	14,645,715	18,290,415	40,688.2	41,812,935	32,782,177.1	5.18	67.64	1.99	34.00
2013	55,165	55,165	85,056	2,540,032	3,143,474	7,049.8	31,395,633	7,407,404.7	1.76	46.04	1.54	29.86
Incident with Respect to Miscellaneous Anti-Depressants												
2000	33,744	33,744	83,607	3,169,553	4,354,075	8,788.0	7,200,994	3,320,591.3	4.69	93.93	2.48	37.91
2001	66,381	66,381	161,942	6,134,274	8,488,430	17,007.6	7,763,265	6,553,173.6	8.55	92.41	2.44	37.88
2002	69,008	69,008	167,039	6,548,100	9,698,647	18,145.6	7,859,306	6,607,010.1	8.78	94.89	2.42	39.20

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2003	67,619	67,619	161,471	6,409,292	10,377,521	17,758.6	7,758,202	6,519,304.5	8.72	94.79	2.39	39.69
2004	69,165	69,165	164,864	6,453,937	14,103,482	17,881.2	8,265,938	6,685,723.0	8.37	93.31	2.38	39.15
2005	67,315	67,315	140,946	5,748,468	7,626,135	15,902.9	8,489,660	7,030,064.5	7.93	85.40	2.09	40.78
2006	89,215	89,215	198,493	8,100,453	10,591,243	22,421.2	19,368,125	11,793,530.1	4.61	90.80	2.22	40.81
2007	111,693	111,693	248,116	9,653,533	12,559,737	26,753.1	23,134,343	16,858,260.2	4.83	86.43	2.22	38.91
2008	164,544	164,544	375,104	13,553,742	17,423,251	37,632.2	44,268,106	27,953,852.0	3.72	82.37	2.28	36.13
2009	214,867	214,867	490,854	17,236,930	22,106,162	47,904.3	46,074,618	35,933,522.3	4.66	80.22	2.28	35.12
2010	215,130	215,130	488,432	17,232,876	22,080,112	47,874.7	44,213,242	34,629,748.3	4.87	80.10	2.27	35.28
2011	216,277	216,277	471,061	16,542,307	20,917,654	45,953.7	42,973,265	34,000,222.8	5.03	76.49	2.18	35.12
2012	216,374	216,374	430,357	14,630,269	18,264,073	40,645.3	41,809,775	32,778,959.4	5.18	67.62	1.99	34.00
2013	55,143	55,143	85,016	2,538,867	3,142,082	7,046.6	31,392,946	7,406,714.5	1.76	46.04	1.54	29.86
<b>Trimipramine</b>												
Incident with Respect to Itself												
2000	33	33	169	5,327	9,522	14.7	7,277,963	3,374,387.7	0.00	161.42	5.12	31.52
2001	85	85	307	15,202	28,133	41.9	7,850,612	6,677,514.8	0.01	178.85	3.61	49.52
2002	110	110	323	12,725	22,919	35.3	7,996,854	6,773,007.6	0.01	115.68	2.94	39.40
2003	79	79	220	8,819	25,317	24.4	7,941,563	6,722,723.6	0.01	111.63	2.78	40.09
2004	47	47	159	4,872	12,679	13.4	8,502,634	6,933,445.3	0.01	103.66	3.38	30.64
2005	36	36	50	1,610	3,891	4.5	8,765,837	7,314,463.4	0.00	44.72	1.39	32.20
2006	53	53	164	6,857	12,223	18.9	19,699,483	12,108,169.3	0.00	129.38	3.09	41.81
2007	74	74	217	6,986	20,832	19.2	23,534,758	17,252,908.1	0.00	94.41	2.93	32.19
2008	68	68	217	7,413	11,965	20.6	44,824,807	28,485,965.1	0.00	109.01	3.19	34.16
2009	44	44	160	5,257	11,981	14.6	46,705,477	36,591,413.7	0.00	119.48	3.64	32.86
2010	39	39	132	4,303	8,309	11.9	44,937,653	35,365,766.4	0.00	110.33	3.38	32.60
2011	47	47	121	3,857	8,670	10.8	43,783,633	34,816,461.7	0.00	82.06	2.57	31.88
2012	44	44	142	5,050	9,494	14.0	42,693,861	33,639,859.1	0.00	114.77	3.23	35.56
2013	14	14	25	593	1,354	1.6	32,177,881	7,603,180.5	0.00	42.36	1.79	23.72
Incident with Respect to All Cyclics												
2000	23	23	83	2,496	4,610	6.9	7,137,141	3,277,671.0	0.00	108.52	3.61	30.07
2001	52	52	137	4,798	7,157	13.2	7,734,940	6,486,577.4	0.01	92.27	2.63	35.02
2002	67	67	177	6,707	9,471	18.7	7,877,103	6,577,495.8	0.01	100.10	2.64	37.89
2003	49	49	157	6,868	19,667	18.9	7,821,949	6,527,942.8	0.01	140.16	3.20	43.75

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2004	25	25	68	2,144	5,115	6.0	8,368,529	6,728,831.9	0.00	85.76	2.72	31.53
2005	26	26	53	2,435	6,847	6.7	8,633,700	7,109,780.3	0.00	93.65	2.04	45.94
2006	37	37	115	4,254	7,054	11.8	19,503,176	11,885,247.1	0.00	114.97	3.11	36.99
2007	51	51	157	4,996	15,302	13.8	23,296,735	16,972,265.1	0.00	97.96	3.08	31.82
2008	52	52	158	5,614	9,459	15.6	44,462,371	28,073,605.0	0.00	107.96	3.04	35.53
2009	32	32	117	3,918	8,581	10.9	46,360,983	36,102,029.6	0.00	122.44	3.66	33.49
2010	28	28	102	3,388	6,951	9.4	44,595,905	34,882,081.0	0.00	121.00	3.64	33.22
2011	23	23	75	2,387	5,351	6.7	43,443,308	34,327,289.3	0.00	103.78	3.26	31.83
2012	18	18	56	2,073	3,682	5.7	42,347,860	33,152,293.9	0.00	115.17	3.11	37.02
2013	12	12	23	534	1,265	1.5	31,787,457	7,493,634.5	0.00	44.50	1.92	23.22
<b>Venlafaxine</b>												
Incident with Respect to Itself												
2000	11,962	11,962	64,661	2,421,332	3,886,133	6,717.8	7,258,584	3,361,047.7	1.65	202.42	5.41	37.45
2001	28,187	28,187	148,997	5,648,767	9,298,869	15,679.1	7,823,811	6,639,418.8	3.60	200.40	5.29	37.91
2002	38,217	38,217	191,969	7,181,906	12,628,358	19,951.8	7,944,711	6,708,362.5	4.81	187.92	5.02	37.41
2003	40,929	40,929	197,144	7,688,045	14,139,091	21,359.2	7,857,361	6,627,747.2	5.21	187.84	4.82	39.00
2004	35,926	35,926	165,939	6,434,870	15,168,343	17,893.5	8,380,919	6,808,163.8	4.29	179.11	4.62	38.78
2005	25,420	25,420	105,557	4,364,689	6,739,151	12,125.4	8,621,704	7,174,153.3	2.95	171.70	4.15	41.35
2006	46,029	46,029	238,730	9,382,006	12,657,831	26,099.3	19,485,026	11,938,634.2	2.36	203.83	5.19	39.30
2007	66,687	66,687	346,059	12,738,141	16,540,074	35,542.6	23,280,969	17,017,607.4	2.86	191.01	5.19	36.81
2008	95,455	95,455	453,631	16,154,356	21,326,732	45,129.2	44,380,563	28,122,044.4	2.15	169.24	4.75	35.61
2009	101,012	101,012	454,140	16,181,557	21,950,871	45,177.0	46,243,441	36,148,034.5	2.18	160.19	4.50	35.63
2010	96,634	96,634	431,129	15,246,896	20,848,604	42,547.4	44,474,292	34,923,962.8	2.17	157.78	4.46	35.37
2011	103,062	103,062	427,872	14,940,253	19,944,761	41,685.3	43,306,776	34,360,038.4	2.38	144.96	4.15	34.92
2012	109,345	109,345	370,481	12,516,707	16,320,328	34,949.4	42,193,733	33,169,655.2	2.59	114.47	3.39	33.79
2013	26,765	26,765	57,881	1,711,763	2,205,686	4,772.6	31,749,721	7,496,794.8	0.84	63.96	2.16	29.57
Incident with Respect to All SNRIs												
2000	11,962	11,962	64,305	2,404,269	3,854,269	6,671.0	7,258,584	3,361,047.7	1.65	200.99	5.38	37.39
2001	28,187	28,187	148,176	5,603,740	9,219,417	15,555.8	7,823,811	6,639,418.8	3.60	198.81	5.26	37.82
2002	38,217	38,217	191,178	7,139,363	12,549,310	19,835.3	7,944,711	6,708,362.5	4.81	186.81	5.00	37.34
2003	40,929	40,929	195,346	7,605,619	13,883,015	21,133.4	7,857,361	6,627,747.2	5.21	185.82	4.77	38.93
2004	35,819	35,819	164,095	6,353,520	15,038,249	17,669.4	8,380,646	6,807,140.6	4.27	177.38	4.58	38.72

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2005	24,648	24,648	101,697	4,214,202	6,495,723	11,708.5	8,616,718	7,161,340.9	2.86	170.98	4.13	41.44
2006	44,145	44,145	225,955	8,870,375	11,931,576	24,683.8	19,441,407	11,904,191.9	2.27	200.94	5.12	39.26
2007	63,018	63,018	321,912	11,846,822	15,326,127	33,066.5	23,204,622	16,940,248.7	2.72	187.99	5.11	36.80
2008	89,511	89,511	418,805	14,891,111	19,538,341	41,613.7	44,185,187	27,950,891.5	2.03	166.36	4.68	35.56
2009	93,258	93,258	412,144	14,664,499	19,749,362	40,949.2	46,022,536	35,882,228.5	2.03	157.25	4.42	35.58
2010	88,817	88,817	387,996	13,713,570	18,622,147	38,272.5	44,231,654	34,648,385.5	2.01	154.40	4.37	35.34
2011	94,466	94,466	384,136	13,404,655	17,832,676	37,399.8	43,064,524	34,083,808.7	2.19	141.90	4.07	34.90
2012	98,752	98,752	328,887	11,081,729	14,415,494	30,940.4	41,949,348	32,896,917.0	2.35	112.22	3.33	33.69
2013	23,000	23,000	49,672	1,467,910	1,888,415	4,091.1	31,511,723	7,434,616.2	0.73	63.82	2.16	29.55
<b>Vilazodone</b>												
Incident with Respect to Itself												
2000	0	0	0	0	0	0.0	7,278,111	3,374,478.6	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,850,755	6,677,703.2	0.00	---	---	---
2002	0	0	0	0	0	0.0	7,997,059	6,773,247.6	0.00	---	---	---
2003	0	0	0	0	0	0.0	7,941,850	6,723,049.5	0.00	---	---	---
2004	0	0	0	0	0	0.0	8,502,991	6,933,805.3	0.00	---	---	---
2005	0	0	0	0	0	0.0	8,766,218	7,314,842.3	0.00	---	---	---
2006	0	0	0	0	0	0.0	19,699,906	12,108,539.1	0.00	---	---	---
2007	0	0	0	0	0	0.0	23,535,225	17,253,347.2	0.00	---	---	---
2008	0	0	0	0	0	0.0	44,825,438	28,486,529.2	0.00	---	---	---
2009	0	0	0	0	0	0.0	46,706,004	36,591,937.2	0.00	---	---	---
2010	0	0	0	0	0	0.0	44,938,147	35,366,232.5	0.00	---	---	---
2011	9,742	9,742	32,219	1,052,867	1,088,048	2,958.6	43,783,568	34,815,007.6	0.22	108.08	3.31	32.68
2012	24,012	24,012	68,837	2,185,345	2,246,810	6,146.1	42,682,297	33,620,167.7	0.56	91.01	2.87	31.75
2013	4,657	4,657	9,411	274,129	283,814	771.0	32,150,410	7,596,013.2	0.14	58.86	2.02	29.13
Incident with Respect to All SSRIs												
2000	0	0	0	0	0	0.0	7,004,124	3,206,703.1	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,581,236	6,304,385.0	0.00	---	---	---
2002	0	0	0	0	0	0.0	7,671,319	6,329,107.4	0.00	---	---	---
2003	0	0	0	0	0	0.0	7,568,914	6,233,025.9	0.00	---	---	---
2004	0	0	0	0	0	0.0	8,056,939	6,393,078.5	0.00	---	---	---
2005	0	0	0	0	0	0.0	8,312,381	6,760,621.7	0.00	---	---	---

**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2006	0	0	0	0	0	0.0	18,759,402	11,319,522.9	0.00	---	---	---
2007	0	0	0	0	0	0.0	22,394,725	16,112,666.9	0.00	---	---	---
2008	0	0	0	0	0	0.0	42,716,220	26,621,668.8	0.00	---	---	---
2009	0	0	0	0	0	0.0	44,638,661	34,224,920.3	0.00	---	---	---
2010	0	0	0	0	0	0.0	42,890,078	33,037,524.1	0.00	---	---	---
2011	5,066	5,066	16,275	526,626	541,818	1,478.9	41,748,880	32,478,306.5	0.12	103.95	3.21	32.36
2012	13,084	13,084	36,445	1,146,695	1,178,503	3,227.9	40,652,469	31,354,891.2	0.32	87.64	2.79	31.46
2013	2,649	2,649	5,206	149,113	153,262	419.3	30,194,317	7,082,092.5	0.09	56.29	1.97	28.64
<b>Vortioxetine</b>												
Incident with Respect to Itself												
2000	0	0	0	0	0	0.0	7,278,111	3,374,478.6	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,850,755	6,677,703.2	0.00	---	---	---
2002	0	0	0	0	0	0.0	7,997,059	6,773,247.6	0.00	---	---	---
2003	0	0	0	0	0	0.0	7,941,850	6,723,049.5	0.00	---	---	---
2004	0	0	0	0	0	0.0	8,502,991	6,933,805.3	0.00	---	---	---
2005	0	0	0	0	0	0.0	8,766,218	7,314,842.3	0.00	---	---	---
2006	0	0	0	0	0	0.0	19,699,906	12,108,539.1	0.00	---	---	---
2007	0	0	0	0	0	0.0	23,535,225	17,253,347.2	0.00	---	---	---
2008	0	0	0	0	0	0.0	44,825,438	28,486,529.2	0.00	---	---	---
2009	0	0	0	0	0	0.0	46,706,004	36,591,937.2	0.00	---	---	---
2010	0	0	0	0	0	0.0	44,938,147	35,366,232.5	0.00	---	---	---
2011	0	0	0	0	0	0.0	43,784,086	34,816,911.2	0.00	---	---	---
2012	0	0	0	0	0	0.0	42,694,307	33,640,292.0	0.00	---	---	---
2013	0	0	0	0	0	0.0	32,178,261	7,603,274.6	0.00	---	---	---
Incident with Respect to Miscellaneous Anti-Depressants												
2000	0	0	0	0	0	0.0	7,200,994	3,320,591.3	0.00	---	---	---
2001	0	0	0	0	0	0.0	7,785,301	6,567,158.9	0.00	---	---	---
2002	0	0	0	0	0	0.0	7,927,662	6,657,363.4	0.00	---	---	---
2003	0	0	0	0	0	0.0	7,870,188	6,605,301.6	0.00	---	---	---
2004	0	0	0	0	0	0.0	8,418,663	6,807,301.7	0.00	---	---	---
2005	0	0	0	0	0	0.0	8,681,196	7,182,696.2	0.00	---	---	---
2006	0	0	0	0	0	0.0	19,570,874	11,957,643.7	0.00	---	---	---



**Table 4: Summary of Incident Anti-Depressant Use in the Mini-Sentinel Distributed Database between January 1, 2000 and March 31, 2013, by Drug Product, Incidence Criteria, and Year**

	New Users	New Episodes	Dispensings	Days Supplied	Amount Supplied	Years at Risk	Eligible Members	Member- Years	New Users / 1K Eligible Members	Days Supplied/ User	Dispensings / User	Days Supplied/ Dispensing
2007	0	0	0	0	0	0.0	23,378,750	17,056,941.5	0.00	---	---	---
2008	0	0	0	0	0	0.0	44,569,843	28,200,565.9	0.00	---	---	---
2009	0	0	0	0	0	0.0	46,452,401	36,235,972.0	0.00	---	---	---
2010	0	0	0	0	0	0.0	44,675,183	35,000,785.4	0.00	---	---	---
2011	0	0	0	0	0	0.0	43,510,823	34,434,063.9	0.00	---	---	---
2012	0	0	0	0	0	0.0	42,406,851	33,252,217.4	0.00	---	---	---
2013	0	0	0	0	0	0.0	31,860,093	7,513,710.0	0.00	---	---	---

**Appendix A: List of Generic Names Included in this Request**

Generic Name	Brand Name	Drug Form	Drug Route	Strength	Anti-Depressant Category
CITALOPRAM HYDROBROMIDE	CITALOPRAM HBR	SOLUTION, ORAL	ORAL	10 MG/5 ML	SSRI
CITALOPRAM HYDROBROMIDE	CITALOPRAM HBR	TABLET	ORAL	10 MG	SSRI
CITALOPRAM HYDROBROMIDE	CITALOPRAM HBR	TABLET	ORAL	20 MG	SSRI
CITALOPRAM HYDROBROMIDE	CITALOPRAM HBR	TABLET	ORAL	40 MG	SSRI
CITALOPRAM HYDROBROMIDE	CELEXA	TABLET	ORAL	10 MG	SSRI
CITALOPRAM HYDROBROMIDE	CELEXA	TABLET	ORAL	20 MG	SSRI
CITALOPRAM HYDROBROMIDE	CELEXA	TABLET	ORAL	40 MG	SSRI
CITALOPRAM HYDROBROMIDE	CELEXA	SOLUTION, ORAL	ORAL	10 MG/5 ML	SSRI
CITALOPRAM HYDROBROMIDE	CITALOPRAM HBR	SOLUTION, ORAL	ORAL	20 MG/10ML	SSRI
CITALOPRAM HYDROBROMIDE	CITALOPRAM HBR	SOLUTION, ORAL	ORAL	10 MG/5 ML	SSRI
CITALOPRAM HYDROBROMIDE	CITALOPRAM	SOLUTION, ORAL	ORAL	10 MG/5 ML	SSRI
CITALOPRAM HYDROBROMIDE	CITALOPRAM HBR	SOLUTION, ORAL	ORAL	10 MG/5 ML	SSRI
ESCITALOPRAM OXALATE	ESCITALOPRAM OXALATE	TABLET	ORAL	5 MG	SSRI
ESCITALOPRAM OXALATE	ESCITALOPRAM OXALATE	TABLET	ORAL	10 MG	SSRI
ESCITALOPRAM OXALATE	ESCITALOPRAM OXALATE	TABLET	ORAL	20 MG	SSRI
ESCITALOPRAM OXALATE	LEXAPRO	TABLET	ORAL	5 MG	SSRI
ESCITALOPRAM OXALATE	LEXAPRO	TABLET	ORAL	10 MG	SSRI
ESCITALOPRAM OXALATE	LEXAPRO	TABLET	ORAL	20 MG	SSRI
ESCITALOPRAM OXALATE	LEXAPRO	SOLUTION, ORAL	ORAL	5 MG/5 ML	SSRI
ESCITALOPRAM OXALATE	ESCITALOPRAM OXALATE	SOLUTION, ORAL	ORAL	5 MG/5 ML	SSRI
FLUVOXAMINE MALEATE	LUVOX	TABLET	ORAL	25 MG	SSRI
FLUVOXAMINE MALEATE	LUVOX	TABLET	ORAL	50 MG	SSRI
FLUVOXAMINE MALEATE	LUVOX	TABLET	ORAL	100 MG	SSRI
FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE	TABLET	ORAL	50 MG	SSRI
FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE	TABLET	ORAL	100 MG	SSRI
FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE	TABLET	ORAL	25 MG	SSRI
FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE	CAPSULE, EXT RELEASE 24 HR	ORAL	100 MG	SSRI
FLUVOXAMINE MALEATE	FLUVOXAMINE MALEATE	CAPSULE, EXT RELEASE 24 HR	ORAL	150 MG	SSRI
FLUVOXAMINE MALEATE	LUVOX CR	CAPSULE, EXT RELEASE 24 HR	ORAL	100 MG	SSRI
FLUVOXAMINE MALEATE	LUVOX CR	CAPSULE, EXT RELEASE 24 HR	ORAL	150 MG	SSRI
PAROXETINE HCL	PAXIL CR	TABLET, EXTENDED RELEASE 24 HR	ORAL	12.5 MG	SSRI
PAROXETINE HCL	PAXIL CR	TABLET, EXTENDED RELEASE 24 HR	ORAL	25 MG	SSRI
PAROXETINE HCL	PAXIL CR	TABLET, EXTENDED RELEASE 24 HR	ORAL	37.5 MG	SSRI
PAROXETINE HCL	PAXIL	TABLET	ORAL	10 MG	SSRI
PAROXETINE HCL	PAXIL	TABLET	ORAL	20 MG	SSRI
PAROXETINE HCL	PAXIL	TABLET	ORAL	30 MG	SSRI
PAROXETINE HCL	PAXIL	TABLET	ORAL	40 MG	SSRI
PAROXETINE HCL	PAXIL	SUSPENSION, ORAL (FINAL DOSE FORM)	ORAL	10 MG/5 ML	SSRI
PAROXETINE HCL	PAROXETINE HCL	TABLET	ORAL	10 MG	SSRI
PAROXETINE HCL	PAROXETINE HCL	TABLET	ORAL	20 MG	SSRI
PAROXETINE HCL	PAROXETINE HCL	TABLET	ORAL	30 MG	SSRI
PAROXETINE HCL	PAROXETINE HCL	TABLET	ORAL	40 MG	SSRI
PAROXETINE HCL	PAROXETINE HCL	TABLET, EXTENDED RELEASE 24 HR	ORAL	12.5 MG	SSRI
PAROXETINE HCL	PAROXETINE HCL	TABLET, EXTENDED RELEASE 24 HR	ORAL	25 MG	SSRI
PAROXETINE HCL	PAROXETINE HCL	TABLET, EXTENDED RELEASE 24 HR	ORAL	37.5 MG	SSRI
PAROXETINE HCL	PAROXETINE HCL	SUSPENSION, ORAL (FINAL DOSE FORM)	ORAL	10 MG/5 ML	SSRI
PAROXETINE HCL	PAXIL	SUSPENSION, ORAL (FINAL DOSE FORM)	ORAL	10 MG/5 ML	SSRI
PAROXETINE MESYLATE	PEXEVA	TABLET	ORAL	10 MG	SSRI
PAROXETINE MESYLATE	PEXEVA	TABLET	ORAL	20 MG	SSRI
PAROXETINE MESYLATE	PEXEVA	TABLET	ORAL	30 MG	SSRI
PAROXETINE MESYLATE	PEXEVA	TABLET	ORAL	40 MG	SSRI
PAROXETINE MESYLATE	BRISDELLE	CAPSULE	ORAL	7.5 MG	SSRI
FLUOXETINE HCL	PROZAC WEEKLY	CAPSULE, DELAYED RELEASE (ENTERIC COATED)	ORAL	90 MG	SSRI
FLUOXETINE HCL	SARAFEM	CAPSULE	ORAL	10 MG	SSRI
FLUOXETINE HCL	SARAFEM	CAPSULE	ORAL	20 MG	SSRI
FLUOXETINE HCL	PROZAC	TABLET	ORAL	10 MG	SSRI
FLUOXETINE HCL	FLUOXETINE HCL	CAPSULE	ORAL	10 MG	SSRI
FLUOXETINE HCL	FLUOXETINE HCL	CAPSULE	ORAL	20 MG	SSRI
FLUOXETINE HCL	FLUOXETINE HCL	CAPSULE	ORAL	40 MG	SSRI
FLUOXETINE HCL	FLUOXETINE HCL	SOLUTION, ORAL	ORAL	20 MG/5 ML	SSRI
FLUOXETINE HCL	FLUOXETINE HCL	TABLET	ORAL	10 MG	SSRI
FLUOXETINE HCL	SELFEMRA	CAPSULE	ORAL	10 MG	SSRI
FLUOXETINE HCL	SELFEMRA	CAPSULE	ORAL	20 MG	SSRI
FLUOXETINE HCL	PROZAC	CAPSULE	ORAL	20 MG	SSRI
FLUOXETINE HCL	PROZAC	CAPSULE	ORAL	10 MG	SSRI
FLUOXETINE HCL	SARAFEM	TABLET	ORAL	10 MG	SSRI
FLUOXETINE HCL	SARAFEM	TABLET	ORAL	15 MG	SSRI
FLUOXETINE HCL	SARAFEM	TABLET	ORAL	20 MG	SSRI
FLUOXETINE HCL	FLUOXETINE DR	CAPSULE, DELAYED RELEASE (ENTERIC COATED)	ORAL	90 MG	SSRI
FLUOXETINE HCL	FLUOXETINE HCL	TABLET	ORAL	20 MG	SSRI
FLUOXETINE HCL	PROZAC	CAPSULE	ORAL	40 MG	SSRI
FLUOXETINE HCL	PROZAC	SOLUTION, ORAL	ORAL	20 MG/5 ML	SSRI
FLUOXETINE HCL	RAPIFLUX	TABLET	ORAL	20 MG	SSRI
FLUOXETINE HCL	FLUOXETINE HCL	TABLET	ORAL	60 MG	SSRI
FLUOXETINE HCL/DIET. SUPP NO.8	SENTROXATINE	CAPSULE	ORAL	10 MG	SSRI
FLUOXETINE HCL/DIET. SUPP NO.17	GABOXETINE	CAPSULE	ORAL	10 MG	SSRI
OLANZAPINE/FLUOXETINE HCL	SYMBYAX	CAPSULE	ORAL	3MG-25MG	SSRI
OLANZAPINE/FLUOXETINE HCL	SYMBYAX	CAPSULE	ORAL	6MG-25MG	SSRI
OLANZAPINE/FLUOXETINE HCL	SYMBYAX	CAPSULE	ORAL	12MG-25MG	SSRI
OLANZAPINE/FLUOXETINE HCL	SYMBYAX	CAPSULE	ORAL	6MG-50MG	SSRI
OLANZAPINE/FLUOXETINE HCL	SYMBYAX	CAPSULE	ORAL	12MG-50MG	SSRI
OLANZAPINE/FLUOXETINE HCL	OLANZAPINE-FLUOXETINE HCL	CAPSULE	ORAL	3MG-25MG	SSRI
OLANZAPINE/FLUOXETINE HCL	OLANZAPINE-FLUOXETINE HCL	CAPSULE	ORAL	6MG-25MG	SSRI
OLANZAPINE/FLUOXETINE HCL	OLANZAPINE-FLUOXETINE HCL	CAPSULE	ORAL	6MG-50MG	SSRI
OLANZAPINE/FLUOXETINE HCL	OLANZAPINE-FLUOXETINE HCL	CAPSULE	ORAL	12MG-25MG	SSRI
OLANZAPINE/FLUOXETINE HCL	OLANZAPINE-FLUOXETINE HCL	CAPSULE	ORAL	12MG-50MG	SSRI
SERTRALINE HCL	ZOLOFT	TABLET	ORAL	50 MG	SSRI
SERTRALINE HCL	ZOLOFT	TABLET	ORAL	100 MG	SSRI
SERTRALINE HCL	ZOLOFT	CONCENTRATE, ORAL	ORAL	20 MG/ML	SSRI
SERTRALINE HCL	ZOLOFT	TABLET	ORAL	25 MG	SSRI
SERTRALINE HCL	SERTRALINE HCL	TABLET	ORAL	25 MG	SSRI
SERTRALINE HCL	SERTRALINE HCL	TABLET	ORAL	50 MG	SSRI
SERTRALINE HCL	SERTRALINE HCL	TABLET	ORAL	100 MG	SSRI
SERTRALINE HCL	SERTRALINE HCL	CONCENTRATE, ORAL	ORAL	20 MG/ML	SSRI
VILAZODONE HYDROCHLORIDE	VIIBRYD	TABLET, DOSE PACK	ORAL	10-20-40MG	SSRI
VILAZODONE HYDROCHLORIDE	VIIBRYD	TABLET	ORAL	10 MG	SSRI
VILAZODONE HYDROCHLORIDE	VIIBRYD	TABLET	ORAL	20 MG	SSRI
VILAZODONE HYDROCHLORIDE	VIIBRYD	TABLET	ORAL	40 MG	SSRI

DULOXETINE HCL	CYMBALTA	CAPSULE,DELAYED RELEASE (ENTERIC COATED)ORAL	20 MG	SNRI
DULOXETINE HCL	CYMBALTA	CAPSULE,DELAYED RELEASE (ENTERIC COATED)ORAL	60 MG	SNRI
DULOXETINE HCL	CYMBALTA	CAPSULE,DELAYED RELEASE (ENTERIC COATED)ORAL	30 MG	SNRI
DULOXETINE HCL	DULOXETINE HCL	CAPSULE,DELAYED RELEASE (ENTERIC COATED)ORAL	20 MG	SNRI
DULOXETINE HCL	DULOXETINE HCL	CAPSULE,DELAYED RELEASE (ENTERIC COATED)ORAL	30 MG	SNRI
DULOXETINE HCL	DULOXETINE HCL	CAPSULE,DELAYED RELEASE (ENTERIC COATED)ORAL	60 MG	SNRI
DESVENLAFAXINE	KHEDEZLA	TABLET, EXTENDED RELEASE 24 HR	50 MG	SNRI
DESVENLAFAXINE	KHEDEZLA	TABLET, EXTENDED RELEASE 24 HR	100 MG	SNRI
DESVENLAFAXINE	DESVENLAFAXINE ER	TABLET, EXTENDED RELEASE 24 HR	50 MG	SNRI
DESVENLAFAXINE	DESVENLAFAXINE ER	TABLET, EXTENDED RELEASE 24 HR	100 MG	SNRI
DESVENLAFAXINE SUCCINATE	PRISTIQ ER	TABLET, EXTENDED RELEASE 24 HR	50 MG	SNRI
DESVENLAFAXINE SUCCINATE	PRISTIQ ER	TABLET, EXTENDED RELEASE 24 HR	100 MG	SNRI
VENLAFAXINE HCL	EFFEXOR	TABLET	25 MG	SNRI
VENLAFAXINE HCL	EFFEXOR	TABLET	50 MG	SNRI
VENLAFAXINE HCL	EFFEXOR	TABLET	75 MG	SNRI
VENLAFAXINE HCL	EFFEXOR	TABLET	100 MG	SNRI
VENLAFAXINE HCL	EFFEXOR	TABLET	37.5 MG	SNRI
VENLAFAXINE HCL	EFFEXOR XR	CAPSULE, EXT RELEASE 24 HR	75 MG	SNRI
VENLAFAXINE HCL	EFFEXOR XR	CAPSULE, EXT RELEASE 24 HR	150 MG	SNRI
VENLAFAXINE HCL	EFFEXOR XR	CAPSULE, EXT RELEASE 24 HR	37.5 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL	TABLET	25 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL	TABLET	37.5 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL	TABLET	50 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL	TABLET	75 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL	TABLET	100 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL ER	CAPSULE, EXT RELEASE 24 HR	37.5 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL ER	CAPSULE, EXT RELEASE 24 HR	75 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL ER	CAPSULE, EXT RELEASE 24 HR	150 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL ER	TABLET, EXTENDED RELEASE 24 HR	37.5 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL ER	TABLET, EXTENDED RELEASE 24 HR	75 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL ER	TABLET, EXTENDED RELEASE 24 HR	150 MG	SNRI
VENLAFAXINE HCL	VENLAFAXINE HCL ER	TABLET, EXTENDED RELEASE 24 HR	225 MG	SNRI
LEVOMILNACIPRAN HYDROCHLORIDE	FETZIMA	CAPSULE,EXTENDED RELEASE 24 HR DOSE PAC	20-40MG	SNRI
LEVOMILNACIPRAN HYDROCHLORIDE	FETZIMA	CAPSULE, EXTENDED RELEASE 24HR	120 MG	SNRI
LEVOMILNACIPRAN HYDROCHLORIDE	FETZIMA	CAPSULE, EXTENDED RELEASE 24HR	20 MG	SNRI
LEVOMILNACIPRAN HYDROCHLORIDE	FETZIMA	CAPSULE, EXTENDED RELEASE 24HR	40 MG	SNRI
LEVOMILNACIPRAN HYDROCHLORIDE	FETZIMA	CAPSULE, EXTENDED RELEASE 24HR	80 MG	SNRI
NEFAZODONE HCL	NEFAZODONE HCL	TABLET	100 MG	Miscellaneous Anti-Depressant
NEFAZODONE HCL	NEFAZODONE HCL	TABLET	150 MG	Miscellaneous Anti-Depressant
NEFAZODONE HCL	NEFAZODONE HCL	TABLET	200 MG	Miscellaneous Anti-Depressant
NEFAZODONE HCL	SERZONE	TABLET	50 MG	Miscellaneous Anti-Depressant
NEFAZODONE HCL	SERZONE	TABLET	100 MG	Miscellaneous Anti-Depressant
NEFAZODONE HCL	SERZONE	TABLET	200 MG	Miscellaneous Anti-Depressant
NEFAZODONE HCL	SERZONE	TABLET	150 MG	Miscellaneous Anti-Depressant
NEFAZODONE HCL	SERZONE	TABLET	250 MG	Miscellaneous Anti-Depressant
NEFAZODONE HCL	NEFAZODONE HCL	TABLET	250 MG	Miscellaneous Anti-Depressant
NEFAZODONE HCL	NEFAZODONE HCL	TABLET	50 MG	Miscellaneous Anti-Depressant
TRAZODONE HCL	TRAZODONE HCL	TABLET	50 MG	Miscellaneous Anti-Depressant
TRAZODONE HCL	TRAZODONE HCL	TABLET	100 MG	Miscellaneous Anti-Depressant
TRAZODONE HCL	TRAZODONE HCL	TABLET	150 MG	Miscellaneous Anti-Depressant
TRAZODONE HCL	DESYREL	TABLET	50 MG	Miscellaneous Anti-Depressant
TRAZODONE HCL	DESYREL	TABLET	100 MG	Miscellaneous Anti-Depressant
TRAZODONE HCL	DESYREL	TABLET	150 MG	Miscellaneous Anti-Depressant
TRAZODONE HCL	DESYREL	TABLET	300 MG	Miscellaneous Anti-Depressant
TRAZODONE HCL	TRAZODONE HCL	TABLET	300 MG	Miscellaneous Anti-Depressant
TRAZODONE HCL	OLEPTRO ER	TABLET, EXTENDED RELEASE 24 HR	150 MG	Miscellaneous Anti-Depressant
TRAZODONE HCL	OLEPTRO ER	TABLET, EXTENDED RELEASE 24 HR	300 MG	Miscellaneous Anti-Depressant
TRAZODONE HCL/DIET8	TRAZAMINE	COMBINATION PACKAGE (EA)	50 MG	Miscellaneous Anti-Depressant
VORTIOXETINE HYDROBROMIDE	BRINTELLIX	TABLET	5 MG	Miscellaneous Anti-Depressant
VORTIOXETINE HYDROBROMIDE	BRINTELLIX	TABLET	10 MG	Miscellaneous Anti-Depressant
VORTIOXETINE HYDROBROMIDE	BRINTELLIX	TABLET	20 MG	Miscellaneous Anti-Depressant
AMITRIPTYLINE HCL	AMITID	TABLET	10 MG	Cyclic
AMITRIPTYLINE HCL	AMITID	TABLET	25 MG	Cyclic
AMITRIPTYLINE HCL	AMITID	TABLET	50 MG	Cyclic
AMITRIPTYLINE HCL	AMITID	TABLET	75 MG	Cyclic
AMITRIPTYLINE HCL	AMITID	TABLET	100 MG	Cyclic
AMITRIPTYLINE HCL	ENDEP	TABLET	10 MG	Cyclic
AMITRIPTYLINE HCL	ENDEP	TABLET	25 MG	Cyclic
AMITRIPTYLINE HCL	ENDEP	TABLET	50 MG	Cyclic
AMITRIPTYLINE HCL	ENDEP	TABLET	75 MG	Cyclic
AMITRIPTYLINE HCL	ENDEP	TABLET	100 MG	Cyclic
AMITRIPTYLINE HCL	ENDEP	TABLET	150 MG	Cyclic
AMITRIPTYLINE HCL	AMITRIPTYLINE HCL	TABLET	10 MG	Cyclic
AMITRIPTYLINE HCL	AMITRIPTYLINE HCL	TABLET	25 MG	Cyclic
AMITRIPTYLINE HCL	AMITRIPTYLINE HCL	TABLET	50 MG	Cyclic
AMITRIPTYLINE HCL	AMITRIPTYLINE HCL	TABLET	75 MG	Cyclic
AMITRIPTYLINE HCL	AMITRIPTYLINE HCL	TABLET	100 MG	Cyclic
AMITRIPTYLINE HCL	ELAVIL	TABLET	10 MG	Cyclic
AMITRIPTYLINE HCL	ELAVIL	TABLET	25 MG	Cyclic
AMITRIPTYLINE HCL	ELAVIL	TABLET	50 MG	Cyclic
AMITRIPTYLINE HCL	ELAVIL	TABLET	75 MG	Cyclic
AMITRIPTYLINE HCL	ELAVIL	TABLET	100 MG	Cyclic
AMITRIPTYLINE HCL	ELAVIL	TABLET	150 MG	Cyclic
AMITRIPTYLINE HCL	SK-AMITRIPTYLINE	TABLET	10 MG	Cyclic
AMITRIPTYLINE HCL	SK-AMITRIPTYLINE	TABLET	25 MG	Cyclic
AMITRIPTYLINE HCL	SK-AMITRIPTYLINE	TABLET	50 MG	Cyclic
AMITRIPTYLINE HCL	SK-AMITRIPTYLINE	TABLET	75 MG	Cyclic
AMITRIPTYLINE HCL	SK-AMITRIPTYLINE	TABLET	100 MG	Cyclic
AMITRIPTYLINE HCL	SK-AMITRIPTYLINE	TABLET	150 MG	Cyclic
AMITRIPTYLINE HCL	AMITRIPTYLINE HCL	TABLET	150 MG	Cyclic
AMITRIPTYLINE HCL	STABANIL	TABLET	25 MG	Cyclic
AMITRIPTYLINE HCL	Q.E.L	TABLET	10 MG	Cyclic
AMITRIPTYLINE HCL	Q.E.L	TABLET	25 MG	Cyclic
AMITRIPTYLINE HCL	Q.E.L	TABLET	50 MG	Cyclic
AMITRIPTYLINE HCL	Q.E.L	TABLET	75 MG	Cyclic
AMITRIPTYLINE HCL	Q.E.L	TABLET	100 MG	Cyclic
AMITRIPTYLINE HCL	EMITRIP	TABLET	100 MG	Cyclic
AMITRIPTYLINE HCL	EMITRIP	TABLET	50 MG	Cyclic
AMITRIPTYLINE HCL	KENVIL	TABLET	10 MG	Cyclic
AMITRIPTYLINE HCL	KENVIL	TABLET	25 MG	Cyclic
AMITRIPTYLINE HCL	KENVIL	TABLET	50 MG	Cyclic

AMITRIPTYLINE HCL	KENVIL	TABLET	ORAL	75 MG	Cyclic
AMITRIPTYLINE HCL	KENVIL	TABLET	ORAL	100 MG	Cyclic
AMITRIPTYLINE HCL	E-VILL 10	TABLET	ORAL	10 MG	Cyclic
AMITRIPTYLINE HCL	E-VILL 25	TABLET	ORAL	25 MG	Cyclic
AMITRIPTYLINE HCL	E-VILL 50	TABLET	ORAL	50 MG	Cyclic
AMITRIPTYLINE HCL	E-VILL 75	TABLET	ORAL	75 MG	Cyclic
AMITRIPTYLINE HCL	E-VILL 100	TABLET	ORAL	100 MG	Cyclic
AMITRIPTYLINE HCL	RE-LIVE	TABLET	ORAL	25 MG	Cyclic
AMITRIPTYLINE HCL	RE-LIVE	TABLET	ORAL	50 MG	Cyclic
AMITRIPTYLINE HCL	VANATRIP	TABLET	ORAL	50 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	AMITRIPTYLINE W/PERPHENAZINE	TABLET	ORAL	2 MG-10 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	AMITRIPTYLINE W/PERPHENAZINE	TABLET	ORAL	2 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	AMITRIPTYLINE W/PERPHENAZINE	TABLET	ORAL	4MG-10MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	AMITRIPTYLINE W/PERPHENAZINE	TABLET	ORAL	4 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	AMITRIPTYLINE W/PERPHENAZINE	TABLET	ORAL	4MG-50MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	TRIAVIL 4-50	TABLET	ORAL	4MG-50MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	TRIAVIL 2-10	TABLET	ORAL	2 MG-10 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	TRIAVIL 4-10	TABLET	ORAL	4MG-10MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	ETRAFON A 4-10	TABLET	ORAL	4MG-10MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	ETRAFON 2-10	TABLET	ORAL	2 MG-10 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	ETRAFON 2-25	TABLET	ORAL	2 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	ETRAFON FORTE 4-25	TABLET	ORAL	4 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	PER-TRIP	TABLET	ORAL	2 MG-10 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	PER-TRIP	TABLET	ORAL	2 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	PER-TRIP	TABLET	ORAL	4MG-10MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	PER-TRIP	TABLET	ORAL	4 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	PER-TRIP	TABLET	ORAL	4MG-50MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	PERPHENAZINE-AMITRIPTYLINE	TABLET	ORAL	4MG-10MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	PERPHENAZINE-AMITRIPTYLINE	TABLET	ORAL	4MG-50MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	PERPHENAZINE-AMITRIPTYLINE	TABLET	ORAL	2 MG-10 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	PERPHENAZINE-AMITRIPTYLINE	TABLET	ORAL	2 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	PERPHENAZINE-AMITRIPTYLINE	TABLET	ORAL	4 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	TRIAVIL 2-10	TABLET	ORAL	2 MG-10 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	TRIAVIL 4-25	TABLET	ORAL	4 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	TRIAVIL 2-25	TABLET	ORAL	2 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	AMITRIPTYLINE-PERPHENAZINE	TABLET	ORAL	2 MG-10 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	AMITRIPTYLINE-PERPHENAZINE	TABLET	ORAL	2 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	PERPHENAZINE-AMITRIPTYLINE	TABLET	ORAL	4 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	TRIAVIL 10-2	TABLET	ORAL	2 MG-10 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	TRIAVIL 25-2	TABLET	ORAL	2 MG-25 MG	Cyclic
PERPHENAZINE/AMITRIPTYLINE HCL	TRIAVIL 25-4	TABLET	ORAL	4 MG-25 MG	Cyclic
AMOXAPINE	AMOXAPINE	TABLET	ORAL	100 MG	Cyclic
AMOXAPINE	AMOXAPINE	TABLET	ORAL	50 MG	Cyclic
AMOXAPINE	AMOXAPINE	TABLET	ORAL	25 MG	Cyclic
AMOXAPINE	ASENDIN	TABLET	ORAL	25 MG	Cyclic
AMOXAPINE	ASENDIN	TABLET	ORAL	50 MG	Cyclic
AMOXAPINE	ASENDIN	TABLET	ORAL	100 MG	Cyclic
AMOXAPINE	ASENDIN	TABLET	ORAL	150 MG	Cyclic
AMOXAPINE	AMOXAPINE	TABLET	ORAL	150 MG	Cyclic
DOXEPIN HCL	DOXEPIN HCL	CAPSULE	ORAL	10 MG	Cyclic
DOXEPIN HCL	DOXEPIN HCL	CAPSULE	ORAL	25 MG	Cyclic
DOXEPIN HCL	DOXEPIN HCL	CAPSULE	ORAL	50 MG	Cyclic
DOXEPIN HCL	DOXEPIN HCL	CAPSULE	ORAL	75 MG	Cyclic
DOXEPIN HCL	DOXEPIN HCL	CAPSULE	ORAL	100 MG	Cyclic
DOXEPIN HCL	DOXEPIN HCL	CAPSULE	ORAL	150 MG	Cyclic
DOXEPIN HCL	ADAPIN	CAPSULE	ORAL	10 MG	Cyclic
DOXEPIN HCL	ADAPIN	CAPSULE	ORAL	25 MG	Cyclic
DOXEPIN HCL	ADAPIN	CAPSULE	ORAL	50 MG	Cyclic
DOXEPIN HCL	ADAPIN	CAPSULE	ORAL	100 MG	Cyclic
DOXEPIN HCL	ADAPIN	CAPSULE	ORAL	75 MG	Cyclic
DOXEPIN HCL	ADAPIN	CAPSULE	ORAL	150 MG	Cyclic
DOXEPIN HCL	DOXEPIN HCL	CONCENTRATE, ORAL	ORAL	10 MG/ML	Cyclic
DOXEPIN HCL	SINEQUAN	CONCENTRATE, ORAL	ORAL	10 MG/ML	Cyclic
DOXEPIN HCL	SINEQUAN	CAPSULE	ORAL	10 MG	Cyclic
DOXEPIN HCL	SINEQUAN	CAPSULE	ORAL	25 MG	Cyclic
DOXEPIN HCL	SINEQUAN	CAPSULE	ORAL	50 MG	Cyclic
DOXEPIN HCL	SINEQUAN	CAPSULE	ORAL	150 MG	Cyclic
DOXEPIN HCL	SINEQUAN	CAPSULE	ORAL	100 MG	Cyclic
DOXEPIN HCL	SINEQUAN	CAPSULE	ORAL	75 MG	Cyclic
DOXEPIN HCL	SILENOR	TABLET	ORAL	3 MG	Cyclic
DOXEPIN HCL	SILENOR	TABLET	ORAL	6 MG	Cyclic
IMIPRAMINE HCL	IMIPRAMINE HCL	TABLET	ORAL	10 MG	Cyclic
IMIPRAMINE HCL	IMIPRAMINE HCL	TABLET	ORAL	25 MG	Cyclic
IMIPRAMINE HCL	IMIPRAMINE HCL	TABLET	ORAL	50 MG	Cyclic
IMIPRAMINE HCL	SK-PRAMINE	TABLET	ORAL	10 MG	Cyclic
IMIPRAMINE HCL	SK-PRAMINE	TABLET	ORAL	25 MG	Cyclic
IMIPRAMINE HCL	SK-PRAMINE	TABLET	ORAL	50 MG	Cyclic
IMIPRAMINE HCL	TOFRANIL	TABLET	ORAL	25 MG	Cyclic
IMIPRAMINE HCL	TOFRANIL	TABLET	ORAL	10 MG	Cyclic
IMIPRAMINE HCL	TOFRANIL	TABLET	ORAL	50 MG	Cyclic
IMIPRAMINE HCL	IMAVATE	TABLET	ORAL	25 MG	Cyclic
IMIPRAMINE HCL	IMAVATE	TABLET	ORAL	50 MG	Cyclic
IMIPRAMINE HCL	JANIMINE	TABLET	ORAL	10 MG	Cyclic
IMIPRAMINE HCL	JANIMINE	TABLET	ORAL	25 MG	Cyclic
IMIPRAMINE HCL	JANIMINE	TABLET	ORAL	50 MG	Cyclic
IMIPRAMINE HCL	NORFRANIL	TABLET	ORAL	25 MG	Cyclic
IMIPRAMINE HCL	NORFRANIL	TABLET	ORAL	50 MG	Cyclic
IMIPRAMINE HCL	ETNOFRIL	TABLET	ORAL	10 MG	Cyclic
IMIPRAMINE HCL	ETNOFRIL	TABLET	ORAL	25 MG	Cyclic
IMIPRAMINE HCL	DECONIL	TABLET	ORAL	25 MG	Cyclic
IMIPRAMINE PAMOATE	TOFRANIL-PM	CAPSULE	ORAL	75 MG	Cyclic
IMIPRAMINE PAMOATE	TOFRANIL-PM	CAPSULE	ORAL	150 MG	Cyclic
IMIPRAMINE PAMOATE	TOFRANIL-PM	CAPSULE	ORAL	100 MG	Cyclic
IMIPRAMINE PAMOATE	TOFRANIL-PM	CAPSULE	ORAL	125 MG	Cyclic
IMIPRAMINE PAMOATE	IMIPRAMINE PAMOATE	CAPSULE	ORAL	75 MG	Cyclic
IMIPRAMINE PAMOATE	IMIPRAMINE PAMOATE	CAPSULE	ORAL	100 MG	Cyclic
IMIPRAMINE PAMOATE	IMIPRAMINE PAMOATE	CAPSULE	ORAL	125 MG	Cyclic
IMIPRAMINE PAMOATE	IMIPRAMINE PAMOATE	CAPSULE	ORAL	150 MG	Cyclic
NORTRIPTYLINE HCL	AVENTYL HCL	CAPSULE	ORAL	10 MG	Cyclic
NORTRIPTYLINE HCL	AVENTYL HCL	CAPSULE	ORAL	25 MG	Cyclic
NORTRIPTYLINE HCL	AVENTYL HCL	SOLUTION, ORAL	ORAL	10 MG/5 ML	Cyclic

NORTRIPTYLINE HCL	PAMELOR	SOLUTION, ORAL	ORAL	10 MG/5 ML	Cyclic
NORTRIPTYLINE HCL	PAMELOR	CAPSULE	ORAL	50 MG	Cyclic
NORTRIPTYLINE HCL	PAMELOR	CAPSULE	ORAL	75 MG	Cyclic
NORTRIPTYLINE HCL	PAMELOR	CAPSULE	ORAL	10 MG	Cyclic
NORTRIPTYLINE HCL	PAMELOR	CAPSULE	ORAL	25 MG	Cyclic
NORTRIPTYLINE HCL	NORTRIPTYLINE HCL	CAPSULE	ORAL	10 MG	Cyclic
NORTRIPTYLINE HCL	NORTRIPTYLINE HCL	CAPSULE	ORAL	25 MG	Cyclic
NORTRIPTYLINE HCL	NORTRIPTYLINE HCL	CAPSULE	ORAL	50 MG	Cyclic
NORTRIPTYLINE HCL	NORTRIPTYLINE HCL	CAPSULE	ORAL	75 MG	Cyclic
NORTRIPTYLINE HCL	NORTRIPTYLINE HCL	SOLUTION, ORAL	ORAL	10 MG/5 ML	Cyclic
DESIPRAMINE HCL	DESIPRAMINE HCL	TABLET	ORAL	25 MG	Cyclic
DESIPRAMINE HCL	DESIPRAMINE HCL	TABLET	ORAL	50 MG	Cyclic
DESIPRAMINE HCL	DESIPRAMINE HCL	TABLET	ORAL	75 MG	Cyclic
DESIPRAMINE HCL	NORPRAMIN	TABLET	ORAL	10 MG	Cyclic
DESIPRAMINE HCL	NORPRAMIN	TABLET	ORAL	25 MG	Cyclic
DESIPRAMINE HCL	NORPRAMIN	TABLET	ORAL	50 MG	Cyclic
DESIPRAMINE HCL	NORPRAMIN	TABLET	ORAL	75 MG	Cyclic
DESIPRAMINE HCL	NORPRAMIN	TABLET	ORAL	100 MG	Cyclic
DESIPRAMINE HCL	NORPRAMIN	TABLET	ORAL	150 MG	Cyclic
DESIPRAMINE HCL	DESIPRAMINE HCL	TABLET	ORAL	100 MG	Cyclic
DESIPRAMINE HCL	DESIPRAMINE HCL	TABLET	ORAL	10 MG	Cyclic
DESIPRAMINE HCL	DESIPRAMINE HCL	TABLET	ORAL	150 MG	Cyclic
PROTRIPTYLINE HCL	VIVACTIL	TABLET	ORAL	5 MG	Cyclic
PROTRIPTYLINE HCL	VIVACTIL	TABLET	ORAL	10 MG	Cyclic
PROTRIPTYLINE HCL	PROTRIPTYLINE HCL	TABLET	ORAL	5 MG	Cyclic
PROTRIPTYLINE HCL	PROTRIPTYLINE HCL	TABLET	ORAL	10 MG	Cyclic
CLOMIPRAMINE HCL	ANAFRANIL	CAPSULE	ORAL	25 MG	Cyclic
CLOMIPRAMINE HCL	ANAFRANIL	CAPSULE	ORAL	50 MG	Cyclic
CLOMIPRAMINE HCL	ANAFRANIL	CAPSULE	ORAL	75 MG	Cyclic
CLOMIPRAMINE HCL	CLOMIPRAMINE HCL	CAPSULE	ORAL	25 MG	Cyclic
CLOMIPRAMINE HCL	CLOMIPRAMINE HCL	CAPSULE	ORAL	50 MG	Cyclic
CLOMIPRAMINE HCL	CLOMIPRAMINE HCL	CAPSULE	ORAL	75 MG	Cyclic
TRIMIPRAMINE MALEATE	SURMONTIL	CAPSULE	ORAL	25 MG	Cyclic
TRIMIPRAMINE MALEATE	SURMONTIL	CAPSULE	ORAL	50 MG	Cyclic
TRIMIPRAMINE MALEATE	SURMONTIL	CAPSULE	ORAL	100 MG	Cyclic
TRIMIPRAMINE MALEATE	TRIMIPRAMINE MALEATE	CAPSULE	ORAL	25 MG	Cyclic
TRIMIPRAMINE MALEATE	TRIMIPRAMINE MALEATE	CAPSULE	ORAL	50 MG	Cyclic
TRIMIPRAMINE MALEATE	TRIMIPRAMINE MALEATE	CAPSULE	ORAL	100 MG	Cyclic
MIRTAZAPINE	REMERON	TABLET	ORAL	15 MG	Cyclic
MIRTAZAPINE	REMERON	TABLET,DISINTEGRATING	ORAL	15 MG	Cyclic
MIRTAZAPINE	REMERON	TABLET	ORAL	30 MG	Cyclic
MIRTAZAPINE	REMERON	TABLET,DISINTEGRATING	ORAL	30 MG	Cyclic
MIRTAZAPINE	REMERON	TABLET	ORAL	45 MG	Cyclic
MIRTAZAPINE	REMERON	TABLET,DISINTEGRATING	ORAL	45 MG	Cyclic
MIRTAZAPINE	MIRTAZAPINE	TABLET	ORAL	15 MG	Cyclic
MIRTAZAPINE	MIRTAZAPINE	TABLET	ORAL	30 MG	Cyclic
MIRTAZAPINE	MIRTAZAPINE	TABLET	ORAL	45 MG	Cyclic
MIRTAZAPINE	MIRTAZAPINE	TABLET,DISINTEGRATING	ORAL	15 MG	Cyclic
MIRTAZAPINE	MIRTAZAPINE	TABLET,DISINTEGRATING	ORAL	30 MG	Cyclic
MIRTAZAPINE	MIRTAZAPINE	TABLET,DISINTEGRATING	ORAL	45 MG	Cyclic
MIRTAZAPINE	MIRTAZAPINE	TABLET	ORAL	7.5 MG	Cyclic
MAPROTILINE HCL	MAPROTILINE HCL	TABLET	ORAL	25 MG	Cyclic
MAPROTILINE HCL	MAPROTILINE HCL	TABLET	ORAL	50 MG	Cyclic
MAPROTILINE HCL	MAPROTILINE HCL	TABLET	ORAL	75 MG	Cyclic
MAPROTILINE HCL	LUDIOMIL	TABLET	ORAL	50 MG	Cyclic
MAPROTILINE HCL	LUDIOMIL	TABLET	ORAL	25 MG	Cyclic
MAPROTILINE HCL	LUDIOMIL	TABLET	ORAL	75 MG	Cyclic

**Appendix B: Modular Program Specifications for Query ID to09y05\_mpr\_wp22\_v01 - Anti-depressant Use**

Modular Program #3 was used to investigate the use of several anti-depressants among individuals in the Mini-Sentinel Distributed Database. No event was queried. In total, 50 different scenarios were examined in this request with differing drugs of interest. See below for a description of each of these scenarios.

Query Period	January 1, 2000 - March 31, 2013
Coverage Requirement	Drug and Medical
Enrollment Requirement	183 days
Age Stratifications	0-17, 18-40, 41-64, 65-79, 80+ years
Enrollment Gap	45 Days
Indicator	Yes (Only applies to scenarios 26-50)

Scenario	Drug/Exposure								Event/Outcome
	Incident exposure	Incident w/ respect to:	Minimum Days Supplied	Minimum Episode Duration	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Event/ Outcome
1	Citalopram	Citalopram	0	0	183	01 (SING)	10	0	None
2	Escitalopram	Escitalopram	0	0	183	01 (SING)	10	0	None
3	Fluvoxamine	Fluvoxamine	0	0	183	01 (SING)	10	0	None
4	Paroxetine	Paroxetine	0	0	183	01 (SING)	10	0	None
5	Fluoxetine	Fluoxetine	0	0	183	01 (SING)	10	0	None
6	Sertraline	Sertraline	0	0	183	01 (SING)	10	0	None
7	Vilazodone	Vilazodone	0	0	183	01 (SING)	10	0	None
8	Duloxetine	Duloxetine	0	0	183	01 (SING)	10	0	None
9	Desvenlafaxine	Desvenlafaxine	0	0	183	01 (SING)	10	0	None
10	Venlafaxine	Venlafaxine	0	0	183	01 (SING)	10	0	None
11	Levomilnacipran	Levomilnacipran	0	0	183	01 (SING)	10	0	None
12	Nefazodone	Nefazodone	0	0	183	01 (SING)	10	0	None
13	Trazodone	Trazodone	0	0	183	01 (SING)	10	0	None
14	Vortioxetine	Vortioxetine	0	0	183	01 (SING)	10	0	None
15	Amitriptyline	Amitriptyline	0	0	183	01 (SING)	10	0	None
16	Amoxapine	Amoxapine	0	0	183	01 (SING)	10	0	None
17	Doxepin	Doxepin	0	0	183	01 (SING)	10	0	None
18	Imipramine	Imipramine	0	0	183	01 (SING)	10	0	None
19	Nortriptyline	Nortriptyline	0	0	183	01 (SING)	10	0	None
20	Desipramine	Desipramine	0	0	183	01 (SING)	10	0	None

**Appendix B: Modular Program Specifications for Query ID to09y05\_mpr\_wp22\_v01 - Anti-depressant Use**

Modular Program #3 was used to investigate the use of several anti-depressants among individuals in the Mini-Sentinel Distributed Database. No event was queried. In total, 50 different scenarios were examined in this request with differing drugs of interest. See below for a description of each of these scenarios.

Query Period	January 1, 2000 - March 31, 2013
Coverage Requirement	Drug and Medical
Enrollment Requirement	183 days
Age Stratifications	0-17, 18-40, 41-64, 65-79, 80+ years
Enrollment Gap	45 Days
Indicator	Yes (Only applies to scenarios 26-50)

Scenario	Drug/Exposure								Event/Outcome
	Incident exposure	Incident w/ respect to:	Minimum Days Supplied	Minimum Episode Duration	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Event/ Outcome
21	Protriptyline	Protriptyline	0	0	183	01 (SING)	10	0	None
22	Clomipramine	Clomipramine	0	0	183	01 (SING)	10	0	None
23	Trimipramine	Trimipramine	0	0	183	01 (SING)	10	0	None
24	Mirtazapine	Mirtazapine	0	0	183	01 (SING)	10	0	None
25	Maprotiline	Maprotiline	0	0	183	01 (SING)	10	0	None
26	Citalopram	All SSRIs	0	0	183	01 (SING)	10	0	None
27	Escitalopram	All SSRIs	0	0	183	01 (SING)	10	0	None
28	Fluvoxamine	All SSRIs	0	0	183	01 (SING)	10	0	None
29	Paroxetine	All SSRIs	0	0	183	01 (SING)	10	0	None
30	Fluoxetine	All SSRIs	0	0	183	01 (SING)	10	0	None
31	Sertraline	All SSRIs	0	0	183	01 (SING)	10	0	None
32	Vilazodone	All SSRIs	0	0	183	01 (SING)	10	0	None
33	Duloxetine	All SNRIs	0	0	183	01 (SING)	10	0	None
34	Desvenlafaxine	All SNRIs	0	0	183	01 (SING)	10	0	None
35	Venlafaxine	All SNRIs	0	0	183	01 (SING)	10	0	None
36	Levomilnacipran	All SNRIs	0	0	183	01 (SING)	10	0	None
37	Nefazodone	All Miscellaneous	0	0	183	01 (SING)	10	0	None
38	Trazodone	All Miscellaneous	0	0	183	01 (SING)	10	0	None
39	Vortioxetine	All Miscellaneous	0	0	183	01 (SING)	10	0	None
40	Amitriptyline	All Cyclics	0	0	183	01 (SING)	10	0	None
41	Amoxapine	All Cyclics	0	0	183	01 (SING)	10	0	None

**Appendix B: Modular Program Specifications for Query ID to09y05\_mpr\_wp22\_v01 - Anti-depressant Use**

Modular Program #3 was used to investigate the use of several anti-depressants among individuals in the Mini-Sentinel Distributed Database. No event was queried. In total, 50 different scenarios were examined in this request with differing drugs of interest. See below for a description of each of these scenarios.

Query Period	January 1, 2000 - March 31, 2013
Coverage Requirement	Drug and Medical
Enrollment Requirement	183 days
Age Stratifications	0-17, 18-40, 41-64, 65-79, 80+ years
Enrollment Gap	45 Days
Indicator	Yes (Only applies to scenarios 26-50)

Scenario	Drug/Exposure								Event/Outcome
	Incident exposure	Incident w/ respect to:	Minimum Days Supplied	Minimum Episode Duration	Washout (days)	Cohort Definition	Episode Gap	Exposure Extension Period	Event/ Outcome
42	Doxepin	All Cyclics	0	0	183	01 (SING)	10	0	None
43	Imipramine	All Cyclics	0	0	183	01 (SING)	10	0	None
44	Nortriptyline	All Cyclics	0	0	183	01 (SING)	10	0	None
45	Desipramine	All Cyclics	0	0	183	01 (SING)	10	0	None
46	Protriptyline	All Cyclics	0	0	183	01 (SING)	10	0	None
47	Clomipramine	All Cyclics	0	0	183	01 (SING)	10	0	None
48	Trimipramine	All Cyclics	0	0	183	01 (SING)	10	0	None
49	Mirtazapine	All Cyclics	0	0	183	01 (SING)	10	0	None
50	Maprotiline	All Cyclics	0	0	183	01 (SING)	10	0	None

National Drug Codes (NDC) checked against First Data Bank's "National Drug Data File (NDDF®) Plus"  
 International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) diagnosis and procedure codes checked against Ingenix 2012 ICD-9-CM Data File provided by OptumInsight  
 Healthcare Common Procedure Coding System (HCPCS) codes checked against "Optum 2012 HCPCS Level II Data File" provided by OptumInsight  
 Common Procedural Terminology, Fourth Edition (CPT-4) codes checked against "Optum 2012 Current Procedure Codes & Relative Values Data File" provided by OptumInsight